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Abstract
Diabetes mellitus is an increasingly prevalent metabolic disorder that is estimated to affect over 300 million
people by 2025. Common to either type 1 or type 2 diabetes is a progressive inadequacy of functional beta-
cell mass. Recent studies have shown that during times of prolonged metabolic demand for insulin, the
endocrine pancreas can respond by increasing beta-cell mass by beta-cell proliferation. Advances that further
our knowledge of the molecular factors that control beta-cell proliferation will be crucial for understanding
the homeostasis of beta-cell mass during adulthood, and are pivotal for any attempt to use instructive cues to
induce the proliferation of terminally differentiated fully functional insulin-producing beta-cells that are
suitable for transplantation. In the first part of my thesis, I investigated the role of CISH on beta cell
proliferation in pregnant mice by using a pancreas-specific Cish-ablation mouse model. My results
demonstrated that CISH is not required for beta cell proliferation or glucose homeostasis before, during, and
after pregnancy. Socs2 expression is up-regulated in Cish-ablation islets at pregnant day 9.5, indicating that
SOCS2 might be compensating for CISH deficiency. In the second part of my thesis, I studied the role of
HNF4-alpha in beta cell proliferation during obesity by inducing beta-cell-specific Hnf4-alpha ablation in ob/
ob mice. My results indicated that HNF4-alpha is required for beta-cell proliferation during obesity.
Furthermore, I also demonstrated that overexpression of Hnf4-alpha in beta cells had no protective effect in
glucose homeostasis in high-fat-diet fed obese mice. In the third part of my thesis, I investigated the role of
betatrophin on human beta cell replication by transplanting human islets under kidney capsule of
immunodeficient mice and induce betatrophin overexpressing in the liver. In spite of the mitogenic role of
betatrophin on mouse beta-cells, it does not promote replication in human beta cells. In summary, my thesis
work furthered the understanding of the role of CISH, HNF4-alpha, and betatrophin on beta-cell
proliferation.
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ABSTRACT 
REGULATORS OF MOUSE AND HUMAN BETA CELL PROLIFERATION 
Yang Jiao 
Klaus H. Kaestner 
Diabetes mellitus is an increasingly prevalent metabolic disorder that is estimated to 
affect over 300 million people worldwide by 2025. Common to either type 1 or type 2 
diabetes is a progressive inadequacy of functional beta-cell mass. Recent studies have 
shown that during times of prolonged metabolic demand for insulin, the endocrine 
pancreas can respond by increasing beta-cell mass by beta-cell proliferation. Advances 
that further our knowledge of the molecular factors that control beta-cell proliferation 
will be crucial for understanding the homeostasis of beta-cell mass during adulthood, and 
are pivotal for any attempt to use instructive cues to induce the proliferation of terminally 
differentiated fully functional insulin-producing beta-cells that are suitable for 
transplantation. In the first part of my thesis, I investigated the role of CISH on beta cell 
proliferation in pregnant mice by using a pancreas-specific Cish-ablation mouse model. 
My results demonstrate that CISH is not required for beta cell proliferation or glucose 
homeostasis before, during, and after pregnancy. Socs2 expression is up-regulated in 
Cish-ablation islets at pregnant day 9.5, indicating that SOCS2 might be compensating 
for CISH deficiency. In the second part of my thesis, I studied the role of HNF-4α in beta 
cell proliferation during obesity by inducing beta-cell-specific Hnf4α ablation in ob/ob 
mice. My results indicated that HNF-4α is required for beta-cell proliferation during 
obesity. In the third part of my thesis, I investigated the role of betatrophin on human beta 
cell replication by transplanting human islets under kidney capsule of immunodeficient 
	   vi	  
mice and induce betatrophin overexpressing in the liver. In spite of the mitogenic role of 
betatrophin on mouse beta-cells, betatrophin does not promote replication in human beta 
cells. In summary, my thesis work furthered the understanding of the role of CISH, HNF-
4α, and betatrophin on beta-cell proliferation. 
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1.	  Blood	  glucose	  homeostasis	  
         Glucose is an essential fuel for all mammalian cells. Blood glucose levels are 
tightly regulated as a part of metabolic homeostasis. The process of maintaining blood 
glucose at a steady-state level is called glucose homeostasis, which is accomplished by 
hormonal regulation of peripheral glucose uptake, hepatic glucose production, and 
carbohydrate uptake during ingestion (Bergman, 2007).  
         After a carbohydrate containing meal, blood glucose increases, which triggers 
insulin secretion from the beta cells in the pancreatic islets of Langerhans. Insulin 
secretion follows two phases: the first phase of secretion of ‘docked’ insulin granules, 
and the second phase of secretion of newly synthesized insulin. Circulating insulin acts 
on the liver, muscle, and adipose tissue to increase glucose uptake and reduce glucose 
output by increasing glycogenesis (synthesis of glycogen from glucose), and decreasing 
gluconeogenesis (generation of glucose from non-carbohydrate substrates) and 
glycogenolysis (breakdown of glycogen to glucose). As a result, blood glucose levels are 
down-regulated to counteract hyperglycemia. In contrast, during fasting, blood glucose 
levels decrease, which induces glucagon secretion from the alpha-cells in the pancreatic 
islets. Glucagon is the major counter regulatory hormone to insulin. Glucagon 
exclusively acts on the liver to increase glucose output by activating hepatic 
glycogenolysis, followed by gluconeogenesis, both of which leads to releasing of glucose 
into the blood stream. As a result, blood glucose levels are increased to prevent 
hypoglycemia (Fig 1.1) (Muhammad Z. Shrayyef, 2010).  
             The gastrointestinal tract also plays an important role in regulating blood glucose 
levels. Nutrient stimulated secretion of hormones from the gut enteroendocrine cells 
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Figure 1.1 (Adapted from (Marieb E.N, 2005)) Blood glucose homeostasis. When blood 
glucose increases, pancreatic islet beta cells secrete insulin to decrease glucose output 
from liver and increase glucose uptake of liver, muscle and fat, so that blood glucose 
level is lowed to normal range. When blood glucose level is low, glucagon is secreted 
from pancreatic islet alpha cells, which induces hepatic glucose output and increases 
blood glucose level to normal range.  
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participates in postprandial glucose clearance by functioning through a number of 
metabolic processes, including stimulated secretion of insulin, inhibition of glucagon 
output, and reduced feeding. These gut hormones are called incretins, which are secreted  
from specialized gastrointestinal enteroendocrine cells to the blood stream. Intestinal L-
cell secreted Glucagon-Like Peptide-1 (GLP-1) and K-cell secreted Glucose-Dependent 
Insulinotropic Polypeptide (GIP) are two well-characterized incretins. Both GLP-1 and 
GIP are secreted after food intake to stimulate glucose-dependent insulin secretion to 
lower blood glucose. Indeed, it is demonstrated that ingested food causes a more potent 
release of insulin than glucose infused intravenously. And this effect is termed the 
‘incretin effect’ (Drucker, 2013). 
2.	  	  Pancreas	  and	  beta	  cell	  function	  
2.1	  Pancreas	  development	  	  
       The pancreas is a glandular organ located in the upper abdomen, behind the stomach, 
nestling the duodenum, and ending at the spleen. During mouse embryogenesis, pancreas 
development is framed by two major transitions (Fig 1.2). The ‘primary transition’ from 
embryonic day 8.5 (E8.5) to E10.5 marks the initiation of pancreatic organ formation and 
proliferation of pancreas progenitor cells. Around E8.5, the initial expression of Pdx1 
marks the pre-pancreatic endoderm at the foregut/midgut junction. Another transcription 
factor, Ptf1a, also plays a crucial role in pancreas specification. Pdx1 is expressed 
throughout the pancreatic epithelium from E11.5 to E15.5, and becomes restricted in beta 
cells afterwards. Ptf1a, however, becomes restricted to acinar progenitor cells at this later  
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Figure 1.2 (Adapted from (Collombat, Hecksher-Sorensen, Serup, & Mansouri, 2006)) 
Embryonic mouse pancreas morphogenesis. Pancreas development is operationally 
framed by two major transitions. The primary regulatory transition (E8.5-E10.5) marks 
the two pancreatic buds formation from foregut endoderm and proliferation of pancreas 
progenitor cells expressing Pdx1 and Ptf1a. The secondary transition (E13.5-E14.5) is the 
major phase of endocrine islet development and acinar cell genesis, marked by 
proliferation of endocrine progenitor Ngn3+ cells proliferation and clustering of islet 
cells. At later embryonic stage (E18), the two pancreatic buds merge and fully organized 
islets are formed. 
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stage.  Around E9.5, two pancreatic buds emerge from the foregut endoderm, first on the 
dorsal (E9.5), and subsequently on the ventral gut tube (E9.75).  Both pancreatic buds  
proliferate, thicken, branch and invade into the surrounding mesenchyme. The ventral 
bud rotates and eventually merges with the dorsal bud to form the intact pancreas around 
E18 (Collombat et al., 2006; Murry & Keller, 2008). The endocrine cells of the pancreas 
originate on E9.5 in the early gut endoderm and are marked by Ngn3 expression in a 
small subset of pancreatic cells. Development of the endocrine pancreas is a complex 
process that requires orchestrated action of multiple transcription factors during different 
stages of development. Ngn3 expressing cells are multipotent endocrine progenitor cells 
that give rise to all types of endocrine cells in the islet. Expression of additional 
transcription factors including Nkx2.2, Nkx6.1, and Foxa2 further restrict cells into 
distinct endocrine lineages (C. S. Lee, Sund, Behr, Herrera, & Kaestner, 2005; Sander et 
al., 2000; Sussel et al., 1998). Notably, there are some early glucagon+ (E11.5) and 
insulin+ cells, occasionally cells co-expressing insulin and glucagon, but they do not 
contribute to later mature islet cells. The function of these early endocrine cells is 
unclear. The major phase of islet development occurs during the secondary transition 
(E13.5-E14.5), with a burst of endocrine and acinar cell genesis, leading to full 
differentiation and generation of mature beta cells and alpha cells. Delta cells emerge 
around E15.5, and pancreatic polypeptide (PP) cells appear around E18, when endocrine 
cells begin to cluster into islets. About 2 to 3 weeks after birth, maturely organized and 
functional islets are formed (Murtaugh, 2007; Oliver-Krasinski & Stoffers, 2008). 
2.2	  Exocrine	  and	  endocrine/islets	  function	  	  
       The pancreas has two distinct functional portions (Fig 1.3a). The exocrine portions  
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Figure 1.3 (Adapted from (Cabrera et al., 2006; Edlund, 2002)) Pancreas and islets 
structure a) Pancreas has two distinct functional portions. 90% are exocrine portions, 
which consist of acini and ducts. Acinar cells secret digesting enzymes to the gut for food 
digestion. 1-2% of the pancreas consists of endocrine portions, which are the islets of 
Langerhans. Each islet consists of four to five cell types: insulin-producing beta cells, 
glucagon-producing alpha cells, somatostatin-producing delta-cells, pancreatic 
polypeptide-producing PP cells, and ghrelin producing epsilon cells. b) Different cell 
composition of human islets and mouse islets. Human islets have lower percentage of 
beta cells and higher percentage of alpha cells comparing to mouse islets. c) Human islets 
have different construction than mouse islets, with all cells types mixed together. Mouse 
islets have the vast majority of beta cells clustering in the core of the islets, while other 
cell types locating in the periphery of the islets. 
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constitute more than 90%, while the endocrine portions make up of 1 to 2% of the 
pancreas mass. The exocrine portions consist of acini as functional units of pancreatic  
enzyme production and ducts for delivering digestive enzymes into duodenum. Acini 
have the architecture of blind-ended tubules surrounded by polarized acinar cells. These  
tubules are organized into grape-like lobules. Acinar cells synthesize, store, and secrete 
digestive enzymes into the lobular lumens, called the intercellular canaliculi, which are 
connected to intralobular ducts. Intralobular ducts drain into larger extralobular ducts, 
which in turn merge into the bile duct and empty into the duodenum. Acinar cells secrete 
three major types of digestive enzymes, alpha-amylases, lipases, and proteases, which 
facilitate food digestion by catalyzing the hydrolysis of carbohydrates, fats, and proteins, 
respectively (Leung & Ip, 2006).  
       The endocrine portions of the pancreas consist of islets of Langerhans as functional 
units. A healthy human adult has about 1 million islets dispersed throughout the pancreas, 
with sizes ranging from 50 to 300 micrometers in diameter. Islets are considered as 
micro-organs. Each islet consists of four to five cell types: insulin-producing beta cells, 
glucagon-producing alpha cells, somatostatin-producing delta-cells, pancreatic 
polypeptide- producing PP cells, and ghrelin producing epsilon cells (Fig 1.3a). The 
architecture and composition of pancreatic islets differs among species. The rodent islets 
are usually spherically-shaped, with the vast majority of beta cells clustering in the core 
of the islets, while other cell types, namely alpha cells, delta cells, and PP cells locating 
to the periphery of the islets. Human islets, however, are usually irregularly shaped, with 
all cell types mixed and scattered within the islets without segregating into distinct 
regions (Fig 1.3c).  Most human beta cells (~70%) neighbor non beta cells (heterotypic 
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contacts), while most rodent beta cells (70%) appose beta cells (homotypic contacts). 
Furthermore, rodent islets consist of a higher proportion of beta cells (~77%) than human 
islets (~55%), and a lower proportion of alpha cells (~18%) than human islets (38%) (Fig  
1.3b) (Cabrera et al., 2006).  
2.3	  Insulin	  secretion	  by	  the	  beta	  cell	  
       Beta cells secrete a low basal level of insulin under substimulatary conditions.  
Glucose-stimulated insulin secretion (GSIS) is the main mechanism for stimulated insulin 
secretion. When blood glucose is high, glucose is rapidly transported across the beta cell 
membrane by the glucose transporter 2 (GLUT2) in mice, or GLUT1 and GLUT2 in 
humans (Fig 1.4).  Intracellular glucose is phosphorylated into glucose-6-phospate by 
glucokinase, and metabolized via the glycolytic pathway and the tricarboxylic acid cycle 
(TCA cycle). Glucose metabolism produces ATP. The increased ATP/ADP ratio results 
in closure of ATP-sensitive K+ channels in the plasma membrane, preventing K+ ions 
from being transported from the cytoplasm into the extracellular space. Accumulation of 
K+ ions in the beta cells provokes cell membrane depolarization. Voltage-gated Ca2+ 
channels are activated, which leads to influx of Ca2+ ions. Increasing Ca2+ ions in the beta 
cell trigger exocytosis of insulin. Insulin granules fuse with the plasma membrane, and 
insulin is secreted from the beta cells. There are two phases of insulin secretion. The 
rapid burst of first phase insulin secretion features the exocytosis of pre-packaged insulin 
granules docked at the plasma membrane, which happens 1 to 3 minutes after blood 
glucose increase. The sustained rising of second phase insulin secretion involves the 
release of both stored and newly synthesized insulin. Insulin mRNA is transcribed and 
translated into preproinsulin, which is cleaved into proinsulin by removal of its signal  
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Figure 1.4 Glucose stimulated insulin secretion (from BCBC) When blood glucose is 
high, glucose is uptaken rapidly across the beta cell membrane by the high capacity, low 
affinity glucose transporter 2 (GLUT2).  Intracellular glucose is phosphorylated into 
glucose-6-phospate by glucokinase, the rate-limiting enzyme for metabolizing glucose, 
and metabolized via the glycolytic pathway and the tricarboxylic acid cycle (TCA cycle). 
Glucose metabolism produces ATP. The increased ATP/ADP ratio causes ATP-sensitive 
K+ channels (KATP channels) in the plasma membrane to shut down, preventing K+ ions 
from being transported from the cytoplasm to the extracellular region. Accumulation of 
K+ ions in the beta cells provokes cell membrane depolarization. Voltage-gated Ca2+ 
channels are activated, which leads to influx of Ca2+ ions. Increasing Ca2+ ions in the 
beta cells triggers exocytosis of insulin. Insulin granules fuse with the cellular plasma, 
and insulin is secreted from the beta cells to the nearby blood vessels. !  
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peptide upon insertion into the endoplasmic reticulum. Proinsulin is exposed to several 
endopeptidases in the endoplasmic reticulum and is cleaved into free C peptide and  
insulin. Free C peptide and insulin are packaged in the Golgi into secretary granules. 
Second phase insulin secretion is turned off when blood glucose levels decrease (Gregory 
& Moore, 2011).  
3.	  Diabetes	  mellitus	  
       Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia 
(elevated blood glucose concentration), which leads to a series of classical symptoms 
including polyuria, polydipsia, and polyphagia. Diabetes can cause many complications, 
including cardiovascular disease, renal failure, and retinal damage. The world prevalence 
of diabetes was 6.4% among adults >20 years of age (285 million people) in 2010, and is 
estimated to increase to 7.7% (439 million) by the year 2030 (Shaw, Sicree, & Zimmet, 
2010). Diabetes is an increasing international health burden both to the patients and to the 
society, which is worsened by ageing, urbanization, and increasing prevalence of obesity 
and physical inactivity. In many countries, about 5-10% of the total health care budget is 
used for diabetes. The total cost of diagnosed diabetes in the U.S. alone in 2012 was $245 
billion. The major types of diabetes include Type 1 diabetes mellitus (T1DM), Type 2 
diabetes mellitus (T2DM), gestational diabetes mellitus (GDM), and maturity onset 
diabetes of the young (MODY).  
3.1	  Type	  1	  diabetes	  mellitus	  
3.1.1	  Pathogenesis	  of	  T1DM	  
       T1DM is observed in approximately 10% of patients with diabetes mellitus. It was  
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Figure 1.5 Pathogenesis of Type 1 diabetes and Type 2 diabetes. T1DM results from 
autoimmune progressive destruction of beta cells. Long standing T1DM patients have 
~99% deficit in beta cell mass, which leads to hypoinsulinemia and hyperglycemia. 
T2DM develops from a combination of insulin resistance and relative insulin deficiency. 
In T2DM patients, insulin sensitivity decreases ~50% in the liver, muscle and fat. Beta 
cell mass also decreases by ~60%, which leads to failure of compensation for insulin 
resistance and development of T2DM. !
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previously known as juvenile or insulin-dependent diabetes. T1DM results from 
autoimmune progressive destruction of beta cells by CD4+ and CD8+ T cells and  
macrophages infiltrating the islets (Fig 1.5). The autoimmune-mediated depletion within 
the islets is beta cell-specific. In the non-obese diabetic (NOD) mouse model of T1DM, 
beta cell proliferation initially increases in response to beta cell loss, but beta cell mass is 
progressively reduced (Sreenan et al., 1999). These mice do not become hyperglycemic 
until residual beta cell mass is reduced to less than 30% of controls. Similarly in humans, 
destruction of beta cells precedes the clinical onset of T1DM, because impaired insulin 
secretion in T1DM patients can be detected several years before hyperglycemia. As a 
consequence, new-onset T1DM patients display a ~80-90% deficit in beta cell mass, 
while long-standing T1DM patients have lost ~99% of their beta cells (Meier, 2008; 
Sreenan et al., 1999). Impaired beta cell function is also suggested to be involved in the 
pathogenesis of T1DM in addition to beta cell mass deficiency, since the degree of beta 
cell dysfunction exceeds the percentage beta cell loss in T1DM patients. T1DM is a 
complex polygenic disorder with many different genes contributing to its onset, via either 
dominant, recessive, or other models of inheritance. To date, no single gene has been 
identified as either necessary or sufficient to predict the development of T1DM.  
3.1.2	  Current	  strategies	  for	  glycemic	  control	  in	  TIDM	  patients	  and	  their	  limitations	  
       Insufficient beta cell number and insulin secretion, as well as unopposed glucagon 
secretion constitute the pathogenesis of T1DM. Therapeutic strategies to control normal 
blood glucose levels are based on two mechanisms: (1) increase insulin in the system by 
injecting exogenous insulin when needed, which has been in practice since the discovery 
of insulin in the 1920s; and (2) increase beta cell mass by islet transplantation, which 
	   15	  
represents a relative new strategy substantially developed and progressed during the last 
three decades (Shapiro et al., 2006).  
       Both regimens have demonstrated considerable improvement for glycemic control in 
the T1DM patients; however, they also have side effects. Insulin therapy needs to be 
administrated in precise dosage and timing, which is often difficult to predict. The 
incorrect usage of insulin is associated with refractory hypoglycemic episodes, defined as 
blood glucose levels below 70 mg/dl and symptoms such as feeling shaky, sweaty, and 
pounding heart (1.3 severe hypoglycemic episodes per T1DM patient per year (McCall & 
Shapiro, 2012)), which present great risks for the patients.  
       Great progress has been made over the past two decades with islet transplantation 
strategy. During the first ten years of practice (1990-2000), only 8.2% of the 267 patients 
that received an islet allograft remained insulin independent for more than a year 
(Shapiro et al., 2000). This situation was much improved in 2000, when a glucocorticoid-
free immunosuppressive regimen (known as the ‘Edmonton protocol’) was developed, in 
which all the seven islets recipients remained insulin independent after a year. From 2000 
until 2012, >750 T1DM patients have received islet transplants world-wide, and recent 
data indicate that 50% of the recipients remained insulin-independent 3 years after the 
procedure (McCall & Shapiro, 2012). Although promising, islets transplantation faces the 
following obstacles: (1) the extreme scarcity of organ donors relative to the diabetic 
population, especially since often islets from multiple donors are required for one 
transplantation, and multiple rounds of islet transplantation are necessary for each 
recipient; (2) extremely high financial burden of the procedure with up to $150,000 per  
patient (McCall & Shapiro, 2012).  
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       Therefore, it is tempting to develop alternative strategy for limitless expandable 
source of beta cells to restore beta cell mass, including stem cell or xenograft-derived 
insulin secreting cells, or beta cells obtained by proliferation. 
3.2	  Type	  2	  diabetes	  mellitus	  
       Type 2 diabetes mellitus (T2DM) constitutes about 90% of all cases of diabetes 
mellitus. It was previously called ‘non-insulin-dependent diabetes mellitus’. The 
pathogenesis of T2DM is not fully understood. Current theories favor that T2DM 
develops from a combination of insulin resistance and relative insulin deficiency (Fig 
1.5).  
3.2.1	  Obesity,	  insulin	  resistance,	  and	  T2DM.	  
       Obesity is associated with an increased risk of insulin resistance and T2DM. The risk 
of diabetes increases linearly with body mass index (BMI), from 2% in the 25-29.9 BMI 
group, to 8% in the 30-34.9 BMI group, and finally to 13% in people with a BMI 
exceeding 35 (Yaturu, 2011). In obesity, the initial triglycerides deposition occurs in 
subcutaneous adipose tissue, and BMI increases in parallel with subcutaneous adipose 
tissue accumulation. This provokes insulin resistance, and limits further subcutaneous 
lipid accumulation. Later on, triglycerides deposit into visceral fat (intra-abdominal fat) 
as well as ectopic sites, leading to an increase of waist circumference (WC), which is the 
prime determinant of insulin resistance in obese and overweight subjects (Yaturu, 2011). 
       Insulin resistance is characterized by a failure of peripheral tissues to respond to  
insulin, including a decreased ability of skeletal muscle and adipose tissue to take up  
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glucose upon insulin secretion, and a failure of the liver to reduce hepatic glucose output 
in the presence of insulin. Since skeletal muscle is responsible for ~75% of whole body 
insulin-stimulated glucose uptake, defects in this tissue have a major role in the impaired 
glucose homeostasis in T2DM patients (Kennedy et al., 1999). In skeletal muscle, insulin 
signals through insulin receptor/ insulin receptor substrate (IR/IRS)/PI3K/AKT, which 
activates multiple protein phosphatases and phospholipid phosphatases to modulate the 
strength and duration of insulin signaling, the biological output being translocation of 
glucose transporter 4 (GLUT4) to the plasma membrane and glucose uptake via GLUT4 
(Zaid, Antonescu, Randhawa, & Klip, 2008; Zorzano, Palacin, & Guma, 2005) . T2DM 
patients have dysregulation of the IR/IRS pathway, impairment of PI3K activation, or 
defects in GLUT4 translocation in response to insulin in their muscles (Bjornholm & 
Zierath, 2005; Zierath, Krook, & Wallberg-Henriksson, 2000).  
       Adipose tissue exhibits decreased GLUT4 expression in T2DM patients (Shepherd & 
Kahn, 1999), but since skeletal muscle is the main glucose disposal site, down-regulation 
of GLUT4 in adipose tissue contributes less to insulin resistance and hyperglycemia in 
T2DM patients. Instead, adipose tissue generates multiple circulating factors, e.g., free 
fatty acids (FFA), adiponectin, and other adipokines, that serve in both endocrine and 
paracrine fashions, communicating with other organs and ultimately altering insulin 
sensitivity by regulating systemic insulin action and hepatic glucose production (Gimeno 
& Klaman, 2005; Lazar, 2005). Patients with T2DM have decreased oxidative capacity 
for fatty acids and high levels of circulating FFA (Blaak et al., 2000; Kelley & Simoneau, 
1994). The latter promotes accumulation of lipid inside the skeleton muscle cells, causing 
insulin resistance by reducing glucose uptake (Boden, 1999), which is a key component  
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for skeleton muscle insulin resistance. 
      Liver is a main target of the anabolic hormone insulin and its catabolic counterpart 
glucagon. Hepatic glucose metabolism includes glycogenesis, gluconeogenesis, 
glycolysis, and glycogenolysis (Klover & Mooney, 2004). Liver is also the major organ 
for lipid metabolism, including fatty acid oxidation, de novo synthesis of fatty acids, 
cholesterol and bile acid synthesis, and lipoprotein assembly (Postic, Dentin, & Girard, 
2004). These metabolic pathways are coordinately regulated to maintain glucose and lipid 
homeostasis (Raddatz & Ramadori, 2007). IRS-1 and IRS-2 are the key players in hepatic 
insulin signaling, as well as lipid metabolism (Fritsche, Weigert, Haring, & Lehmann, 
2008). Defects in IRS signaling promotes insulin resistance by dysregulated insulin actin 
and increased hepatic glucose production, and is considered as a major component of the 
pathogenesis of liver insulin resistance and T2DM (Dong et al., 2006; Taniguchi, Ueki, & 
Kahn, 2005). 
       Most (80%) obese people do not develop T2DM, and not all subjects with T2DM are 
obese (80% T2DM patients are obese) (Lin & Sun, 2010; Venables & Jeukendrup, 2009).  
In obese and insulin-resistant subjects, failure of beta cells to compensate for insulin 
insensitivity ultimately leads to T2DM (Lin & Sun, 2010). In T2DM patients, beta cell 
mass is decreased by ~60% in both obese and lean subjects compared to their nondiabetic 
age- and weight-matched counterparts (Butler et al., 2003). The reduced beta cell mass in 
T2DM has been shown to result from a 3- to 10-fold increase of beta cell apoptosis, while 
islet neogenesis remains intact, as shown by analysis of human pancreas autopsy 
specimens (Butler et al., 2003). Several mechanisms have been proposed to trigger 
increased beta cell mass loss in T2DM. First, ‘glucose toxicity’ caused by chronic 
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hyperglycemia is capable of generating reactive oxygen species (ROS) in beta cells (R. P. 
Robertson, Harmon, Tran, & Poitout, 2004). In T2DM patients, excess and prolonged 
hyperglycemia accompanied by elevated ROS leads to chronic oxidative stress, with 
deleterious effects in the islets, which exhibit low levels of intrinsic antioxidant defenses. 
Among the adverse effects are decreased insulin gene expression, impaired insulin 
secretion, and increased apoptosis (R. P. Robertson, 2004), hence ‘glucose toxicity’. 
Second, ‘lipotoxicity’ caused by non-esterified fatty acid (NEFA) accumulation can 
contribute to endoplasmatic reticulum (ER) stress (Laybutt et al., 2007) and induce beta 
cell death. Third, islet amyloid polypeptide oligomers (IAPP) aggregate in human islets, 
form islet amyloid deposits, become cytotoxic, and play a role in beta cell death (Janson, 
Ashley, Harrison, McIntyre, & Butler, 1999). Cytotoxicity of h-IAPP is suggested to 
result from dramatic disruption of beta cell membrane.  
3.2.2	  Genetics	  of	  T2DM	  
       The etiology of human T2DM is multifactorial, the two critical components being 
genetic background and the afore-mentioned environmental factors like obesity and diet. 
Genetic predisposition is an important contributing factor for T2DM since (1) T2DM has 
a high prevalence in ethnic minorities and indigenous groups with low population 
admixture; (2) T2DM runs in families; and (3) monozygotic twins demonstrate a 
considerably higher disease concordance than dizygotic twins (70% vs. 10%) (Elbein, 
1997). Importantly, T2DM does not follow simple Mendelian inheritance, indicating that 
it is a polygenic disease. During the last decade, tremendous effort and considerable 
progress have been made in the identification of T2DM risk genes by (1) candidate gene  
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Figure 1.6 (Adapted from (Staiger, Machicao, Fritsche, & Haring, 2009; Voight et al., 
2010)) Time-course of the discovery of 38 T2DM risk alleles up to date. At least 38 
T2DM risk alleles have been identified. White bars indicate genes discovered during 
candidate research approach. Black bars indicate genes discovered by GWA studies. 
Confirmed risked genes are labeled in black and potential risk genes are listed in grey. 
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approaches and (2) hypothesis-free genome-wide association studies (GWAS) (Staiger et 
al., 2009). GWAS compare several hundred thousands Single nucleotide polymorphisms 
(SNPs) in large case-control cohorts to map and catalog SNPs. SNPs cover about 90% of 
the sequence variation within the human genome and are considered a major determinant 
of the individual predisposition for complex diseases. For example, a meta-analysis of 
GWAS studies derived data from a total of approximately 60,000 subjects in 2008, and 
identified six diabetic risk loci (Zeggini et al., 2008). Another meta-analysis in 2009 of 
13 GWAS (~83,000 subjects) revealed one gene of increased risk for T2DM 
(Prokopenko et al., 2009). To date, GWAS has identified at least 38 (confirmed and 
potential) T2DM susceptibility genes (Watanabe, 2011) (Fig 1.6). Interestingly, the 
majority of T2DM risk genes are thought to affect beta cell function, which favors the 
theory that in T2DM, beta cell dysfunction primarily results from genetic causes, while 
insulin resistance predominantly results from environmental influences (Florez, 2008). 
Therefore, T2DM emerges when environmentally triggered insulin resistance happens in 
the context of genetically programmed beta cell dysfunction.  
        T2DM risk gene variants affect beta cell insulin secretion in several aspects. For 
example, KCNJ11 encodes the pore-forming subunit Kir6.2 of the ATP-sensitive K 
channel of beta cells (Schwanstecher, Meyer, & Schwanstecher, 2002). CAPN10 encodes 
calpain10, a Ca-dependent cysteine protease, which has been proposed to serve as a 
calcium sensor that triggers actin reorganization and stimulates exocytosis of insulin 
granules following cytosolic calcium accumulation. The CAPN10 SNP is associated with 
glucose-stimulated insulin secretion (Turner, Cassell, & Hitman, 2005). WFS1 encodes 
wolframin, a protein that regulates Ca transport in the ER (Florez et al., 2008). SLC30A8 
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encodes the ZnT-8 transporter responsible for insulin maturation and storage by 
transporting zinc into insulin secretory granules (Chimienti, Devergnas, Favier, & Seve, 
2004). PPARGC1A encodes PGC1α, a central regulator of mitochondrial function, which 
is required for mitochondrial ATP formation for stimulus-secretion coupling in beta cells. 
The potential T2DM risk SNP in PPARGC1A produced the missense mutation G482S, 
which markedly reduces glucose-stimulated insulin secretion in human islets (Ling et al., 
2008).  
      In addition to glucose-stimulated insulin secretion, T2DM risk genes also affect 
incretin-stimulated insulin secretion. TCF7L2 encodes a component of the TCF7L2 
transcription factor complex that is involved in the Wnt signaling. Some experiments 
suggest that TCF7L2 affects GLP-1 stimulated insulin secretion (Florez, 2008). MTNR1B 
encodes a member of the melatonin receptor family, while CRY2 encodes a member of 
the cryptochrome family that regulates the clock gene, pointing to the contribution of 
‘clock’ genes and circadian rhythms to T2DM (Prokopenko et al., 2009). These latter two 
genes are likely to function in non-beta-cells (Gupta et al., 2005). 
       Furthermore, transcription factors like HNF4A, TCF1, TCF2, and HHEX encode  
transcription factors in the beta cells, which are implicated in pancreatic development. 
However, recent unpublished data from the Kaestner lab have shown that HHEX 
functions in somatostatin producing delta cells, not in beta cells as had been assumed.  
In addition to affecting insulin secretion, several T2DM risk genes also affect insulin 
sensitivity, glucagon secretion, and adiposity. Unfortunately, however, all T2DM risk 
alleles do not provide better disease prediction than simple, conventional clinical risk 
assessments (e.g., BMI, age, gender, family history, etc.), nor do they explain the 
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heritability of T2DM (Lango et al., 2008). It is possible that copy number variants, 
affecting gene dosage, could also contribute to the genetic component of T2DM. 
Furthermore, epigenetic inheritance might explain some of the familial clustering of 
T2DM. 
3.2.3	  Treatment	  and	  medication	  of	  T2DM	  
       T2DM patients have more fluctuating and higher circulating blood glucose levels 
than normal subjects as a result of insulin resistance and impaired beta cell function. 
Management of T2DM focuses on lifestyle intervention, maintaining blood glucose 
levels in the normal range, and lowering cardiovascular risk factors. A healthy lifestyle 
includes proper diet and exercise. Some T2DM patients need insulin therapy as well. 
Bariatric surgery might also be considered, which is a surgery that removes a portion of 
the stomach to control body weight and blood sugar levels. On the molecular level, the 
ultimate goal of understanding the insulin signaling pathway and diabetes susceptibility 
genes is to (1) predict the development of the disease, and (2) identify manipulatable 
molecular targets to improve glucose uptake, lower hepatic glucose production, and 
prevent hyperglycemia (Bjornholm & Zierath, 2005).  
       Several currently used diabetes drugs have ill-defined mechanism of action. 
Metformin is the most commonly used anti-diabetic medicine. It inhibits hepatic glucose 
production and hepatic steatosis (Ballav & Gough, 2013). PPARγ agonists constitute 
another universally studied class of compounds to treat T2DM. They function as 
senitizers for insulin sensitivity. PPARγ agonists increase insulin sensitivity in peripheral 
adipocytes, resulting in lower plasma fatty acids and redistribution of muscle and liver 
lipid to adipocytes (Bajaj et al., 2007) (Bjornholm & Zierath, 2005). PPARγ agonists 
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have fallen out of favor because their adverse effects including weight increase, edema, 
and congestive cardiac failure (Bermudez et al., 2010). Another class of anti-diabetic 
drugs is insulin secretagogues, including sulfonylureas, GLP-1 agonists, and dipeptidyl 
peptidase 4 (DPP-4) inhibitors. GLP-1 agonists are the ‘incretin mimetics’, which prime 
insulin secretion and have a lower risk of causing hypoglycemia like sulfonylureas 
(Pratley, 2008). DPP-4 is the main enzyme responsible for GLP-1 degradation. DPP-4 
inhibitors slow down the clearance of GLP-1 and lower glucose levels by prolonged 
incretin signaling (Karagiannis, Paschos, Paletas, Matthews, & Tsapas, 2012). 
Sulfonylureas bind to KATP channel on beta cells and increase insulin secretion by 
depolarizing the membrane and opening of Ca2+ channels ("Intensive blood-glucose 
control with sulphonylureas or insulin compared with conventional treatment and risk of 
complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes 
Study (UKPDS) Group," 1998). 
3.3	  Maturity	  onset	  diabetes	  of	  the	  young	  (MODY)	  
       MODY is a monogenic and autosomal dominant disorder that is characterized by a 
familial, young-onset non-insulin dependent form of diabetes with pancreatic beta cell 
dysfunction. MODY typically presents in lean children, adolescents, or young adults 
before 25 years old, and accounts for 2-5% of all diabetes cases (Shaat et al., 2006). 
MODY is different from T1DM in that there is no autoimmune destruction of beta cells. 
MODY is also different from T2DM in that the MODY patients are usually lean and not 
insulin resistant. Eleven MODY genes have been identified to date, including seven 
transcription factors and two metabolic enzymes, namely, hepatocyte nuclear factor 4α 
(HNF4α, MODY1), Glucokinase (GCK, MODY2), hepatocyte nuclear factor 1α 
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(HNF1α, MODY3), pancreatic and duodenal homeobox 1 (PDX1, MODY4), hepatocyte 
nuclear factor 1β (HNF1β, MODY5), Neurogenic differentiation 1 (NEUROD1, 
MODY6), kruppel-like factor 11 (KLF11, MODY7), bile salt dependent lipase (BSDL), 
also known as carboxyl ester lipase (CEL) (MODY8), paired box gene 4 (PAX4, 
MODY9), insulin (INS, MODY10), and B-lymphocyte kinase (BLK, MODY11). Some 
of the MODY genes have also been associated with increased risk of T2DM and 
increased risk of GDM (Shaat et al., 2006). 
       Mutations in different MODY genes result in a spectrum of clinical symptoms and 
require different treatment strategies. The frequency of specific MODY gene mutations 
varies in MODY families from different countries. Mutation in Hnf4α results in MODY1, 
which is characterized by a defect in glucose-stimulated insulin release. HNF4α is a 
transcription factor that is part of a complex regulatory network important for glucose 
homeostasis in the liver and pancreas. Hnf4α is under regulation of two promoters: the 
liver-specific P1 promoter and the pancreatic beta cell-specific P2 promoter. Loss of 
function of Hnf4α leads to impaired expression of genes involved in glucose transport 
and glycolysis in the liver (Stoffel & Duncan, 1997). MODY1 is typically treated by oral 
hypoglycemics (Watanabe, 2011). In the beta cells, HNF4α has been suggested to 
regulate glucose-stimulated insulin secretion (GSIS) in a Kir6.2 dependent manner 
(Gupta et al., 2005). GCK mutations cause MODY2, which is characterized by a lifelong 
mild fasting hyperglycemia due to reduced glucose sensing in the beta cell. GCK acts as a 
glucose sensor and stimulates beta cell insulin secretion. Glucokinase facilitates 
phosphorylation of glucose to glucose-6-phosphate, which is the first step of glycolysis. 
Glycosis produces ATP, which causes depolarization of membrane, influx of Ca2+, and 
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eventually insulin secretion. MODY2 can be managed by lifestyle modification alone. 
MODY3, caused by mutations in the Hnf1α gene, is characterized by severely defective 
insulin secretion but retained sensitivity to sulfonylureas. MODY3 is the most common 
type of MODY in populations with European ancestry (Frayling et al., 2001). HNF1α is a 
transcription factor regulating cellular functions including glucose metabolism and lipid 
transport. MODY3 is also treated by oral hypoglycemics. MODY4-11 are very rare, 
some reported in fewer than 10 families (Watanabe, 2011). 
4.	  Regulation	  of	  beta	  cell	  mass	  
4.1	  Establishment	  of	  beta	  cell	  mass	  
       Total beta cell mass is determined by beta cell neogenesis (which mainly happens 
during embryogenesis), beta cell replication, beta cell hypertrophy, and beta cell 
apoptosis. There is a rapid expansion of beta cell number in early childhood (Meier et al., 
2008), from both beta cell replication (accounting for ~90% of beta cell mass expansion 
during the neonatal stage) and beta cell/islet neogenesis (contributing to ~10% of beta 
cell mass expansion after birth). During the perinatal stage, beta cells have a relatively 
high proliferation rate (~1% of -2 to 2 months old infants) with a peak wave of apoptosis 
(~1.3% during the same period). Both proliferation and apoptosis decrease rapidly from 2 
to 6 months (0.6% and 0.2%, respectively) and after 6 months of age, only rare beta cells 
replicate (0.13%) (Kassem, Ariel, Thornton, Scheimberg, & Glaser, 2000). Similarly in 
mice, the postnatal period between birth and 2 weeks is also characterized by a massive 
increase in beta cell mass by beta cell replication (Georgia & Bhushan, 2004). 
      After early childhood, beta cell mass slightly increases during adolescence, in  
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proportion to the increase of body weight (Meier et al., 2008). Although the beta cell 
proliferation rate is extremely low (0.13% after 6 months of age (Kassem et al., 2000)), it 
has been suggested to be the primary mechanism of beta cell mass increase during 
adolescence, because islet number does not change after infancy (2 years old), while the 
mean islet size increases about two-fold, with no change in cell size (Meier et al., 2008).  
4.2	  The	  regenerative	  capacity	  of	  beta	  cells	  
       Postnatal beta cells have an impressive regeneration capacity in situations of 
increased metabolic demand (Lysy, Weir, & Bonner-Weir, 2012) (Fig 1.7). Evidence for 
beta cell regeneration includes: (1) Beta cell mass linearly correlates with body weight in 
adult rats (Montanya, Nacher, Biarnes, & Soler, 2000); (2) In the obese mouse model 
(ob/ob), total islet mass increases 3.6 times without increasing total islet number, 
indicating that cells within the existing islets undergo hypertrophy or hyperplasia, or both 
(Bock, Pakkenberg, & Buschard, 2003). (3) In both nondiabetic subjects and T2DM 
subjects, beta cell mass increases with BMI (Willcox, Richardson, Bone, Foulis, & 
Morgan, 2010), indicating an adaptive capacity of beta cell regeneration. It is noteworthy 
that beta cell replication capacity observed in the obese rodents (5-10 fold increase) is 
more profound than the increase in obese humans (~1.5 fold), indicating that different 
mechanisms might be underlying beta cell replication among different species (Butler et 
al., 2003). (4) In rats following partial pancreatectomy, where 60% of the pancreas is 
removed, normal glycemia is maintained by a 3-fold increase of beta cell proliferation 5 
days after surgery, accompanied by enhanced glucose metabolism in existing beta cells 
(Y. Q. Liu, Montanya, & Leahy, 2001). Similarly, in a beta cell injury model in mice,  
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Figure 1.7 Evidence for in vivo regeneration capacity of beta cells. Beta cells have a low 
basal proliferation rate after the boost of replication during perinatal stage, unless 
challenged by metabolic demands like pregnancy, obesity, and pancreas injury, during 
which beta cells adaptively proliferate and increase hypertrophy for beta cell expansion. 
Shown in this complex table here are the conditions during which beta cell proliferation 
increases and beta cell mass expanses. On the left are studies in rodents, and on the right 
are studies in humans. 
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where 70-80% beta cells are specifically ablated by diphthia toxin mediated cell ablation,  
significant regeneration of beta cell mass takes place, spontaneously normalizing blood 
glucose levels (Nir, Melton, & Dor, 2007). (5) During pregnancy, when the mother 
becomes insulin resistant, beta cell mass increases 3-4 fold in rodents by both increase of 
beta cell proliferation and beta cell hypertrophy. Interestingly, beta cell mass shrinks to 
pre-pregnancy levels within 10 days after delivery by cell apoptosis, supporting the 
intrinsic adaptive plasticity of beta cells (Karnik et al., 2007; Rieck & Kaestner, 2010). 
(6) In early onset T1DM patients, beta cell proliferation is detected with a 10-fold higher 
rate than in control subjects as an apparent attempt to compensate for the autoimmune 
mediated loss of beta cell mass, which contributes to the ‘honeymoon period’ of T1DM 
(Willcox et al., 2010). Remarkably, in  one 89-year old patient with ongoing T1DM, 
proliferating beta cells were detected in the islets, indicating the capacity of beta cell 
proliferation even after aging (Willcox et al., 2010). 
4.3	  Proliferation	  is	  the	  primary	  source	  of	  new	  beta	  cells	  during	  adulthood	  	  
       The origins of new beta cells that maintain beta cell homeostasis in adulthood and 
during regenerative repair has been controversial (Dor, Brown, Martinez, & Melton, 
2004). Studies challenging beta cells adaptive regeneration capacity in different models 
have revealed several options as sources of new beta cells (Fig 1.8). First, neogenesis of 
islets or beta cells (i.e. the production of new beta cells from differentiation of progenitor 
cells) (Bonner-Weir & Weir, 2005a). Although it remains unclear whether there are 
‘facultative’ stem cells or progenitor cells in the pancreas, neogenesis of beta cells from 
pancreatic duct cells has been extensively investigated (Xiao et al., 2013). The pancreatic 
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Figure 1.8 (Adapted from (Juhl, Bonner-Weir, & Sharma, 2010)) Different sources of 
new beta cells. 1) Transdifferentiating from acinar cells to beta cells. 2) Neogenesis of 
beta cells from facultative ductal progenitor cells. 3) Transdifferentiating from 
hepatocytes. 4) Transdifferentiating from alpha cells, and 5) Proliferating from beta cells. 
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ductal epithelium has been suggested to be a potential pool for beta cells progenitors 
(Bonner-Weir et al., 2004). Evidences for existence of ductal progenitor cells include the 
appearance of insulin+ cells near the duct (referred to as the ‘budding new islets’), the 
appearance of Ngn3+ cells near the duct after pancreatic ductal ligation (PDL) (X. Xu et 
al., 2008), and the increase in the ratio of small to large islets in beta cell regeneration 
models such as obesity (Bonner-Weir et al., 2004). A recent study shows that 14% of the 
newly formed beta cells after PDL are attributed to beta cell neogenesis from Ngn3+ 
progenitor cells (Van de Casteele et al., 2013). It has also been suggested that beta cell 
neogenesis, rather than replication, predominates in newly diagnosed glucose intolerant 
diabetic patients (Yoneda et al., 2013). Controversially, genetic lineage tracing of ductal 
cells disproves the existence of progenitor cells in the duct epithelium (Collombat et al., 
2009).  
        Second, transdifferentiation of beta cells from acinar cells, pancreatic alpha cells, or 
hepatocytes (Lysy et al., 2012). Other cells within the pancreas or other tissues have been 
investigated for their potential to transdifferentiate into beta cells (Lysy et al., 2012). 
Adult acinar cells have demonstrated the capacity to be converted into insulin-secreting 
beta cells in vitro (Mashima et al., 1996), but in vivo studies show controversial results 
(Desai et al., 2007; Zhou, Brown, Kanarek, Rajagopal, & Melton, 2008). In one study, 
acinar cells failed to convert into beta cells in several beta cell regeneration models 
(Desai et al., 2007). In another study, ectopic expression of Ngn3, Pdx1 and Mafa 
successfully reprogrammed acinar cells into cells that resemble beta cells in vivo (Zhou et 
al., 2008). Islet alpha cells physiologically highly resemble beta cells, and several groups 
have demonstrated the capacity of reprogramming alpha cells to beta cells by ectopic 
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expression of Pax4 or loss of Arx (Collombat et al., 2009; Yoneda et al., 2013). In an 
extreme beta cell ablation model (99% ablation), a fraction of alpha cells is shown to 
convert to beta cells by genetic lineage tracing (Chung, Hao, Piran, Keinan, & Levine, 
2010; Thorel et al., 2010). Interestingly, many beta cell signature genes are actively 
marked in beta cells, while bivalently marked in alpha cells, indicating reprogramming 
plasticity of alpha cells to beta cells. Indeed, epigenetic manipulation of histone marks by 
a histone methyltransferase inhibitor successfully converts alpha cells to insulin 
producing cells in human islets, suggesting that epigenomic manipulation could provide a 
path for alpha-to-beta cell reprogramming (Bramswig et al., 2013). Hepatocytes are also 
on the list, with the rational that liver and pancreas arise from the common endodermal 
origin in the foregut (Kojima et al., 2003). Adult human liver cells can transdifferantiate 
into insulin+ cells after treated with PDX1 and soluble factors in vitro (Sapir et al., 2005). 
These studies all have had some success, but their ability to reproductively create 
abundant ‘true’ functional insulin producing beta cells that response to glucose has been 
limited.  
       Third, replication of pre-existing mature beta cells. One genetic lineage tracing 
study in mice shows that adult pancreatic beta cells are formed largely by self-replication, 
rather than stem cell differentiation under normal physiological conditions and even 
during the regenerative repair after partial pancreatectomy (Dor et al., 2004). Another 
genetic lineage tracing study made possible the detection of newly formed beta cells from 
non-beta cells, and found no evidence of such cell transition after PDL, suggesting that 
the replication of pre-existing beta cells is the major source of new beta cells in adulthood 
(Xiao et al., 2013). In summary, although there are several studies showing the possibility 
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of beta cell neogenesis from adult progenitor cells and transdifferentiation of other 
differentiated cell types to beta cells, the primary source of new beta cells during 
adulthood is proliferation of pre-existing beta cells. This is the case under normal 
physiology conditions, during pregnancy, obesity, and injury models like PDL. Islet 
neogenesis, if there is any, only plays a small role in the homeostasis of beta cell mass 
during adulthood. 
4.4	  Signals	  and	  mechanisms	  of	  beta	  cell	  proliferation	  
       Since proliferation is the main mechanism of maintaining beta cell mass, it is critical 
to elucidate the external and internal regulators of beta cell proliferation. The ultimate 
goal will be to manipulate key regulators for beta cell proliferation and produce more 
beta cells in vivo as a therapeutic strategy for diabetes treatment. The current knowledge 
of mechanisms underlying adaptive beta cell proliferation relies heavily on experimental 
models of physiological stimuli of beta cell mass expansion, including insulin-resistance 
induced by obesity or pregnancy.  
4.4.1	  Intrinsic	  cell	  cycle	  regulators	  
       The mammalian cell cycle machinery possesses two key checkpoints: the G1/S 
transition and the G2/M transition checkpoints. Regulatory proteins called cyclins 
associate with specific cyclin-dependent kinases (CDKs) and activate the catalytic 
activity of CDKs, which allows the cells to traverse cell cycle checkpoints. During the 
G1/S phase of the cell cycle, cyclin D is up-regulated, which complexes with CDK4 
and/or CDK6. The activated CDK4/6 complexes inactivate ‘pocket proteins’ 
(retinoblastoma protein (pRb), p107, and p130) by phosphorylation. Inactivation of the 
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pocket proteins releases the E2F family of transcription factors and facilitates the 
subsequent transcription of E2F target genes required for DNA synthesis during S phase, 
and cell cycle genes like cyclin A needed for the G2/M transition. Later on, cyclin E-
dependent CDK2 is induced. The cyclin E/CDK2 complex also phosphorylates non-Rb 
substrates to further power the cell through the G1/S checkpoint. During G2/M phase, 
cyclin A-dependent CDK1 is required for the onset of mitosis. Upon nuclear envelope 
breakdown, A-type cyclins are degraded, allowing the formation of the cyclin B/CDK1 
complex, which facilitates the progression through mitosis (Malumbres & Barbacid, 
2009) (Fig 1.9). 
       Cell cycle checkpoints are surveillance mechanisms that ensure the fidelity of cell 
division by verifying that each phase of cell cycle is accurately completed before 
progress into the next phase. Cell cycle arrest is achieved by cyclin-dependent kinase 
inhibitors (CKIs). There are two families of CKIs, the INK family (inhibitory kinases) 
and the CIP/KIP family (cyclin inhibitory proteins/kinase inhibitory proteins). The INK 
family has four members (p16INK4a, p15INK4b, p18INK4c, and p19INK4d), which bind to and 
inhibit cyclin D-dependent CDK4/6, causing cell cycle inhibition or arrest at the G1/S  
checkpoint (Malumbres & Barbacid, 2009). The CIP/KIP group consists of three 
members (p21CIP1, p27KIP1, p57KIP1), which have bifunctional effects on cell cycle. On the 
one hand, CIP/KIP family members inhibit the activity of cyclinE/CDK2 during the G1/S 
transition and CDK2/1 during the G2/M transition. On the other hand, p21 and p27 act as 
chaperones for cyclinD-dependent CDK4/6 to augment cell cycle progression during the 
G1/S phase (Malumbres & Barbacid, 2009). 
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Figure 1.9 (Adapted from (Cozar-Castellano, Fiaschi-Taesch, et al., 2006)) Cell cycle 
machinery and its regulators. An overview of the proteins that control β-cell cycle with 
emphasis on the G1/S-phase transition. Key regulators of beta cell proliferation include 
cyclins, cyclin-dependent kinases (CDKs), and cyclin-dependent kinase inhibitors 
(CKIs). Cell cycle regulators that have been shown to play important role in beta cell 
proliferation are circled in red. Cell cycle inhibitor regulators are circled in green. 
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         In studies of mice with targeted global or cell-type-specific mutation of cell cycle 
regulators, it is revealed that CDKs have a cell type-specific pattern of expression. 
Therefore, it is essential to decipher the unique cell cycle regulators in beta cells. For 
example, islets are more susceptible to CDK4 deficiency than other tissues. Global 
ablation of CDK4 yields a milder phenotype than expected given the essential role of 
CDK4 during cell cycle progression (Rane et al., 1999). CDK4 mutant mice demonstrate 
abnormalities only in the ovary, the testis, and beta cells. CDK4 mutants are born 
euglycemic with normal beta cell mass, but develop diabetes during the first two months 
of life, due to a deficiency of postnatal beta cell replication. Other tissues are less 
susceptible to CDK4 deficiency, probably due to the compensation from CDK6. In islets, 
mRNA levels of CDK4 are two orders of magnitude higher than those of CDK6, 
explaining the lack of compensating from CDK6 (Martin et al., 2003). Later studies 
demonstrate that cell cycle machinery of beta cells could be accelerated by manipulating 
CDK4 levels. CDK4 knockin mice have significantly increased beta cell mass, and 
human islets expressing CDK4 cDNA exhibite higher beta cell proliferation (Marzo et 
al., 2004). 
        Interestingly, cyclin mutant mice exhibit variable phenotypes in different mouse 
genetic backgrounds. For example, during G1 phase, cyclin D2 is the most abundant 
cyclin in mouse islets (Kushner et al., 2005). Cyclin D2-/- mice on the C57BL/6 
background develop severe diabetes due to deficiency of beta cell proliferation at 3 
months of age, indicating that cyclin D2 is the primary D-type cyclin for beta cell 
replication in these mice (Kushner, 2006). However, on a mixed B6/129 background, 
cyclin D2-/- mice develop diabetes at 12 months of age caused by decreased beta cell 
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proliferation. Removing one allele of cyclin D1 in cyclin D2-/- mice accelerates the onset 
of diabetes from 12 months to 3 months (Kushner et al., 2005), indicating that both cyclin 
D1 and cyclin D2 levels need to be tightly regulated for proper beta cell mass expansion 
after birth. However, forced over-expression of stabilized cyclin D2 fails to induce beta 
cell proliferation (He et al., 2009). Overexpression of cyclin D1 in the beta cells also fails 
to stimulate beta cell proliferation at young age (3 months), but yields more beta cell 
proliferation in older mice (12 months) (X. Zhang et al., 2005). These studies emphasize 
the essential role of CDK4 inhibitors such as p15 and p16, and demonstrate that cell cycle 
arrest is difficult to overcome by overexpression of just one cyclin. 
       Intriguingly, human islets seem to utilize distinct cell cycle machinery. First, cyclin 
D3 is the most abundant D-type cyclin in human islets, while only variable and marginal 
quantities of cyclins D1 and D2 could be detected (Fiaschi-Taesch et al., 2010). In 
contrast, cyclin D2 is the most abundant D-type cyclin in mouse islets, as mentioned 
above. Second, CDK4 and CDK6 are easily detected in human islets at comparable 
levels, while mouse islets contain much more CDK4 than CDK6 (Fiaschi-Taesch et al., 
2010). Overexpression of cyclins D1/2/3 and/or CDK4/6 individually or in combination, 
all leads to variable increase in human beta cell replication, with cyclin D3 and CDK6 
being the most potent ones (Fiaschi-Taesch et al., 2010). However, while yielding cell 
cycle entry, overexpression of these cell cycle regulators also caused widespread DNA 
damage and failure to complete the cell cycle (Rieck et al., 2012). 
       CKI proteins mainly function as brakes for cell cycle progression. Recent studies 
have elucidated CKIs as critical inhibitors of beta cell proliferation. For the Cip/Kip 
group of CKIs, p21Cip1 and p27Kip1 are expressed at far higher levels than p57Kip2 in mice. 
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Studies of p21Cip1 and p27Kip1 have suggested that they might response to different 
metabolic or mitogenic cues for beta cell replication. Under normal physiological 
conditions, p27-/- mice are born with doubled beta cell mass due to excess beta cell 
proliferation during embryogenesis (Georgia & Bhushan, 2006). In insulin resistance 
mouse models, p27kip1 accumulates in beta cell nuclei. Ablation of p27kip1 in insulin 
resistant mice yielded compensatory beta cell proliferation, hyperinsulinemia, and 
prevented diabetes (Uchida et al., 2005). P27-/- mice treated with streptozotocin (STZ. It 
is transported into beta cells by GLUT2, and causes DNA damage and cell toxicity 
largely specific to beta cells) have better glycemic control than wild type mice due to 
higher beta cell proliferation rate (Georgia & Bhushan, 2006). Furthermore, gene 
silencing of p27kip1 in islets results in more beta cell replication and shorter duration of 
hyperglycemia after transplantation into induced hyperglycemic mice (S. T. Chen, Fu, 
Hsu, Huang, & Hsu, 2012). P21cip1 is up-regulated in HGF or placental lactogen 
overexpressing islets, and p21cip1 null islets are released from growth inhibition and 
demonstrate markedly enhanced proliferation in response to mitogenic stimulation by 
HGF and prolactin (Cozar-Castellano, Weinstock, et al., 2006). These studies suggest that 
p27kip might be responsible for metabolic signals such as hyperglycemia/lipotoxicity, 
whereas p21cip may respond to mitogenic growth factors (Cozar-Castellano, Weinstock, 
et al., 2006). Although p57Kip2 is the least abundant Cip/Kip protein among the three in 
mice, the loss of p57Kip2 in humans is associated with hyperinsulinism of infancy, 
indicating an important cell cycle inhibition function of p57Kip2 in human beta cells 
(Kassem et al., 2001). Indeed, suppression of p57Kip2 by shRNA in human islets results in 
higher beta cell proliferation rate. Importantly, newly replicated cells demonstrated 
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normal glucose-induced calcium influx, indicating their functionality (Dana, unpublished 
data). 
      The INK4 family of cell cycle inhibitors consists of four members: p16INK4a, 
p15INK4b, p18INK4c, and p19INK4d. P18-/- mice have approximately 40% more islets than 
wild type controls (Pei, Bai, Tsutsui, Kiyokawa, & Xiong, 2004), suggesting the release 
of cell cycle arrest after ablation of this cell cycle inhibitor. However, loss of p18 in the 
context of CDK4 deficiency (p18-/-; CDK4-/- mice) phenocopies CDK4-/- mice, which are 
diabetic with decreased beta cell mass. This finding suggests that releasing the brake 
(p18) without a functioning ‘accelerator’ leads to cell cycle arrest (Pei et al., 2004). 
Expression of p15 is downregulated during pancreatic endocrine tumorigenesis, 
indicating that p15 needs to be inactivated to promote islet hyperplasia (Karnik et al., 
2005). Expression of p16, but not other CKIs tested (p15, p18, p19, p21, p27), increases 
markedly with ageing (Krishnamurthy et al., 2006), alongside the decline of beta cell 
proliferation. Overexpression of p16 in young mice results in reduced beta cell 
proliferation, suggesting that accumulation of p16 in old mice prevents beta cell 
proliferation. Indeed, inactivation of p16 in old mice rescues the age-induced decrease in 
proliferation (Krishnamurthy et al., 2006). 
4.4.2	  Transcriptional	  and	  epigenetic	  regulators	  of	  cell	  cycle	  inhibitors	  
       Histone modifications of the genes encoding CKIs are dynamically regulated to 
control beta cell proliferation. MEN1 is the gene responsible for the endocrine tumor 
syndrome termed multiple endocrine neoplasia type 1 (MEN1), which is characterized by 
pituitary, parythyroid, and pancreatic islet tumors. The protein product of MEN1 is Menin 
(Stratakis & Marx, 2005), which associates with TrxG (trithorax group) histone 
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methyltransferases such as MLL, to promote the methylation of H3K4 (Karnik et al., 
2005). In islets, Menin-dependent MLL targets H3K4 methylation of p27 and p18, 
making Menin a negative regulator of beta cell proliferation. Menin mutations in mice 
(Men1+/-) result in decreased methylation of the p27 and p18 promoters, decreased 
expression of p27 and p18, increased CDK4 activity, and increased beta cell proliferation 
(Karnik et al., 2005; Schnepp et al., 2006). Furthermore, Menin expression is down-
regulated during pregnancy in parallel with p27 and p18, permitting adaptive beta cell 
proliferation. Overexpression of Men1 in beta cells results in gestational diabetes due to 
deficient beta cell replication (Karnik et al., 2007). 
       Bmi-1, a polycomb group protein (PcG), is a part of the polycomb-repressive 
complex 1 (PRC1), which possesses H2A ubiquitin E3 ligase activity. Together with 
PRC2, which possesses H3K27 methyltransferase activity mediated by Ezh2 of this 
complex, the Ink4a/Arf locus is repressed (H. Chen et al., 2009; Dhawan, Tschen, & 
Bhushan, 2009). Therefore, Bmi-1 and Ezh2 promote proliferation by down-regulating 
the cell cycle inhibitor p16. Bmi-1 plays an opposing role to MLL1 in controlling the 
Ink4a/Arf locus. In aging islets, Ezh2 and Bmi-1’s binding to the p16 locus is decreased, 
leading to de-repression of the p16 locus and increased MLL1 recruitment. As a result, 
H3K27me3 decreases and H3K4me3 increases in the p16 promoter. These chromatin 
alterations increase expression of p16, which is partially responsible for the decreased 
cell replication in aging islets (Dhawan et al., 2009). Bmi-1-/- mice display glucose 
intolerance caused by a concomitant decrease in beta cell proliferation and beta cell mass. 
Beta-cell-specific Ezh2 mutant mice have increased expression of p16 and p19, and also 
exhibit glucose intolerance with decreased beta cell proliferation (Dhawan et al., 2009). 
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        Besides the above-mentioned epigenetic regulators of CKIs, the ubiquitin-
proteasome pathway also plays a critical role in regulating beta cell replication. For 
example, the SCF ubiquitin ligase complex facilitates the degradation of p27 during the S 
phase of the cell cycle. Skp2 is a receptor component of SCF complex, and upon Skp2 
ablation, mice exhibit nuclear accumulation of p27. In Skp2-/- pancreas, the increased p27 
levels prevent mitosis and cause beta cell endoreduplication (cells undergo DNA 
synthesis without mitosis). As a result, Skp2-/- mice have larger beta cells but decreased 
beta cell mass, resulting in glucose intolerance for both normal conditions and HFD-
induced insulin resistance mouse models (Zhong et al., 2007). 
4.4.3	  External	  mitogens:	  hormones,	  growth	  factors,	  and	  nutrients	  
       A number of cell extrinsic stimuli can initiate beta cell replication, including 
hormones such as insulin, GLP-1, lactogens, and growth hormone; growth factors such as 
insulin-like growth factor (IGF), hepatocyte growth factor (HGF), epidermal growth 
factor (EGF), platelet-derived growth hormone (PDGF); and nutrients, including glucose 
and free fatty acids (FFA). The intracellular intermediates and pathways that link 
extracellular mitogens to the intracellular cell cycle machinery are not well understood. 
However, it is clear that the same intracellular signaling pathways (for example, 
PI3K/Akt pathway) are shared by different extrinsic stimuli, resulting in an orchestrated 
regulation of beta cell proliferation (Fig 1.10). 
Ins/IGFà IR/IGF-RàIRS1/2  
         Insulin and insulin-like growth factor (IGF) are two mitogens critical for beta cell 
proliferation. The receptors for these ligands are the tyrosine kinase receptors Insulin 
Receptor (IR) and IGF-1/2 Receptor (IGF-1/2R), respectively. Upon ligand binding, the  
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Figure 1.10 External mitogens of beta cells and and their intracellular signaling pathways. 
A number of extrinsic stimuli could trigger beta cell replication, including hormones like 
insulin, GLP-1, lactogens, growth hormone; growth factors like insulin-like growth factor 
(IGF), hepatocyte growth factor (HGF), epidermal growth factor (EGF), platelet-derived 
growth hormone (PDGF), and nutrients like glucose and free fatty acids (FFA). The 
intracellular intermediates and pathways that link these extracellular mitogens and the 
intracellular cell cycle machinery are not fully deciphered. But it is clear that same 
signaling pathways (for example, PI3K/Akt pathway) could be shared by different 
extrinsic stimuli, resulting in an orchestrated regulation of beta cell proliferation. !
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intracellular domains of insulin/IGF receptors become auto-phosphorylated, bind cellular 
scaffold proteins, and generate further intracellular signals. Mouse models that disrupt 
insulin or IGF1 signaling provide compelling evidence for insulin/IGF-mediated  
regulation of beta cell mass. Beta-cell-specific ablation of IR (βIRKO) in mice results in 
progressive glucose intolerance accompanied by defects in insulin secretion, reduced beta 
cell mass, and reduced expression of Glut2 and Glucokinase (Gck) (Kulkarni et al., 1999; 
Otani et al., 2004). Beta cell-specific IGFR ablation (βIGFRKO) also causes glucose 
intolerance, but has no affect on  
beta cell mass. Compound ablation of IR and IGFR in beta cells (βDKO) results in 
reduced beta cell mass and overt diabetes at 3 weeks of age (Ueki et al., 2006). Taken 
together, these results suggest that the IR pathway plays a more important role than IGFR 
in regulating beta cell mass (Kulkarni et al., 2002).  
     A recent study shows that overexpressing IR in the beta cells results in higher beta cell 
proliferation and helps ameliorate STZ-induced hyperglycemia (M. H. Kim, Hong, & 
Lee, 2013). However, it has been controversial whether IGF1 can also stimulate beta cell 
proliferation in vivo. One group reports that overexpressing IGF1 in beta cells causes 
increased replication after STZ treatment (George et al., 2002), while another study 
shows that IGF1 overexpression does not promote beta cell replication. This second study 
finds that IGF1 functions as an antiapoptotic factor after STZ treatment, indicating that 
IGF1 is not an in vivo islet growth factor (K. Robertson et al., 2008). Further studies are 
necessary to investigate the mitogenic effect of IGF1 on beta cells using different beta 
cell regenerative models. 
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      Insulin receptor substrates (IRS) are essential intermediates for insulin/IGF signaling 
(M. F. White, 2002). Humans have three IRS proteins, IRS1, 2, and 4, while rodents 
express all four IRS proteins, including IRS-3 (M. F. White, 2002). IRS proteins activate 
PI3K and ERK phosphorylaiton cascades, which stimulate beta cell replication and 
promote survival. IRS1 and IRS2 are the two most important downstream effectors of 
Ins/IGF1 signaling, although IRS1 and IRS2 mutants display distinct phenotypes. IRS1-/- 
mice develop mild glucose intolerance accompanied with a two-fold increase of beta cell 
mass relative to wild type mice. In contrast, IRS2-/- mice become diabetic without beta 
cell mass expansion, indicating that IRS2 plays a more critical role in modulating beta 
cell mass expansion during periods of increased metabolic demand (Withers et al., 1998). 
HGFàc-Met 
       HGF and its receptor c-Met play essential roles in regulating beta cell proliferation. 
Overexpression of HGF in beta cells causes increased beta cell replication and 
hypoglycemia (Garcia-Ocana et al., 2000). Beta-cell specific ablation of c-Met results in 
smaller islets, decreased Glut-2 expression, impaired insulin secretion, and glucose 
intolerance (Dai, Huh, Thorgeirsson, & Liu, 2005). Surprisingly, beta cell mass and beta 
cell proliferation are not affected (Roccisana et al., 2005), indicating that HGF/c-Met 
signaling is not required for maintaining beta cell mass under normal conditions. 
Interestingly, pancreas-specific ablation of c-Met in mice causes increased susceptibility 
to STZ-induced diabetes (Mellado-Gil et al., 2011), indicating that HGF/c-Met signaling 
is critical for beta cell survival after injury. The same mouse model also results in 
gestational diabetes with impaired beta cell proliferation at pregnant day 15 and reduced 
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beta cell mass at pregnant day 19, suggesting that HGF signaling is required for maternal 
beta cell mass expansion during pregnancy (Demirci et al., 2012). 
GLP-1/GIP 
       GLP-1 and GIP are secreted from the intestinal L-cells and K-cells, respectively, in 
response to carbohydrates and fats (Buteau, Foisy, Joly, & Prentki, 2003). GLP-1 and 
GIP account for almost the entire incretin effect (Brubaker & Drucker, 2004). Since 
T2DM is associated with resistance to GIP but not GLP-1, current therapeutic research is 
focused on GLP-1 (Brubaker & Drucker, 2004). GLP-1 is a potent treatment for diabetes 
because it acutely potentiates glucose-stimulated insulin secretion (Buteau et al., 2003), 
promotes beta cell proliferation, and displays antiapoptotic activity (Buteau et al., 2004). 
GLP-1 has a very short half life (2-6 mins) (G. Xu, Stoffers, Habener, & Bonner-Weir, 
1999); therefore, it’s long-lived analog, Exendin-4, has been popularly investigated on its 
role in beta cell function. Although sustained overexpression of Exendin-4 does not alter 
glucose homeostasis or beta cell mass (Baggio, Adatia, Bock, Brubaker, & Drucker, 
2000), short term Exendin-4 treatment in mice results in increased beta cell proliferation 
and beta cell mass under both basal conditions and after partial pancreactomy (G. Xu et 
al., 1999). During metabolic challenges, GLP-1 or Exendin-4 infusion results in 
amelioration of diabetes in Zucker diabetic rats and prevents hyperglycemia in db/db 
mice, respectively (Farilla et al., 2002; Q. Wang & Brubaker, 2002).  
       The mechanism of GLP-1 activity in pancreatic beta cells has been extensively 
studied, and multiple signaling pathways are involved (Z. Liu & Habener, 2008). GLP-1 
binds its high affinity receptor GLP-1R, which activates adenylate cyclase and increases 
intracellular cAMP levels. cAMP stimulates multiple downstream pathways, including 
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PKA, MAPK/ERK, and PI3K/Akt (Cornu et al., 2010). Studies have also shown that 
GLP-1 induces beta cell proliferation via trans-activation of EGFR and translational 
induction of IGF-1R. These proteins form an autocrine loop with IGF-2 and IGF-1R to 
activate the IRS2/Akt signaling pathway (Buteau et al., 2003; Cornu et al., 2010). Further 
downstream factors involved in GLP-1-induced beta cell proliferation include: SirT1, 
FoxO1 (SirT1-dependent), Skp2 (PI3K-dependent) (Tschen, Georgia, Dhawan, & 
Bhushan, 2011), Protein Kinase zeta (PI3K-dependent), mTOR (AMPK-dependent) 
(Miao et al., 2013), and pdx1 (Bastien-Dionne, Valenti, Kon, Gu, & Buteau, 2011; 
Brubaker & Drucker, 2004; Buteau et al., 2001; Buteau, Spatz, & Accili, 2006; X. Wang, 
Zhou, Doyle, & Egan, 2001). Cyclin A2 and cyclin D1 have also been suggested to 
mediate GLP-1 induced beta cell proliferation (Friedrichsen et al., 2006; Song et al., 
2008). 
EGF/EGFR, PDGF/PDGFR 
       Although EGFR can be trans-activated by GLP-1 (Buteau et al., 2003), the 
downstream factors of EGFR in beta cells are not well defined. EGFR-/- mice display 
failed beta cell replication and develop glucose intolerance both under basal conditions 
and upon the metabolic challenges of HFD or pregnancy, while maintained normal 
adaptive beta cell mass expansion after PDL (Hakonen et al., 2011; Miettinen et al., 
2006).  
       PDGF (platelet-derived growth factor) acts through PDGF-R, which activates Ezh2 
in an ERK1/2 dependent manner. Declining PDGF-R associates with down-regulation of 
Ezh2, increased p16, and decreased beta cell proliferation during aging. Ablation of 
PDGF-R in the young mice results in impaired glucose tolerance due to decreased beta 
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cell replication and halved beta cell mass. Overexpressing PDGF-R in old mice induces 
beta cell replication, highlighting the possibility of utilizing PDGF-R in beta cell 
replacement therapy (H. Chen et al., 2011). However, PDGF-R is not as highly expressed 
in human beta cells compared to mouse beta cells, making investigating its function in 
the human beta cells incredibly difficult. 
Circulating factors: Glucose, betatrophin 
       Circulating factors such as glucose, fatty acids, and betatrophin also play an 
important role in regulating beta cell mass expansion. One main critique of insulin acting 
as beta cell mitogen is that insulin deficient neonatal mice actually have larger islets than 
their control littermates. In fact, the insulin-/- mice have increased beta cell proliferation 
(Duvillie et al., 1997; Duvillie et al., 2002), indicating that insulin is dispensable for beta 
cell development and might actually serve as a negative regulator of beta cell replication 
during embryogenesis.  
        In contrast to the observed effects of insulin, glucose infusion has a mitotic effect for 
beta cells both in vitro and in vivo (Levitt et al., 2011; Yi, Park, & Melton, 2013). 
Although the mechanism linking glucose and beta cell replication is not fully understood, 
it has been suggested that glucose sensing and glucose metabolism in beta cells is the key 
signal stimulating beta cell replication in vivo, rather than glucose level per se. Providing 
evidence for this theory is the beta-cell specific Glucokinase (Gck) mutant mouse model. 
In these Gck mutant mice, the first step of glycolysis in beta cells is ablated, resulting in 
uncoupled hyperglycemia with glucose sensing and metabolism. Gck+/- mutant mice 
develop hyperglycemia following HFD feeding and fail to expand beta cell mass 
compared to control mice (Terauchi et al., 2007). Furthermore, beta cell specific Gck-/- 
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mutants exhibit reduced beta cell proliferation, increased beta cell apoptosis, and severe 
hyperglycemia (Porat et al., 2011), suggesting that glycolytic flux mediates beta cell 
proliferation. This GCK-induced beta cell replication is KATP channel-dependent and 
calcium-dependent, ultimately causing down-regulation of cyclin D2 during S-G2-M 
phase (Porat et al., 2011; Salpeter et al., 2011). Glucose has also been proposed to induce 
beta cell proliferation via calcium and cAMP dependent activation of the PI3K/Akt 
pathway, which leads to down-regulation of FoxO1, menin, and p27 (Martinez, Cras-
Meneur, Bernal-Mizrachi, & Permutt, 2006; H. Zhang et al., 2012), but these effects 
might be secondary to insulin secretion and signaling.  
       Although glucose infusion has a mitotic effect on beta cells, chronic hyperglycemia 
has vicious effects on beta cell function partially due to glucotoxicity. The mechanism of 
glucotoxicity is not well understood. One study suggested that glucose promotes beta cell 
apoptosis in synergy with FFA due to impaired IRS signaling and activated GSK3b 
(Tanabe et al., 2011).  
       In summary, the roles of insulin and glucose in regulating beta cell proliferation may 
not be entirely separable. Both mitogens share common intracellular pathways including 
PI3K/Akt and cAMP. One microarray expression profiling dataset shows that glucose 
and insulin treatment of beta cells results in transcriptional regulation of a common set of 
genes, further supporting overlapping roles of glucose and insulin in beta cell regulation 
(Ohsugi et al., 2004). 
      In a recent study, a pharmacologically induced insulin resistance mouse model 
reveals a potential circulating mediator of beta cell proliferation termed betatrophin (Yi et 
al., 2013). Expression of betatrophin is up-regulated in liver and fat in several models of 
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beta cell regeneration including insulin resistant mice, ob/ob mice, and pregnant mice. 
Overexpression of betatrophin in the liver induces a rapid and specific increase of beta 
cell proliferation in mice, suggesting that betatrophin may be secreted by peripheral 
tissues and responsible for adaptive beta cell proliferation (Yi et al., 2013). However, the 
same insulin resistance model does not trigger human beta cell proliferation after human 
islets are transplanted into these insulin resistant mice, producing doubts about the 
importance of betatrophin in human islets. It is critical to decipher how and where 
betatrophin acts to determine if it is acting directly on beta cells. Also, betatrophin was 
previously shown to regulate fatty acid metabolism and serum triglyceride (TG) levels. It 
is crucial to decouple the indirect effects of FFA and TG on beta cell proliferation with 
the potential beta cell mitogenic function of betatrophin. 
4.4.4	  PI3K/Akt	  pathway	  
       The intracellular signaling transmitters between extracellular mitogenic signals and 
the cell cycle machinery and transcriptional regulation of beta cell function are well 
defined. Many signal transduction pathways are involved, including PI3K/Akt, 
MAPK/ERK, cAMP/PKA pathway, and STAT5/JAK2 pathways (Burns, Squires, & 
Persaud, 2000). I will focus on PI3K/Akt pathway.  
        The PI3K/Akt signaling cascade is a well-defined pathway regulating beta cell 
replication (Tarabra, Pelengaris, & Khan, 2012) (Fig 1.11). It is essential for beta cell 
mitogenesis induced by glucose (Srinivasan, Bernal-Mizrachi, Ohsugi, & Permutt, 2002), 
Ins/IGF/IRS (Lingohr et al., 2003), HGF (Vasavada, Wang, et al., 2007), and GLP-1 
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Figure 1.11 PI3K/Akt pathway. PI3K/Akt signaling cascade is one of the best-defined 
pathways regulating beta cell replication. It is essential for beta cell mitogenesis induced 
by glucose, Ins/IGF/IRS, HGF, and GLP-1. PI3K activates PDK1 which in turn activates 
Akt, and function through further downstream targets including mTOR, FoxO1, GSK3b, 
and PKCzeta. !
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 (Cornu et al., 2010). It also plays an important role in anti-apoptosis. PI3K activates 
PI3K dependent protein kinase 1 (Pdk1), which in turn activates Akt, and functions 
through further downstream targets including mTOR, FoxO1, GSK3b, and PKCzeta. 
Beta cell specific ablation of Pdk1 leads to progressive hyperglycemia as a result of 
reduced islet mass and decreased Glut2 expression (Hashimoto et al., 2006). Beta cell 
specific ablation of phosphatase with tensin homology (PTEN), a negative regulator of 
PI3K, results in enhanced PI3K signaling. In turn, this model increases beta cell mass and 
maintains Glut2 and Pdx1 expression, acting to protect both HFD- and genetically-
induced (db/db) hyperglycemic phenotypes (L. Wang et al., 2010). It is noteworthy that 
PTEN-ablated mice maintain normal beta cell function. In contrast, Akt-overexpressing 
mice exhibit augmented beta cell mass, compromised beta cell function (diminished 
relative quantity of insulin release), and hypoglycemia due to inability to autoregluate 
insulin secretion (Tuttle et al., 2001). This discrepancy illustrates the difference between 
removing a brake and adding an accelerator.  
       Downstream effectors of Akt in the beta cell are not fully mapped. Several Akt-
controlled factors have shown critical function in both positive and negative regulation of 
beta cell proliferation, including FoxO1, GSK3b, and mTORC. For example, Akt down-
regulates FoxO1 via phosphorylation-mediated translocation of FoxO1 from the nucleus 
to the cytoplasm, where it is ultimately degraded (Kitamura & Ido Kitamura, 2007). 
FoxO1 functions as a negative regulator of beta cell proliferation by (1) increasing 
expression of the cell cycle inhibitors p27 and p21 (Buteau & Accili, 2007); and (2) 
repressing Pdx1 expression by competitively binding to its promoter with the Pdx1 
activator, FoxA2 (Kitamura & Ido Kitamura, 2007). Therefore, FoxO1 and Pdx1 exhibit 
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mutually exclusive nuclear localization in beta cells (Kitamura et al., 2002), and 
expansion of beta cell mass in response to insulin resistance requires nuclear exclusion of 
FoxO1 (Okamoto et al., 2006). Constitutively active FoxO1 in the nucleus accelerates the 
onset of diabetes due to impaired beta cell replication (Okamoto et al., 2006), while 
haplodeficiency of FoxO1 in an insulin resistance model reserves beta cell failure through 
partially restored beta cell proliferation and increased Pdx1 expression (Kitamura et al., 
2002). 
       Akt also negatively regulates GSK3b by phosphorylation, which leads to its eventual 
degradation (Y. Liu et al., 2010). GSK3b is suggested to form a negative feedback loop 
with the PI3K/Akt pathway to prevent the overshooting of the PI3K signaling. 
Overexpression of GSK3b in the beta cells results in impaired glucose tolerance, 
decreased beta cell mass, decreased beta cell proliferation, and decreased Pdx1 
expression (Z. Liu, Tanabe, Bernal-Mizrachi, & Permutt, 2008). In contrast, beta cell 
specific GSK3b ablation mice exhibit improved glucose tolerance, increased beta cell 
mass, and protection of diabetes induced by HFD (Y. Liu et al., 2010). GSK3b-/- mice 
have elevated IRS/PI3K/Akt protein levels and increased Pdx1 expression, further 
suggesting that GSK3b forms a negative feedback loop with PI3K/Akt pathway. In vitro 
studies of human islets demonstrate that inhibition of GSK3b alone or with activated 
mTORC results in down-regulation of p27 and increased beta cell proliferation (H. Liu et 
al., 2009; Stein, Milewski, Hara, Steiner, & Dey, 2011). 
       mTORC and its repressor Tsc1/2 also function downstream of PI3K/Akt, and 
integrate signals from nutrients and growth factors to mediate beta cell replication 
(Blandino-Rosano et al., 2012). mTOR is a serine/threonine kinase that is essential for 
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cell growth and proliferation. Akt induces mTOR/mTORC1 signaling by phosphorylating 
and inactivating its repressor Tsc2. mTORC1 promotes beta cell proliferation by (1) 
deactivating 4E-BP proteins and releasing elF4E, which leads to transcriptional up-
regulation of its target genes; and (2) inducing tobosomal protein S6 kinase (S6K) and its 
targets. mTORC also forms feedback inhibition loops with the IRS/PI3K pathway. 
Overexpressing mTORC1 and inactivating Tsc2 both result in increased beta cell 
proliferation and beta cell mass (Balcazar et al., 2009; Rachdi et al., 2008). 
Overexpressing S6K in beta cells promotes more beta cells to enter the cell cycle, but 
there is no increase in the number of beta cells completing cell division. This discrepancy 
may be explained by increased p16 and p27 levels and partial inhibition of cyclin 
D/CDK4 and cyclin E/CDK2 (Elghazi et al., 2010). These mice also exhibit lower IRS1/2 
levels and decreased p-GSK3b and p-FoxO1 by the feedback inhibition of S6K (Elghazi 
et al., 2010). A beta cell-specific S6K ablation mouse model will help elucidate its role in 
beta cell replication and function.  
       PKC zeta is an atypical isoform of PKC. It is found to be downstream of PI3K/PDK1 
signaling and promotes cell proliferation in various cell types (Chou et al., 1998), but its 
role in beta cells is not well understood. GLP-1 induced beta cell replication in vitro is 
PKC zeta dependent (Buteau et al., 2001). After activation, PKC zeta translocates from 
the cytoplasm to the nucleus and modifies its target genes expression. Both HGF and 
PTHrP also induce beta cell replication in a PKC zeta dependent manner. Knockdown of 
PKC zeta blocks beta cell proliferation in vitro (Vasavada, Wang, et al., 2007), while 
overexpressing it increases beta cells replication. Transgenic mice with constitutively 
activate PKC zeta in beta cells exhibit increased beta cell proliferation, beta cell mass, 
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and insulin secretion (Velazquez-Garcia et al., 2011). The increased proliferation is 
associated with upregulation of cyclin Ds and downregulation of p21. mTOR is also 
suggested to be downstream of PKC zeta since rapamycin treatment abolishes the 
increase in beta cell proliferation and glucose tolerance in the PKC zeta overexpressing 
mice. Other potential targets of PKC zeta need to be investigated to fully understand its 
role in beta cell proliferation. 
4.4.5	  Transcription	  factors	  
       In addition to kinases, transcription factors also play important roles as intracellular 
proteins that translate external cues into cell intrinsic responses. FoxM1 is a proliferation-
specific member of the Fox family of transcription factors (H. Zhang et al., 2006). 
Pancreas-specific FoxM1 ablation induces overt diabetes in male mice at 9 weeks of age 
(H. Zhang et al., 2006). In female mice, FoxM1 is up-regulated in islets during 
pregnancy, and ablation of FoxM1 causes gestational diabetes due to the resulting 
deficiency in beta cell replication (H. Zhang et al., 2010). FoxM1 is also required for beta 
cell proliferation after partial pancreatectomy and obesity-induced beta cell mass 
expansion (Ackermann Misfeldt, Costa, & Gannon, 2008; Davis et al., 2010). Targets of 
FoxM1 include cyclin D for G1/S phase, and CDK1 for G2/M phase (Davis et al., 2010). 
But how FoxM1 regulates beta cell mass expansion under different physiological stimuli 
is not fully understood. 
       Hnf4α is one of the MODY genes. Mutations of Hnf4α in humans give rise to 
MODY1, which is characterized by impaired insulin secretion. Beta cell specific 
conditional ablation of Hnf4α in mice results in impaired glucose tolerance during 
pregnancy. The beta cell mass of mutant mice is approximately half of that of the control 
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mice due to decreased beta cell replication (Gupta et al., 2007). A direct transcriptional 
target of HNF4α, ST5, is suggested to link HNF4α to the ERK pathway to mediate beta 
cell replication. However, although overexpression of Hnf4α in the human islets increases 
cell cycle entry 300 folds, it is not sufficient for completion of the cell cycle due to DNA 
damage response and loss of beta cell lineage fidelity (Rieck et al., 2012). 
       Carbohydrate response element-binding protein (ChREBP) is a lipogenic glucose-
sensing transcription factor. ChREBP translocates into the nucleus upon glucose 
stimulation and up-regulates fatty acid synthesis genes in a glucose-dependent manner. 
Although chREBP is known to play a lipogenic role in the liver, its role in beta cells has 
only been partially elucidated. ChREBP mutant mouse islets exhibit decreased glucose-
stimulated proliferation and decreased expression of cell cycle accelerators, while 
overexpressing chREBP amplifies glucose-stimulated proliferation in rat and human beta 
cells (Metukuri et al., 2012). This study suggests that chREBP mediates glucose-
stimulated beta cell proliferation; although how chREBP is regulated by glucose and how 
chREBP controls cell cycle machinery need more investigation. 
       The calcineurin/Nuclear Factor of Activated T cells (cn/NFAT) pathway regulates 
gene transcription to mediate proliferation, survival, and differentiation in various cell 
types (Wu, Peisley, Graef, & Crabtree, 2007). 10-30% of patients administrated with 
immunosuppressant drugs such as tacrolimus, a calcineurin inhibitor, develop diabetes, 
suggesting that calcineurin signaling is essential for adult beta cell function (Goodyer et 
al., 2012). A beta-cell specific ablation of the calcineurin subunit, calcineurin b1 (Cnb1) 
in mice results in age-dependent diabetes characterized by decreased beta cell replication 
and mass (Heit, Apelqvist, et al., 2006). This phenotype is accompanied by decreased 
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expression of essential beta cell factors, such as Ins1, Pdx1, and Glut2. Cell cycle 
regulators are also down-regulated, including cyclin D2 (Heit, Apelqvist, et al., 2006), 
which may explain the decreased beta cell proliferation in the mutant mice. Interestingly, 
overexpressing NFAT is sufficient to induce beta cell proliferation and beta cell mass 
expansion in vivo (Heit, Apelqvist, et al., 2006). Later on, an Ngn3-Cre driven deletion of 
Cnb1 reveals that cn/NFAT is required for neonatal beta cell replication as well. Neonatal 
mutant mice exhibit a 7-fold decrease in beta cell mass and a 4-fold decrease of beta cell 
proliferation at 26 days old (Goodyer et al., 2012). Cell cycle regulators cyclin A2, D2 
and FoxM1 are direct targets of NFAT by ChIP assays on islets. Pathways that mediate 
cn/NFAT signaling are not well understood and require further investigation (Heit, 2007). 
4.5	  Reversible	  maternal	  beta	  cell	  mass	  expansion	  during	  pregnancy	  
4.5.1	  Insulin	  resistance	  during	  pregnancy	  
       During normal pregnancy, a complex endocrine-metabolic adaptation process occurs, 
which includes progressive insulin resistance, moderate increases in blood glucose levels, 
and changes in circulating FFA, TG, and cholesterol levels (Di Cianni, Miccoli, Volpe, 
Lencioni, & Del Prato, 2003). Insulin resistance begins around mid-gestation and 
progresses throughout the third trimester. Regardless of initial condition, during the third 
trimester insulin resistance reaches levels similar to those of T2DM patients (Buchanan & 
Xiang, 2005; Di Cianni et al., 2003). There is an estimated 47% reduction in insulin 
sensitivity in obese women and a 56% reduction of insulin sensitivity in lean women in 
the 3rd trimester of gestation. This insulin resistance results from a combination of 
increased maternal adiposity and insulin desensitization, induced by multiple hormones 
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and cytokines. Potential contributing factors include (1) progesterone, which causes 
glucose intolerance by impairing insulin-suppressed hepatic gluconeogenesis; (2) 
glucocorticoids, which in excess, impair insulin receptor phosphorylation and cause 
insulin resistance; (3) leptin, which is encoded by the obese (ob) gene, and secreted by 
the adipose tissue, and (4) lactogens (Lain & Catalano, 2007).  
        Gestational insulin resistance is not a pathological condition; rather, it presents a 
necessary adaptation to meet the energy demand of continually feeding and developing 
fetus (Burdge, Hanson, Slater-Jefferies, & Lillycrop, 2007; Lehnen, Zechner, & Haaf, 
2013; Reece, Leguizamon, & Wiznitzer, 2009). The molecular mechanism of gestational 
insulin resistance involves impaired glucose transport and intracellular glucose 
metabolism in the skeletal muscle, and to a lesser extent, adipose tissue. Although it is 
normal to develop some degree of insulin resistance during pregnancy, these symptoms 
can worsen in pregnant women diagnosed with GDM. For example, phosphorylation of 
IRS1 is reduced in women with GDM by 41%, compared to a 28% reduction during a 
normal pregnancy. GLUT4 in adipose tissue is also reduced more in GDM subjects 
compared to normal pregnant women, indicating impaired insulin signaling in the 
periphery tissue. The gestational insulin resistance rapidly resolves after delivery. 
4.5.2	  Beta	  cell	  proliferation	  during	  pregnancy	  
       In order to meet the higher demand of insulin secretion to maintain normal glucose 
homeostasis, beta cells mass increases 2-4 fold during pregnancy in rodents (Sorenson & 
Brelje, 1997), and 1.5-2 fold in humans (Butler et al., 2010). The change in islet size 
largely results from dramatically increased beta cell proliferation and beta cell 
hypertrophy, which provides a perfect example of the plasticity of beta cells. 
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Furthermore, to compensate for increased insulin resistance during pregnancy, beta cell 
function improves both by lowering the glucose-stimulated insulin secretion threshold 
and by increasing first phase insulin secretion. Multiple hormones help modify insulin 
secretion, including estrogens, progesterone, and glucocorticoids(Di Cianni et al., 2003). 
The peak of beta cell proliferation occurs about two-thirds into the gestation period, 
which roughly correlates with the peak of placental lactogen (PL), causing many 
researchers to speculate that PL regulates beta cell proliferation during pregnancy (Fig 
1.12). 
4.5.3	  Molecular	  mechanisms	  for	  beta	  cell	  proliferation	  during	  pregnancy 
        β-cell proliferation during pregnancy is regulated by many factors, and has been 
only partly elucidated through previous studies (Rieck & Kaestner, 2010; Sorenson & 
Brelje, 1997). One of the most important hormonal factors during pregnancy is lactogen. 
There are two kinds of lactogens in mice and humans: prolactin (Prl) and placental 
lactogen(PL), both of which are induced during pregnancy. In mice, Prl peaks at day 6 of 
gestation and decreases when PL levels begin to rise. PL is expressed from approximately 
day 8 of gestation and peaks around day 12 during pregnancy (Brelje et al., 1993a). Both 
Prl and PL share a common receptor, prolactin receptor (Prl-R), which is a member of the 
cytokine receptor superfamily (Brelje et al., 1993a). Lactogens increase beta cell 
proliferation and insulin secretion both in vitro and in vivo (Fujinaka, Takane, Yamashita, 
& Vasavada, 2007). In fact, the onset of PL coincides with the earliest detection of 
increased beta cell proliferation during pregnancy, and culturing both human and rodent 
islets in medium containing PL induces beta cell proliferation and enhanced insulin 
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Figure1.12 (Adapted from (Karnik et al., 2007; Schraenen, de Faudeur, et al., 2010; 
Soares, 2004)) Beta cell proliferation and lactogen dynamics during pregnancy. a) Beta 
cell proliferation during pregnancy peaks at around 12 to 15 days during gestation, which 
rapidly decreases to pre-pregnancy level after delivery. b) Beta cell mass increases 2-4 
times during pregnancy in rodents due to both beta cell proliferation and beta cell 
hypertrophy. It rapidly decreases to pre-pregnancy stage several days after delivery due 
to beta cell apoptosis. c) Prolactin exhibits a twice-daily surge during early pregnancy, 
produced by the maternal anterior pituitary. During mid-gestation, placental lactogen-I 
peaks at around 11 days of pregnancy. During the second half of gestation, placental 
lactogen-II dominates. The fetal pituitary begins producing prolactin at the end of 
pregnancy. d) Time-dependent changes in the number of up-regulated cell cycle regulator 
genes during pregnancy. Most of the cell cycle regulator genes peak at around 9.5 days of 
pregnancy, when beta cell proliferation begins to increase. 
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secretion (Brelje et al., 1993a). A transgenic mouse line overexpressing Prl exhibits 
protection against streptozotocin-induced beta cell specific injury via increased beta cell 
proliferation and hypertrophy (Fujinaka et al., 2007). Furthermore, Prl-R ablation mice 
show a 25-40% reduction in beta cell mass at non-pregnant stage (Freemark et al., 2002). 
Since Prl-R-/- females are sterile, Prl-R heterozygous mutants (Prl-R+/-) are studied during 
pregnancy. Prl-R+/- pregnant mice exhibit decreased beta cell proliferation and impaired 
glucose tolerance. All of these studies validate the critical role of lactogen signaling in 
beta cell proliferation and function during gestation (Huang, Snider, & Cross, 2009). 
       Prl-R, like other cytokine receptors, acts through a complex signaling network, 
including IRSs/PI3K, MAP kinase, and most importantly, Janus kinase 2/signal 
transducer and activator of transcription 5 (JAK2/STAT5) (Amaral et al., 2004). 
Activation of the JAK2 kinase by Prl-R in turn phosphorylates Prl-R at specific tyrosine 
residues. STAT5 proteins are recruited to these phosphorylated tyrosine residues on Prl-R 
and are also phosphorylated by JAK2. Phosphorylated STAT5 then dimerizes and 
translocates into the nucleus, where it regulates gene expression as a transcription factor 
(Amaral et al., 2004). STAT5 is critical for several cytokine signaling pathways, 
including Prl/PL, growth hormone, IL2, and IL3 (X. Liu et al., 1997). STAT5 
phosphorylation and nuclear translocation is up-regulated in islets during pregnancy by 
Prl/PL signaling (Friedrichsen et al., 2003). An in vitro study shows that STAT5 is 
sufficient to drive proliferation of rat beta cells by activating the expression of Cyclin D2 
(Friedrichsen et al., 2003). Furthermore, Stat5a ablation mice demonstrate deficiency in 
both mammary gland development and lactogenesis due to loss of prolactin signaling (X. 
Liu et al., 1997). Beta cell specific dominant-negative STAT5 mice display higher blood  
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Figure 1.13 (Adapted from (Jiao, Rieck, Le Lay, & Kaestner, 2013)) Molecular 
mechanisms for beta cell proliferation during pregnancy. Latogens are key hormones 
regulating beta cell proliferation during pregnancy. After PL/PRL binds to PRL-R, the 
receptor dimerizes and triggers downstream signaling, including PI3K/Akt pathway, 
MAPK/ERK pathway, and JAK2/STAT5 pathway. STAT5 is recruited to phosphorylated 
PRL-R and is phosphorylated in turn by JAK2. Phosphorylated STAT5 then dimerizes 
and translocates into the nucleus to regulate gene expression as a transcription factor. A 
group of known targets of STAT5 are up-regulated during pregnancy, including Prl-r, 
Glut-2, Glucokinase and Cyclin D2, resulting in increased beta cell proliferation and 
insulin secretion. 
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glucose levels and lower beta cell proliferation rates compared to control mice after six 
months on HFD, which establishes STAT5 as a critical factor for beta cell proliferation 
and function in vivo (Jackerott et al., 2006). 
       Some targets of STAT5, such as menin and p27/p18, are down-regulated during 
pregnancy to allow beta cell proliferation (Hughes & Huang, 2011). In contrast, 
JAK2/STAT5 up-regulates anti-apoptotic protein Bcl-XL to promote beta cell survival 
during pregnancy (Fujinaka et al., 2007). Cyclin D2 is a STAT5 target gene that leads to 
beta cell proliferation in vitro (Friedrichsen et al., 2003). Serotonin levels are also 
increased in beta cells during pregnancy in a JAK2/STAT5-dependent way, but its 
biological role needs to be further investigated (Schraenen, Lemaire, et al., 2010). Other 
regulators, such as FoxM1, are up-regulated in maternal islets during pregnancy. 
Deficiency in FoxM1 results in decreased beta cell proliferation and GDM (H. Zhang et 
al., 2010). Glucokinase activity is also upregulated in the beta cells during pregnancy by 
prolactin, which partially explains the increased glucose-stimulated insulin secretion 
during pregnancy (Weinhaus, Stout, Bhagroo, Brelje, & Sorenson, 2007). Interestingly, 
previous study in our lab demonstrated that Cytokine-induced SH2 domain-containing 
(Cish) and Suppressor of the cytokine signaling 2 (Socs2), two targets and negative 
regulators of STAT5 signaling, are also upregulated during pregnancy.  
       mRNA expression analysis of cell cycle genes in islets of pregnant mice reveals an 
orchestrated peak of cell cycle genes at P9.5, after which beta cell replication increases, 
and peaks at between P12.5 and P14.5 (Schraenen, de Faudeur, et al., 2010). How this 
sharp peak of cyclin genes regulates a sustained cell replication peak for nearly a week is 
not fully understood. 
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5.	  Summary	  and	  specific	  aims	  
       Previous studies have established beta cell proliferation as the main mechanism of 
maintaining beta cell mass during adulthood in rodents. The regenerative capacity of beta 
cells has been demonstrated in multiple experimental schemes including HFD, 
pregnancy, and pancreas injury. The extracellular mitogens and intrinsic cell cycle 
regulators and signaling pathways that regulate beta cell proliferation have been 
intensively investigated for better understanding the mechanisms underlying beta cell 
replication. The ultimate goal is to provide an unlimited source of beta cells for the 
regenerative therapy strategy for diabetes. 
        This dissertation describes our effort to investigate the function of several potential 
beta cell replication regulators in different models stimulating beta cell replication. 
Chapter 2 presents the data to answer the question of whether CISH and SOCS2 
negatively regulate beta cell replication during pregnancy. Lactogens are the main 
hormone factor stimulating beta cell proliferation during pregnancy. STAT5 is the key 
downstream effector of lactogen signaling. CISH and SOCS2 are two negative regulators 
of STAT5 signaling, composing a negative feedback loop of the lactogen/STAT5 
signaling. Expressions of Cish and Socs2 are upregulated during pregnancy. Therefore, 
we hypothesized that ablation of Cish and/or Socs2 may result in upregulated STAT5 
signaling and increased beta cell proliferation during pregnancy. Chapter 3 describes 
results regarding the role of HNF-4α in regulating beta cell proliferation during obesity. 
Previous studies in our lab demonstrate that HNF-4α is required for beta cell replication 
during pregnancy. We hypothesized that HNF-4α is also required for beta cell 
proliferation during obesity, which is another insulin-resistant model and is more relevant 
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to human disease. Chapter 4 presents our progress in investigating the role of betatrophin 
on human beta cell replication. Betatrophin has been suggested to be a potent beta cell 
mitogen in mouse. We are curious about its role in human beta cells. Conclusions, 
implications and future directions for this dissertation are presented in Chapter 5. In 
addition, Appendices describes my effort to characterize epigenetic profiles for beta cell 
development during embryogenesis by performing FOXA2 and NKX6.1 chromatin 
immunoprecipitation on Ngn3+ endocrine progenitor cells. 
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Chapter 2   CISH has no non-redundant functions in glucose homeostasis or beta 
cell proliferation during pregnancy in mice 
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Abstract	  
       Beta cell proliferation increases during pregnancy in response to increased lactogen 
levels. This response is mediated by the Janus kinase 2/signal transducer and activator of 
transcription 5 (JAK2/STAT5) signaling pathway. Activation of the JAK2/STAT5 
pathway leads to transcriptional up-regulation of Cytokine-induced SH2 domain-
containing (Cish) and Suppressor of the cytokine signaling 2 (Socs2), two members of the 
“Suppressor of cytokine signaling” (SOCS) family of genes, which form a negative 
feedback loop. It is not known whether CISH and SOCS2 play key roles in regulating 
beta cell proliferation or beta cell function during pregnancy. Here, I examined whether 
conditional gene ablation of Cish in the mouse pancreas improved beta cell proliferation 
and beta cell function during pregnancy. Beta cell proliferation was quantified by 
Bromodeoxyuridine (BrdU) labeling. Glucose homeostasis was examined by glucose 
tolerance tests (GTT) and plasma insulin level measurements. Q-PCR was utilized to 
determine mRNA expressions of other Socs genes and target genes of p-STAT5 related to 
beta cell function and beta cell proliferation. There are no differences in beta cell 
proliferation or glucose homeostasis between the Cish mutant group and the control 
group. p-STAT5 protein levels are the same in the Cish mutant mice and the control 
mice. Socs2 gene expression is higher in islets of the Cish mutant mice than control mice 
at pregnant day 9.5. Other Socs genes, Socs3-Socs7, are expressed at the same levels in 
control and mutant mice. Global Socs2-/- mice were also examined, and they exhibit 
increased beta cell mass during pregnancy. In summary, my results suggest that CISH has 
no non-redundant functions in beta cell proliferation or glucose homeostasis during 
pregnancy. Socs2 might be compensating for the loss of Cish during pregnancy. 
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Introduction	  
     An insufficient number of insulin-producing beta cells is a hallmark of both type 1 and 
type 2 diabetes. Therefore, one therapeutic strategy is to increase functional beta cell 
mass in order to overcome insulin deficiency (Bonner-Weir & Weir, 2005b). The 
majority of postnatal beta cell mass expansion in rodents is caused primarily by 
replication of preexisting beta cells, rather than by differentiation from progenitors or 
other cell types, thus making the pathways regulating beta cell proliferation an area of 
acute interest for research (Melton, Dor, Brown, & Martinez, 2004). However, one 
practical issue is that β-cells have a relatively long lifespan with very low proliferate rate 
(<1%), making accessing proliferating beta cells impractical (Bonner-Weir, 2001; 
Kaestner et al., 2007). However, beta cells have the capacity to expand by proliferation 
when metabolically challenged, such as during pregnancy, diet-induced insulin 
resistance, and experimental beta cell ablation, as shown in rodent models (Heit, Karnik, 
& Kim, 2006b).  
     Beta cell proliferation during pregnancy is regulated by many factors, chiefly the 
hormone signaling lactogens (placental lactogen (PL) and prolactin (PRL)) (Kaestner et 
al., 2009; Parsons, Brelje, & Sorenson, 1992). The essential mediator of lactogen 
signaling is the JAK2/STAT5 pathway (Boschero et al., 2004). Many known STAT5 
target genes are up-regulated during pregnancy, including PRL-R, which forms a positive 
feedback loop with the PRL/PL signaling pathway (Fleenor & Freemark, 2001); Glucose 
transporter-2 (Glut-2), which transports glucose into beta cells; and cyclin D2, which 
drives beta cell proliferation (Fleenor & Freemark, 2001; Galsgaard, Nielsen, & Moldrup, 
1999; Glaser et al., 2011; Solimena et al., 2006; Sorenson, Weinhaus, Stout, Bhagroo, & 
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Brelje, 2007). As an apparent limit to unbridled replication, two of the negative feedback 
regulators of PRL/PL signaling, Cish and Suppressors of the Cytokine Signaling 2 
(Socs2), are also up-regulated during pregnancy (Kaestner et al., 2009; Laz, Sugathan, & 
Waxman, 2009; Matsumoto et al., 1997). 
      The “Suppressors of the Cytokine Signaling (SOCS)” gene family is composed of 
eight genes, all of which have similar protein structure and function as inhibitors of 
cytokine signaling (Dalpke, Heeg, Bartz, & Baetz, 2008). All family members, including 
CISH and SOCS2, contain a central SH2 domain for binding to phosphorylated tyrosines 
and a C-terminal ‘SOCS-box’ domain for directing targeted proteins to proteasomal 
degradation (Fig 2.1). SOCS1 and SOCS3 also contain an N-terminal kinase inhibitory 
region (KIR) domain, which is responsible for inhibition of cytokine receptor-associated 
JAKs (Dalpke et al., 2008). Cytokines are important mediators of multiple physiological 
responses, including survival, proliferation, differentiation and functional activities of 
immune cells and other cell types (Trengove & Ward, 2013). Cytokines and growth 
hormones bind to their specific receptors, activate JAKs, which in turn phosphorylate the 
receptors. Phosphorylated receptors provide intracellular  
docking sites for SH2-containing signaling proteins, including STATs and SOCS 
proteins. For example, IFN-g activates JAK1/2, which mainly function through STAT1, 
whereas PRL/PL primarily activates JAK2 and STAT5 (Yoshimura, Nishinakamura, 
Matsumura, & Hanada, 2005). SOCS proteins serve as negative regulators for cytokine 
signaling to prevent sustained and/or excessive cytokine signaling, which can be harmful 
to organismal health.  
          SOCS proteins can be grouped into two categories reflecting their evolutionary 
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Fig. 2.1 (Adapted from (Trengove & Ward, 2013)) Structure and sub-grouping of SOCS 
proteins. There are eight mammalian SOCS family members; SOCS1-7 and CISH. 
SOCS1-3 and CISH are most often associated with regulation of cytokine receptor 
signaling through the JAK/STAT pathway, while SOCS4-7 predominantly regulate 
growth factor receptor signaling. Each SOCS protein contains three distinct domains: an 
N-terminal domain of low conservation, a conserved central SH2 domain, and a more 
highly conserved C-terminal SOCS box domain. The SH2 domain interacts with 
phosphorylated tyrosine residue on target proteins, including cell surface receptors. The 
SOCS box is comprised of two functional sub-domains; a BC box that recruits Elongin B 
and C, and a Cul box that mediates Cullin5 binding. Together, the BC box and Cul box 
activities lead to recruitment of the remaining components of an E3 ubiquitin ligase 
complex, and direct target protein degradation. CytoR: Cytokine receptor; RTK: Receptor 
tyrosine kinase; KIR: kinase inhibitory region; NTCR: N-terminal conserved region; 
ESS: extended SH2 sequence; eB: Elongin B; eC: Elongin C 
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history and signaling pathway preferences. CISH and SOCS1-3 are most often associated 
with cytokine receptor signaling through the JAK/STAT pathway, while SOCS4-7 
primarily regulate growth factor receptor signaling through receptor tyrosine kinase 
(Trengove & Ward, 2013) (Fig 2.1). Of the first group, CISH and SOCS1-3 inhibit 
JAK/STAT signaling by various mechanisms. For example, SOCS1 binds to JAK2 and 
inhibits its phosphorylation of cytokine receptors and STAT5. SOCS2 and SOCS3 bind 
to phosphorylated tyrosine sites on growth-hormone receptors, which might also be 
STAT5-binding sites, thus inhibiting the activation of STAT5. In addition, CISH binds to 
the phosphorylated tyrosine site of PRL-R, which also results in blocking of STAT5 
recruitment. Furthermore, all SOCS proteins may promote proteasomal degradation of 
their targets (Ahmed & Farquharson, 2010; Endo, Sasaki, Minoguchi, Joo, & Yoshimura, 
2003; Ronn, Billestrup, & Mandrup-Poulsen, 2007).  
        Since SOCS proteins are responsible for a wide range of cytokine and growth 
hormone signaling repression, different Socs gene ablation mouse models and Socs 
transgenic mice have been generated. These mice exhibit various phenotypes depending 
on which particular cytokine signal is altered by Socs gene mutation or overexpression 
(Dalpke et al., 2008). For example, global Socs2-/- mice exhibit gigantism, with a 30-40% 
increase in body weight and proportional increase in bones and other organs, indicating 
an essential role for SOCS2 in negatively regulating growth hormone signaling 
(Alexander et al., 2000). SOCS2 has also been indicated to regulate insulin secretion. 
Mice with beta cell-specific overexpression of Socs2 exhibit impaired insulin secretion 
and hyperglycemia (Lebrun et al., 2010). Socs3 overexpressing mice have a 30% 
reduction in beta cell mass. Furthermore, islets from these mice exhibit reduced p-STAT5 
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levels in response to growth hormone in vitro, indicating negative regulation of SOCS3 
on the STAT5 signaling pathway in islets (Lindberg K, 2005). 
      CISH was identified as an immediate-early gene induced in hematopoietic cells in 
response to cytokines such as erythropoietin (EPO), interleukin-2 (IL-2), and IL-3 
(Yoshimura et al., 1995). Subsequent studies have revealed that Cish is also induced by 
growth hormone, prolactin (PRL), IL-9, and granulocyte colony-stimulating factor (G-
CSF), each of which stimulates STAT5 (Helman et al., 1998; Hunter et al., 2004; 
Lejeune, Demoulin, & Renauld, 2001). Stat5a/b-/- mice have no detectable Cish 
expression, indicating the key role of STAT5 in Cish gene regulation (Moriggl et al., 
1999; Teglund et al., 1998). Indeed, Cish has been shown to be a direct target gene of 
STAT5 (Moriggl et al., 2005; Yoshimura et al., 1995). CISH is known to negatively 
regulate signaling induced by EPO, GH, IL2, IL-3, and PRL (Aman et al., 1999; Dif, 
Saunier, Demeneix, Kelly, & Edery, 2001; Matsumoto et al., 1997; Pezet, Favre, Kelly, 
& Edery, 1999; Ram & Waxman, 1999; Yoshimura et al., 1995). CISH suppresses 
signaling by binding via its SH2 domain to phosphorylated tyrosine residues of cytokine 
receptors, leading to either a block to STAT5 docking or degradation of cytokine 
receptors (Hanada et al., 2003; J. A. Hansen, Lindberg, Hilton, Nielsen, & Billestrup, 
1999; Piessevaux, De Ceuninck, Catteeuw, Peelman, & Tavernier, 2008; Ram & 
Waxman, 1999; Verdier et al., 1998). Cish transgenic mice exhibit impaired STAT5 
signaling in liver, mammary glands and T cells (Matsumoto et al., 1999). However, the 
function of CISH and SOCS2 in regulating lactogen-dependent JAK2/STAT5 signaling 
in beta cells, as well as their potential function in beta cell proliferation during pregnancy, 
has not been previously studied. 
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     Since lactogen-JAK2/STAT5 signaling is critical for beta cell proliferation and beta 
cell function during pregnancy, and Cish/Socs2 are induced during pregnancy (Kaestner 
et al., 2009), I hypothesized that these two SOCS proteins negatively regulate beta cell 
proliferation and beta cell function by suppressing JAK2/STAT5 signaling. In order to 
test this hypothesis, I used a novel mouse model derived in our lab with conditional 
ablation of the Cish gene in the pancreas. I also investigated the role of SOCS2 in beta 
cell proliferation using global Socs2-/- mice.  
Results	  
Derivation	  of	  pancreas-­‐specific	  Cish	  ablation	  mice	  	  	  
      A novel conditional allele of Cish was constructed by inserting two loxP sites 
flanking exon 2 of the Cish gene, which encodes the tyrosine binding SH2 domain. 
Deletion of exon 2 of the Cish gene results in a frameshift mutation and no CISH protein 
would be produced. Pancreas-specific Cish-/- mice were derived by breeding CishloxP/loxP 
mice with Pdx1-CreEarly transgenic mice (Gu, Dubauskaite, & Melton, 2002), in which 
expression of the Cre recombinase is driven by the Pdx1 promoter (Fig. 2.2a). The 
resulting CishloxP/+; Pdx1-CreEarly mice were bred to CishloxP/loxP mice to obtain 
CishloxP/loxP; Pdx1-CreEarly mutant mice and CishloxP/loxP control mice. Pdx1-CreEarly 
expression starts at approximately embryonic day 8.5 in all pancreatic progenitor cells. 
Therefore, Cish is ablated in the whole pancreas in CishloxP/loxP; Pdx1-CreEarly mutant 
mice. PCR primers for differentiating Cish loxP allele and Cish wild type allele were 
designed upstream of the single loxP site and within exon 3 of the Cish gene, respectively 
(Fig. 2.2a). The primers amplify a 250bp product for the wild type allele and a 388bp 
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Fig. 2.2 Cish ablation in pancreatic islets. a CishloxP mice were crossed with Pdx1-CreEarly 
mice to induce Cish ablation in the pancreas. PCR primers for genotyping of the Cish 
allele were designed upstream of the single loxP site and within exon 3 of the Cish gene, 
indicated by arrows. b Genotying for Cish alleles. The primers amplify a 250bp product 
in the wild type allele and a 388bp product in the loxP allele. c Quantitative RT-PCR 
showed dramatic reduction of Cish mRNA in CishloxP/loxP; Pdx1-CreEarly islets. **p<0.01 
(t-test). Black bars: CishloxP/loxP controls; grey bars: CishloxP/loxP; Pdx1-CreEarly mutants 
(n=5-6). d Quantitative RT-PCR showed enriched Cish mRNA expression in the sorted 
beta cells from virgin CishloxP/loxP; Mip-GFP (CT) mice and virgin CishloxP/loxP; Mip-GFP 
; Pdx1-CreEarly (MT) mice. GFP+ indicates the sorted GFP positive beta cells. GFP- 
indicates the sorted GFP negative islet non-beta islet cells. Pancreas sections from mice 
of indicated genotypes were co-stained with antibodies against insulin (red) and glucagon 
(green) (e,f), or alternatively, antibodies against insulin(red) and somatostatin (green) 
(g,h). All mice were sacrificed on day 14.5 of pregnancy except when virgin female mice 
were used (d). Ins: insulin; Gcg: glucagon; Sst: Somatostatin. 
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product for the loxP allele (Fig. 2.2b). 
     To evaluate the efficiency of Cish gene ablation, Cish mRNA expression levels in 
mouse islets were determined by qPCR using primers designed within exon 2 of the Cish 
gene. Cish mRNA levels were reduced by more than 90% in pancreatic islets isolated 
from CishloxP/loxP; Pdx1-CreEarly mice compared to islets from control CishloxP/loxP mice  
(Fig. 2.2c). In order to ascertain that Cish was ablated in beta cells without a reliable 
CISH antibody, CishloxP/loxP; Pdx1-CreEarly mice were bred to Mip-GFP mice to allow for 
efficient fluorescence-activated cell sorting (FACS) of beta cells. Analysis of Cish 
mRNA levels in sorted islet cells provided new knowledge. First, in islets of control 
mice, Cish mRNA was highly enriched in beta cells (GFP+ cells from CishloxP/loxP; Mip-
GFP mice) compared to islet non-beta cells (GFP- cells from CishloxP/loxP; Mip-GFP 
mice). Second, Cish mRNA expression was efficiently ablated in mutant beta cells (GFP+ 
cells from CishloxP/loxP; Pdx1-CreEarly mice) relative to control beta cells (GFP+ cells from 
CishloxP/loxP mice) (Fig. 2.2d). Furthermore, mutant islets maintained normal morphology 
and hormone expression as shown by co-staining for insulin, glucagon, and somatostatin 
(Fig. 2.2 e-h). In summary, CISH is not required for maintenance of normal islet 
architecture. 
CISH	  is	  not	  required	  for	  beta	  cell	  proliferation	  or	  glucose	  homeostasis	  in	  mice	  
       Having established a mouse model for pancreas-specific ablation of Cish, I 
proceeded to investigate whether Cish ablation affects beta cell mass and/or glucose 
homeostasis. I found no differences in beta cell mass, body weight, resting insulin, 
fasting insulin, or glucose tolerance between control virgin mice and mutant virgin mice 
(Fig. 2.3a-d), although Cish was ablated in 90% of islet cells in these mice (Fig. 2.3e). 
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Therefore, CISH is not required for beta cell homeostasis or proliferation in non-pregnant 
mice. This result was expected because expression of Cish is upregulated during 
pregnancy, when we hypothesize that CISH functions as key repressor for PRL signaling 
to prevent overshooting of cell cycle entry. In other words, Cish is relatively lowly  
expressed under normal physiological condition, possibly with minimal functional  
activity. Therefore, deleting Cish in virgin mice did not have any effect on beta cell 
function or glucose homeostasis.  
       Next, I proceeded to investigate whether Cish ablation augmented beta cell 
proliferation during pregnancy, which was my original hypothesis. In order to measure 
beta cell proliferation, 24 hours prior to being sacrificed, day 13.5 pregnant mice were 
injected with bromodeoxyuridine (BrdU) intraperitoneally to label proliferating cells 
during S-phase. Immunofluorescence staining was performed on pancreas sections of 
control mice (n=9) and mutant mice (n=9). Since pregnancy is a robust model to induce 
beta cell proliferation, BrdU+ proliferating beta cells were easily detected in islets (Fig. 
2.4a-b). For each animal, more than 15 islets, or 1,000 beta cells, were quantified 
manually. The proliferation rate was about 1.5% in both CishloxP/loxP mice and 
CishloxP/loxP; Pdx1-CreEarly mice (Fig. 2.4c). Thus, Cish deficiency in beta cells is not 
sufficient to increase beta cell DNA replication during pregnancy. There also was no 
difference in beta cell mass between control and mutant mice, either (Fig. 2.4d).  
       Although I detected no difference in the rate of beta cell proliferation in Cish-
deficient mice, it was possible that beta cell function was enhanced without affecting 
proliferation. To address this question, glucose tolerance tests (GTT) were performed on 
eleven CishloxP/loxP; Pdx1-CreEarly mice and eleven CishloxP/loxP mice, all on day 14.5 of 
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Fig 2.3 CISH is not required for beta cell proliferation or beta cell function in virgin 
mice. a-d Beta cell mass, body weight, glucose tolerance test, and resting and fasting 
plasma insulin levels of virgin mice. No difference was observed between control and 
mutant groups (t-test for a,b,d; MANOVA for c). e Cish mRNA levels are dramatically 
reduced in non-pregnant mutant mice (t-test, * p<0.05). Error bars show standard error of 
the mean. CishloxP/loxP mice and Pdx1-CreEarly mice were used as controls. a,c,e Black 
bars: CishloxP/loxP  controls; grey bars: CishloxP/loxP ; Pdx1-CreEarly mutants. b,d Black bars: 
CishloxP/loxP  controls; dark grey bars: Pdx1-CreEarly controls; light grey bars: CishloxP/loxP ; 
Pdx1-CreEarly mutants (n=3-6). !
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Fig 2.4 CISH is not required for beta cell proliferation or glucose homeostasis during 
pregnancy. BrdU (green) and insulin (red) co-staining of pancreata from day 14.5 
pregnant (p14.5) CishloxP/loxP  (a); and CishloxP/loxP ; Pdx1-CreEarly (b) mice. c Percentage of 
beta cell nuclei staining positive for BrdU showed no difference between CishloxP/loxP and 
CishloxP/loxP; Pdx1-CreEarly mice (t-test). d,e,f,g Beta cell mass, body weight, blood 
glucose levels during glucose tolerance test, and resting and fasting plasma insulin levels, 
respectively, of pregnant day 14.5 mice. No difference was observed between control and 
mutant groups (t-test for d,e, and g; MANOVA for f). h Control (Black trace) and mutant 
(grey trace) islets from pregnant day 14.5 mice were perfused for a glucose-stimulated 
insulin secretion assay. No difference was detected between the two groups . Error bars 
show standard error of the mean. c-g Black bars: p14.5 CishloxP/loxP controls; grey bars: 
p14.5 CishloxP/loxP; Pdx1-CreEarly mutants (n=5-11). !
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pregnancy. No difference was observed in body weight or glucose tolerance between the 
control and mutant group (Fig. 2.4e-f). In addition, fed and fasted insulin level levels 
were the same in two groups (Fig. 2.4g). To exclude the beta cell non-autonomous effect 
of Cish ablation in the hypothalamus, where Pdx1 is also expressed, I performed islet 
perifusion studies of insulin secretion on isolated islets from day 14.5 pregnant mice. 
There was no difference in glucose stimulated insulin secretion between the two groups 
(Fig. 2.4h). Thus, Cish deficiency in beta cells does not alter glucose tolerance or beta 
cell function during pregnancy. 
       After gestation, beta cell mass quickly returns to pre-pregnancy levels via decreased 
proliferation and increased apoptosis. Expression of Cish maintains elevated at later 
stages of pregnancy (P18.5), when the beta cell proliferating rate is reduced to pre-
gestation levels. To test whether CISH is required for the cessation of the proliferative 
response of beta cells following pregnancy, mice five days post-partum (PP5) were  
analyzed. No statistically significant differences were observed in beta cell mass, body 
weight, resting insulin, fasting insulin, or glucose tolerance between control and mutant 
PP5 mice (Fig. 2.5a-d). Since there was a trend towards lower plasma insulin levels in 
Cish-deficient mice, I further tested islet function by perifusion assays. Islets from mice 
five days after birth were cultured, placed in a perifusion chamber, and subjected to a 
glucose ramp. I found no difference in glucose-stimulated-insulin secretion between  
control and mutant islets (Fig. 2.5e). In conclusion, Cish is not required for beta cell 
homeostasis in mice before, during, or after pregnancy. 
Cish	  ablation	  is	  not	  sufficient	  to	  increase	  activation	  of	  STAT5	  
       Since CISH competes with STAT5 to bind prolactin receptor, Cish ablation may 
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Fig 2.5 CISH is not required for beta cell proliferation or beta cell function in mice five 
days after pregnancy. a-d Beta cell mass, body weight, glucose tolerance test, and resting 
and fasting plasma insulin levels of mice five days after pregnancy. No statistically 
significant difference was observed between control and mutant mice, although there was 
a trend of lower resting insulin in the mutant mice (t-test for a, b, and d; MANOVA for 
c). e Control and mutant islets from PP5 mice were perifused for glucose-stimulated 
insulin secretion assay. No difference was detected between the two groups (Black trace: 
control; Grey trace: mutant). Error bars show standard error of the mean. a-d Black bars: 
CishloxP/loxP controls; grey bars: CishloxP/loxP; Pdx1-CreEarly mutants (n=4-6). !
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promote increased STAT5 binding to the receptor, which would result in elevated STAT5 
phosphorylation levels. Islets from virgin mice and p14.5 mice were isolated and whole 
cell lysates were resolved using SDS-PAGE gel. P-STAT5 protein levels were detected 
using a specific antibody. P-STAT5 is undetectable in islets from non-pregnant mice, and 
is up-regulated with detectable bands in islets from p14.5 mice. However, no differences 
were observed in pSTAT5 levels between control and mutant pregnant mice (Fig. 2.6a), 
although there was some variability in phosphorylation status among animals with the 
same genotype. To further investigate the activity of the STAT5 pathway, I determined 
Tph1, Tph2, Glut2, and Gck mRNA levels in the islets, as these genes have been 
suggested to be downstream of JAK2/STAT5 pathway and regulate beta cell proliferation 
and beta cell function during pregnancy (Schraenen, Lemaire, et al., 2010; Sorenson et 
al., 2007). No differences were detected in mRNA levels of these genes between control 
and mutant islets (Fig. 2.6b), providing more evidence that STAT5 signaling was 
unperturbed by absence of CISH from beta cells. Therefore, ablation of Cish is not 
sufficient to induce elevated STAT5 activation.  
Socs2	  gene	  is	  up-­‐regulated	  upon	  Cish	  ablation	  at	  pregnancy	  day	  9.5	  	  
       Since Cish ablation does not lead to elevated STAT5 activation, I hypothesized that 
other Socs family members might be up-regulated to compensate for the loss of Cish.  
Our lab had previously shown that Socs2 is also up-regulated in islets during pregnancy,  
making it a prime candidate for the compensatory effector. qPCR were performed on 
cDNA from islets of control and mutant mice, both before and during pregnancy. At 
p14.5 in control mice, expressions of Cish and Socs2 are increased, consistent with 
published work (Fig. 2.6c) (Kaestner et al., 2009). mRNA expression of other Socs genes 
	   83	    
 
Fig 2.6 P-STAT5 western blot and quantitative RT-PCR of Cish family members in islets 
from non-pregnant mice, pregnant day 14.5 mice and pregnant day 9.5 (p9.5) mice a p-
STAT5 was detected by western blot. p-STAT5 level is undetectable in the virgin mice, 
but highly induced during pregnancy. No difference between control pregnant mice and 
mutant pregnant mice p-STAT5 was detected. Beta-actin was used as the loading control. 
b mRNA levels of Glut2, Gck, Tph1, and Tph2 were not affected in mutant mice at 
pregnant day 14.5. Black bars: p14.5 CishloxP/loxP controls; grey bars: p14.5 CishloxP/loxP; 
Pdx1-CreEarly mutants (n=5-6) (t-test).c Cish and Socs2 are up-regulated during 
pregnancy (t-test). Socs2 is not further up-regulated in the Cish mutant mice at pregnant 
day 14.5. Furthermore, none of the other family members (Socs3-Socs7) showed up-
regulation at pregnant day 14.5 upon Cish ablation. Black bars: CishloxP/loxP virgins; light 
grey bars: p14.5 CishloxP/loxP mice; dark grey bars: CishloxP/loxP; Pdx1-CreEarly virgins; 
white bars: p14.5 CishloxP/loxP; Pdx1-CreEarly mice (n=5-6). (t-test) d mRNA expression of 
Socs2 is higher in the Cish mutant mice than control mice at pregnant day 9.5. mRNA 
expression of Glut2, Gck, CyclinB1 had no difference between control and mutant mice 
(t-test). Black bars: p9.5 CishloxP/loxP mice; grey bars: p9.5 CishloxP/loxP; Pdx1-CreEarly 
mutants (n=5). Error bars show standard error of the mean. * p<0.05; ** p<0.01 (t-test). 
	   84	  
 was also determined, and none of them are up-regulated significantly upon Cish ablation 
(Fig. 2.6c). The expression of Socs1 is undetectable in islets. Interestingly, Socs2 mRNA  
levels are higher in Cish mutant mice than control mice at p9.5 (Fig. 2.6d), suggesting 
that Socs2 might be compensating for Cish ablation during this phase of pregnancy. 
Glut2, Gck, and CyclinB1 mRNA levels are the same in Cish control and mutant mice at 
p9.5 (Fig. 2.6d), indicating normal glucose metabolism and beta cell proliferation. 
Socs2	  global	  ablation	  results	  in	  elevated	  beta	  cell	  proliferation	  during	  pregnancy.	  
       Since Socs2 is up-regulated in Cish-deficient islets during pregnancy, I hypothesized 
that Socs2 compensates for Cish ablation and functions as a brake for beta cell 
proliferation. Socs2 global ablation mice exhibit gigantism with normal glucose 
metabolism and adequate beta cell mass after normalizing to body weight (Alexander et 
al., 2000; Puff et al., 2010). But beta cell proliferation was not evaluated in these global 
mutant mice, nor the role of SOCS2 on beta cell proliferation during pregnancy. 
       In order to investigate the role of SOCS2 on beta cell proliferation during pregnancy, 
Socs2+/- mice were bred together to obtain Socs2-/- mutant mice and Socs2+/+ littermates 
as controls. At day 13.5 of pregnancy, BrdU was intraperitoneally injected into both 
control and mutant mice to label proliferating cells. 24 hours later, day 14.5 pregnant 
mice were sacrificed, and pancreas sections from both Socs2-/- and Socs2+/+ mice were 
immunostained for insulin and BrdU (Fig 2.7a). BrdU positive cells were quantified from 
four mice of each group manually. Interestingly, Socs2 ablation resultes in doubled beta  
cell proliferation at p14.5 compared to control mice at p14.5 (Fig 2.7b), indicating that 
SOCS2 plays a key role in repressing beta cell proliferation during pregnancy.  
       Since Socs2-/- mice are gigantic with larger organs, including higher beta cell mass 
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Fig 2.7 Socs2 global mutants exhibit increased beta cell proliferation. a BrdU (red) and 
insulin (green) double staining of pancreata from Socs2+/+ (left) and Socs2-/- (right) mice. 
b Quantification of proliferating cells. Socs2-/- mutant mice have a 2-fold increase in the 
ratio of beta cell nuclei stained positive for BrdU compared to Socs2+/+ mice. !
	   86	  
 (30-40%) than Socs2+/+ control mice, it is possible that the higher beta cell proliferation  
rate is an adaptive response for keeping the adaptive higher beta cell mass in line with 
higher body weight, to maintain normal blood glucose homeostasis. Further studies will 
require beta-cell specific Socs2-/- mice in which body weight is not a contributing factor 
for beta cell proliferation. Conditional Socs2 ablation models will undoubtedly provide 
more knowledge on its role in beta cell proliferation. 
Derivation	  of	  beta-­‐cell-­‐specific	  Cish/Socs2	  double	  ablation	  mice	  
       An ES cell clone with heterozygous Socs2 conditional ablation potential was 
obtained from EUCOMM. Exon 3 of Socs2 is flanked by two loxP sites (Fig 2.8a). These 
JM8A3 agouti/brown ES cells were injected into 4-day-old Albino-B6 blastocysts and 
transferred into the uterine horn of pseudopregnant females. Male chimeric pups were 
backcrossed with Albino-B6 mice. Albino pups were removed while agouti and black 
pups were genotyped for the presence of Socs2 loxP allele to determine germline 
transmission from the chimeric mice. Socs2L/+ mice were bred with FLPe mice  
to excise the FRT-neo cassette from the original loxP construct. Two sets of FRT deletion 
primers were designed to confirm the excision of FRT-neo cassette by PCR (Fig 2.8b). 
Socs2L/+;Flp+ mice were then bred with CishL/+; Pdx1-CreER mice to derive Socs2L/+; 
CishL/+; Pdx1-CreER mice. Subsequently, Socs2L/+; CishL/+; Pdx1-CreER mice were mated 
with Socs2L/+; CishL/+ mice to generate Socs2L/L; CishL/L; Pdx1-CreER mice. Upon  
administration of tamoxifen to promote the nucleus translocation of the CreER 
recombinase, these mice have beta-cell specific ablation of both Cish and Socs2. 
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Fig 2.8 Generation of Socs2 conditional ablation mice a Construction of commercially 
available ES cells with Socs2 loxP allele. Two loxP sites flank exon 3 of Socs2 gene, 
which encodes the SH2 binding domain. Genotyping primers for the loxP allele and PCR 
primers for confirming FRT site excision are color-coded. b Genotyping of Socs2loxP 
allele and Socs2 wild type allele. PCR validation of excision of the FRT flanked site were 
performed with FRT deletion primers. !
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Knockdown	  of	  Cish	  and	  Socs2	  in	  human	  islets	  by	  lentiviral	  shRNA 
     Replication incompetent lentivirus is widely used to enforce short hairpin RNA 
(shRNA) expression in cells, which triggers RNA interference and target mRNA 
suppression (Cockrell & Kafri, 2007; Kappes & Wu, 2001). shRNAs are short sequences 
of RNA transcribed by RNA PolIII and subsequently cleaved by Drosha and Dicer to 
produce small interfering RNAs (siRNA) (Rossi, 2008). siRNAs bind to target mRNAs 
and decrease gene expression by cleaving the mRNA or blocking the translation of the 
mRNA. The lentivirus construct contains both microRNA-adapted shRNA (shRNAmir) 
and GFP sequences (Silva et al., 2005) (Fig 2.9a).  
       To determine efficiency of the lentiviral shRNAs, ten clones of lentiviral shRNAmir 
targeting Cish or Socs2 were purchased, respectively (C1~C10, S1~S10). A scrambled 
shRNA was also obtained and used as a negative control (referred to as CT shRNA 
afterwards). Human HEK293T cells were transfected with each clone, respectively (C1-
C10, S1-S10, CT). Two days later, cells were run through fluorescence-activated cell 
sorting (FACS) to isolate GFP+ cells, which were transfected by the lentivirus, from GFP- 
cells, which were not transfected by the lentivirus. Figure 2.9b shows a representative 
FACS result with clear separation of GFP+ and GFP- cell populations. qPCRs of Cish and 
Socs2 mRNA expression were performed. The four shRNA clones that produced the 
highest reduction of target gene expression from GFP- to GFP+ cells were selected for 
both Cish and Socs2, respectively (C1, C5, C7, C8, S4, S5, S7, S8) (Fig. 2.9c-d). The 
plasmids were sent to the Protein Expression and Libraries Facility at Wistar Institute to 
construct lentiviral vectors containing the respective Cish and Socs2 shRNA sequences  
for stable transduction into human islets. 
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Fig 2.9 Validation of Cish and Socs2 lentivirus on human cell line and human islets. a 
Structure of lentiviral constructs targeting Cish or Socs2, with GFP reporter sequence in 
backbone. b GFP+ cells and GFP- cells were differentiated by fluorescent-activated cell 
sorting (FACS). Ratio of mRNA levels of Cish (c) and Socs2 (d) in sorted GFP+ 293T 
cells compared to GFP- 293T cells after transfection with lentiviral vectors. e 
Immunostaining of human islets before transplantation. f Immunostaining of transduced 
human islets under kidney capsule after 14 days of transplantation. !
	   90	  
        Human islets transduced with CT shRNA were transplanted into immunodeficient 
mice under a kidney capsule. The kidney capsule provides an environment enriched for 
capillaries, which makes it relatively easy for the islets to be recapillarized and remain 
functional (S. K. Kim et al., 2007). Before transplantation, only the cells on the periphery 
of the transduced human islets are GFP+ (Fig 2.9e). Two weeks later, the kidney capsule 
was isolated, fixed, and sectioned. The GFP signal penetrated into the transplanted 
human islets (Fig 2.9f).  There are several potential explanations for these results. It is 
feasible that at early stages post-transduction, the GFP protein concentration is simply too 
low for detection. Another possibility is that the GFP signal was transferred through the 
islet cells via gap junctions. 
Discussion	  
       Pregnant mouse islets provide a model for studying the signaling pathways that 
influence and regulate beta cell replication. Substantial evidences demonstrate that 
lactogens promote beta cell proliferation during pregnancy through the JAK2/STAT5 
signaling pathway, at least in rodents (Boschero et al., 2004; Brelje et al., 1993b; 
Kaestner et al., 2009; Parsons et al., 1992; Vasavada, Fujinaka, Takane, & Yamashita, 
2007). Cish and Socs2 are also up-regulated during the same time period when beta cell 
proliferation peaks during pregnancy. Furthermore, CISH/SOCS2 bind to the prolactin 
receptor, block STAT5 docking, and phosphorylation of STAT5 by JAK2, suggesting a 
canonical negative feedback loop for repressing the JAK2/STAT5 pathway (Kaestner et 
al., 2009; Laz et al., 2009; Matsumoto et al., 1997). Based on these findings, I 
hypothesized that ablation of Cish would result in elevated JAK2/STAT5 signaling, 
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increased cyclin D2 expression, and increased beta cell proliferation during pregnancy. 
To test this hypothesis, we generated mice with pancreas-specific Cish ablation. These 
mice represent the first reported mouse model for tissue-specific ablation of Cish. In this 
CishloxP/loxP; Pdx1-CreEarly model, Cish expression is reduced by greater than 90% in the 
islets, demonstrating the efficiency of the system. FACS of control and mutant islets 
reveals that Cish is highly enriched in beta cells compared to other islet cell types, and is 
efficiently deleted in sorted CishloxP/loxP; Pdx1-CreEarly; MIP-GFP islet beta cells. The 
reason for the remaining 5-10% Cish mRNA expression could be that Cre recombination 
does not occur in all beta cells.  The efficacy of Cre mediated gene ablation observed for 
the Cish locus was comparable to that of other loxP flanked targets (Gao et al., 2008). 
The Pdx1-CreEarly transgene is also expressed in a subset of cells in the hypothalamus, 
and because the hypothalamus provides central input to glucose homeostasis (Wicksteed 
et al., 2010b), I performed ex vivo experiments to exclude any potential beta cell non-
autonomous effect. I did not observe any difference between control and mutant islets in 
the insulin secretion studies of the isolated islets, in which any potential neuronal input 
has been removed. Furthermore, in order to evaluate if the Pdx1-CreEarly transgene itself 
might impact the phenotype of our mutant mice, I determined insulin levels in two 
control groups (CishloxP/loxP mice and Pdx1-CreEarly mice). No abnormal phenotypes in 
Pdx1-CreEarly mice were observed, consistent with previous studies using the same mouse 
strain (J. Y. Lee et al., 2007). 
     Cish-deficient mice exhibit normal islet architecture, and normal glucose homeostasis 
before, during, and after pregnancy. Surprisingly, I found no difference in pregnancy-
induced beta cell proliferation or glucose homeostasis in Cish-deficient females 
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compared to controls. Cish ablated islets also exhibit p-STAT5 levels comparable to 
those of control mice, and normal mRNA levels of Tph1 and Tph2, further demonstrating 
that the STAT5 signaling pathway is not affected. mRNA expression levels of other Socs 
gene family members were determined, and Socs2 mRNA levels in the absence of Cish 
are upregulated even compared to the already elevated levels in control mice on day 9.5 
of pregnancy, suggesting that Socs2 might be compensating for Cish ablation during 
pregnancy. Therefore, a mouse model with simultaneous, beta cell specific ablation of 
Cish and Socs2 is necessary to uncover functions of these two proteins in beta cell 
proliferation and function.  
        To investigate possible compensatory effects of Socs2 for Cish, global Socs2-/- mice 
were also analyzed during pregnancy. Socs2-/- mutants exhibit higher beta cell 
proliferation rates than control mice at 14.5 days of pregnancy, suggesting that SOCS2 
plays a key role as a repressor of beta cell proliferation during pregnancy. But since 
global Socs2-/- mice are gigantic with proportional increases in the size of multiple 
organs, including bones, liver, and pancreas, the phenotype of increased beta cell 
proliferation might be an adaptive response to an increase in body weight. Therefore, a 
beta cell-specific ablation of Socs2 would be essential to investigate the role of SOCS2 in 
beta cells independent of the effects of Socs2 ablation on other organs. As mentioned 
above, it would also be helpful to study the effects of combined Cish and Socs2 ablation 
in beta cells. I am currently working on generating beta cell-specific Cish and Socs2 
double-ablation mice. Furthermore, the lentiviral constructs containing shRNA for Cish 
and Socs2 are being tested on human islets to examine the consequences of Cish and 
Socs2 knockdown on human beta cell proliferation.    
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      Alternatively, another explanation of lack of phenotype in pregnant CishloxP/loxP; 
Pdx1-CreEarly mice is that STAT5 is maximally active during pregnancy, and thus its 
capacity for phosphorylation is already saturated. If this were true, then ablation of its 
negative regulator would not be able to increase STAT5 phosphorylation or affect beta 
cell function or proliferation. Furthermore, other mediators of the JAK2/STAT5 signaling 
pathway other than SOCS proteins might be compensating for the loss of Cish. Finally, it 
is possible that other signaling pathways limit the proliferative capacity of beta cells, such 
as the cell cycle inhibitor p16 (Pascoe et al.). 
     In summary, in the pancreas-specific Cish-/- mice, no difference is discovered in 
glucose homeostasis or beta cell function before, during, or after pregnancy. P-STAT5 
levels are not altered in Cish-deficient mice, indicating that other mechanisms 
compensate in the regulation of the STAT5 pathway during pregnancy. Socs2 mRNA is 
further up-regulated in Cish-deficient islets at 9.5 days of pregnancy, suggesting that 
Socs2 might be compensating for the loss of Cish as a repressor of JAK2/STAT5 
pathway and beta cell proliferation. Indeed, Socs2 global ablation mice exhibit higher 
beta cell proliferation rate during pregnancy, indicating the SOCS2 does play a key role 
in regulating beta cell replication. To fully elucidate the role of Cish and Socs2 in beta 
cell replication, it will be necessary to generate and examine beta cell specific Cish-/-; 
Socs2-/- mice. 
Methods	  and	  Materials	  
Mice: Cish loxP mice were crossed with Pdx1-CreEarly mice (kindly provided by Dr. D. 
A. Melton from Harvard University, Cambridge, MA, USA) (Gu et al., 2002) to induce 
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pancreas-specific Cish ablation. CishloxP/loxP mice were used as controls and CishloxP/loxP; 
Pdx1-CreEarly mice constituted the mutant group. Pdx1-CreEarly mice were also used as 
controls in the virgin mice study in addition to the CishloxP/loxP controls, and no difference 
was observed in the insulin levels among the two control groups and the mutant group, 
consistent with previous studies (J. Y. Lee et al., 2007), showing that the Pdx1-CreEarly 
transgene has no impact on beta-cell proliferation or beta-cell function. Therefore, we 
used only CishloxP/loxP mice as control mice in our further studies. In addition, CishloxP/loxP; 
Pdx1-CreEarly mice were crossed with Mip-GFP mice (purchased from The Jackson 
Laboratory, Bar Harbor, Maine, USA) (Hara et al., 2003), a transgenic mouse with green 
fluorescent protein driven by mouse-insulin-promoter to label pancreatic beta cells. This 
mating generated CishloxP/loxP; Pdx1-CreEarly; Mip-GFP and CishloxP/loxP; Mip-GFP mice, 
which were used for sorting of beta cells and non-beta cells from islets. Mice were 
analyzed between 3 and 5 months of age.  
     Socs2L/+ mice were generated by injecting Socs2L/+ targeted ES cells (purchased from 
EUCOMM) into blastocysts and transplantion into pseudopregnant mice. Germline 
transmission of the loxP allele in the chimeric pups was identified by crossing chimeras 
with albino C57BL/6J mice. Germline chimeras were then crossed to FLPe mice to 
excise the FRT-neo cassette. Socs2L/+;Flp+ mice were then bred with CishL/+; Pdx1-CreER 
mice to derive Socs2L/+; CishL/+; Pdx1-CreER mice. Currently, Socs2L/+; CishL/+; Pdx1-
CreER mice are mating with Socs2L/+; CishL/+ mice to generate Socs2L/L; CishL/L; Pdx1-
CreER mice.  
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Proliferation analysis: Twenty-four hours before euthanizing the mice, 1ml/100 g body 
weight of BrdU labeling reagent (Life Technologies, Grand Island, NY, USA) was 
intraperitoneally injected. Pancreata were dissected, flattened by forceps, fixed in 4% 
para-formaldehyde for 24 hours, and paraffin embedded so that tissues with the 
maximum pancreatic footprint were sectioned. Tissues were sectioned to 5µm thickness. 
Deparaffinized and rehydrated slides were subjected to antigen retrieval by pressure 
cooker in 10mmol/l pH 6.0 citric acid buffer. Simultaneous immunofluorescent staining 
was performed for BrdU and insulin. The primary antibodies used were guinea pig anti-
insulin (1:1000 dilution, Dako North America, Inc., Carpinteria, CA, USA) and rat anti-
BrdU (1:500 dilution, AbD Serotec; Raleigh, NC, USA). Secondary antibodies were 
Cy2-anti-guinea pig (1:200) and Cy3-anti-rat (1:200). The beta cell proliferation rate was 
quantified as BrdU/ insulin double positive cells divided by insulin positive cells.  
 
Beta cell mass: Three sections (40 µm apart) from each animal were immunostained for 
insulin using the standard DAB method without counterstaining. The entire tissue section 
was scanned with Meyer PathScan Enabler IV Histology Slide Scanner and Silverfast 
Pathscan 6.6 software. The percentage of beta cell area relative to the total pancreatic 
area was measured and calculated using ImageJ. Beta cell mass was derived from the 
total pancreas weight multiplied by the percentage of beta cell area. 
 
Glucose tolerance test and insulin assay: Animals were fasted overnight and fasting 
glucose levels determined by glucometer. 2g/kg body weight of glucose (Sigma-Aldrich 
Corp., St. Louis, MO, USA) was injected intraperitoneally. Glucose levels were 
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measured at 15, 30, 60, 90, 120 minutes postinjection. Glucose levels were measured by 
Glucometer Breeze2 (Bayer AG, Leverkusen, Germany). To determine plasma insulin 
levels during glucose tolerance tests, blood was collected from the tail vein of mice 
before and after overnight fasting. Plasma insulin concentration was measured by ELISA. 
 
Islet isolation and real-time PCR: Islets were isolated using standard collagenase 
procedures followed by purification through a Ficoll gradient (Sigma-Aldrich Corp, 
Ficoll PM 400) as described preciously (Kaestner et al., 2007). Islets were handpicked 
under a light microscope. Total RNA was isolated in Trizol (Life Technologies) and 
reversely transcribed using 1µg oligo (dT) primer, Superscript II Reverse Transcriptase, 
and accompanying reagents (Life Technologies). PCR reaction mixes were assembled 
using the Brilliant III SYBR Green QPCR Master Mix (Agilent Technologies, Inc., Santa 
Clara CA, USA). PCR reactions were performed on an Mx4000 Multiplex Quantitative 
PCR System (Agilent Technologies). All reactions were performed in triplicate with 
reference dye normalization. Median cycling threshold values were used for analysis.  
 
Islet perifusion: One hundred and fifty islets were hand picked under a light microscope 
and placed into a perifusion chamber (EMD Millipore, Billerica, MA, USA). A 
computer-controlled fast-performance HPLC system (625 LC System, Waters 
Corporation, Huntingdon Valley, PA, USA) allowed programmable rates of flow and 
concentration of the appropriate solutions held in a 37oC water bath. Islets were perifused 
with Krebs bicarbonate buffer (2.2 mmol/l Ca2+, 0.25% bovine serum albumin, 10 mmol/l 
HEPES, and 95% O2/5% CO2 equilibration [pH 7.35]) plus 2mmol/l glucose and 4mmol/l 
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AAM-19 and glutamine to reach baseline hormone secretion values before the addition of 
the appropriate secretagogues. Samples were collected at regular intervals with a fraction 
collector (Waters Corporation). Insulin content was determined using a 
radioimmunoassay. 
 
Western Blotting: For western blot, islets were isolated and lysed in lysis buffer 
containing 50mmol/l Tris (pH 8.0), 5mmol/l EDTA, 150mmol/l NaCl, 1% Triton, 1% 
SDS, 0.5% sodium deoxycholic acid and Complete Protease Inhibitor Cocktail Tablets 
(Genentech Roche, Newtown, PA, USA). Protein concentrations were measured by 
Bradford Assay using SpectraMax Plus 384 (Molecular Devices). 6µg total lysate were 
heated at 95º C for 10 min and loaded on 4-12% Bis-Tris gel (Novex, Wadsworth, OH, 
USA). Proteins were transferred to PVDF membranes by iBlot Dry Blotting System (Life 
Technologies) and detected by antibodies against p-STAT5 (Santa Cruz Biotechnology, 
Inc., Dallas TX, USA) and rat anti-beta-actin (Cell Signaling). The ECL-Plus detection 
system (GE Healthcare Biosciences, Pittsburgh, PA, USA) was used to detect the signal. 
 
FAC-sorting: Islets from two CishloxP/loxP; Pdx1-CreEarly; Mip-GFP mice and two 
CishloxP/loxP; Mip-GFP mice were isolated and pooled by the same genotype. Dissociated 
cells from isolated islets were sorted into GFP+ cell fractions, which were highly enriched 
for beta cells, and GFP- cell fractions, which were enriched for non-beta islet cells. Total 
RNA was extracted from sorted cells and subjected to further analysis. 
 
Lentiviral transduction and xenotransplantation of human cadaveric islets: Ten clones of 
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lentiviral shRNAmir targeting Cish and Socs2 respectively were purchased (C1~C10, 
S1~S10) from Open Biosystems. A scrambled shRNA was obtained from the same 
company as the negative control. Human HEK293T cells were transfected with each 
clone of plasmids separately (C1-C10, S1-S10, CT). Two days later, cells were collected 
and run through fluorescence-activated cell sorting (FACS) to isolate GFP+ cells from 
GFP- cells. Four clones of both Cish and Socs2 shRNAs with highest knockdown 
efficiency of the respective target gene were chosen, and the plasmids were sent to the 
Protein Expression and Libraries Facility at Wistar Institute for packaging lentivirus for 
stable transduction (C1, C5, C7, C8, S4, S5, S7, S8). Cadaveric human islets were 
transduced with packaged CT lentivirus and transplanted under the kidney capsule of 
immunodeficient mice. Mice were given bromodeoxyuridine (BrdU) in the drinking 
water for the whole 14 days and the grafts were retrieved after 14 days of in vivo 
incubation and processed for immunostaining using standard methods. 
 
Statistical analysis: Data are presented as mean±SEM. The statistical significance of 
differences was determined by Student’s t tests or MANOVA. P<0.05 was considered 
statistically significant.  
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Chapter 3   HNF-4α is required for beta cell proliferation during obesity 
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Abstract	  	  
       Hepatocyte nuclear factor 4 alpha (HNF-4α) regulates insulin secretion and beta cell 
proliferation during the metabolic stress of pregnancy. But it is not known whether 
HNF4α also plays a role in beta cell replication during obesity. Therefore, I investigated 
the role of HNF4α in obesity by using two obese mouse models.  
       In the first model, Hnf4α was ablated in pancreatic beta cells on the ob/ob mice 
background via tamoxifen pellet implantation in Hnf4αL/L; Mip-CreER; ob/ob mice. Beta 
cell proliferation rates were halved in Hnf4α mutant mice. However, glucose homeostasis 
was not affected, indicating that although HNF-4α is required for adaptive beta cell 
proliferation in response to obesity, three weeks of Hnf4α ablation is not enough to 
promote beta cell mass change or a physiological phenotype. In the second model, Tre-
Hnf4α; Rip-rtTA mice were put on high-fat-diet to trigger murine obesity, and Hnf4α 
overexpression in beta cells was induced by doxycycline. Hnf4α mRNA expression 
increased 9-folds in beta cells of the overexpressing group. However, no difference in 
glucose homeostasis was observed between the control and the Hnf4α overexpressing 
groups, indicating that overexpressing Hnf4α is not sufficient to improve glucose 
tolerance in high-fat-diet induced obese mice.  
       I also investigated the function of ST5, a transcriptional target of HNF-4α, on beta 
cell proliferation. ST5 is a novel regulator of the Ras/ERK pathway in beta cells. 
Overexpression of St5 in beta cells was induced by doxycycline in Tre-St5; Rip-rtTA 
mice. St5 mRNA expression was up-regulated over 300-folds in beta cells of the 
overexpressing group. However, no statistically significant differences in glucose 
tolerance or beta cell proliferation were observed in the St5 overexpressing group 
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compared to the control group. In summary, my results suggest that HNF-4α is required 
for beta cell proliferation in obese mice. However, overexpression of neither Hnf4α nor 
its downstream target St5 is sufficient to promote protective effects on glucose 
homeostasis. 
Introduction	  
        Maturity onset diabetes of the young (MODY) is a group of monogenic autosomal 
dominant disorders characterized by a familial, early-onset, non-insulin dependent form 
of diabetes (Froguel & Velho, 1999). Using the best-characterized MODY pedigree, the 
RW family, DNA polymorphism of chr. 20q is linked to MODY1, and Hnf4α identified 
as the MODY1 gene (Bell et al., 1991; Stoffel et al., 1996; Yamagata et al., 1996). 
MODY1 patients with Hnf4α mutation exhibit diminished insulin secretion in response to 
glucose while retaining normal insulin sensitivity, indicating that beta cell dysfunction is 
the primary etiology of MODY1 (Byrne et al., 1995; Herman et al., 1997).  
       HNF-4α is the most abundant DNA-binding protein in the liver, regulating genes 
largely involved in hepatic gluconeogenesis and lipid metabolism (Chandra et al., 2013; 
Costa, Grayson, & Darnell, 1989). HNF-4α is also a master regulator in the pancreatic 
islets, controlling an estimated 11% of islet genes (Odom et al., 2004). Cloning of the 
Hnf4α gene and purification of its protein product suggest that HNF-4α is a member of 
the steroid hormone receptor superfamily (Sladek, Zhong, Lai, & Darnell, 1990). HNF-
4α contains a zinc-finger DNA binding domain and a ligand-binding domain (Fig 3.1a). 
HNF-4α dimerizes at its hinge site and subsequently binds DNA at its consensus 
sequence, which consists of two direct repeats separated by one or two nucleotides  
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Fig 3.1 Structure of HNF-4α protein and its isoforms (adapted from (Chandra et al., 2013; 
Eugene Bolotin, 2010)) a Linear depiction of the HNF-4α protein domains and its 
MODY1-linked point mutations identified in human populations. DBD: conserved zinc-
finger DNA binding domain; LBD: ligand binding domain. b Crystal structure of an 
HNF-4α homodimer. c HNF-4α isoforms and their functional domains. At least 6 
isoforms of HNF-4α are generated by differential use of the promoters and alternative 
splicing events specific to the C-terminus. Isoforms 1-3 are derived from the P1 promoter 
and expressed in the adult liver, kidney, intestine, and colon. Isoforms 7-9 are derived 
from the P2 promoter and expressed in the fetal liver, adult intestine, adult colon and 
adult pancreas. A/B: amino-terminal transactivation domain; C: DNA binding domain, D: 
hinge domain; E: ligand binding domain; F: inhibitory carboxy-terminal domain 
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(Bolotin et al., 2010; Sladek et al., 1990) (Fig 3.1b). Point mutations of Hnf4α linked to  
MODY1 are positioned in the interjunctional surface, where two HNF-4α proteins bind to 
each other (Chandra et al., 2013) (Fig 3.1a). Mutations in this hinge site disrupt the 
interaction between two HNF-4α proteins and lead to failure of recognizing and binding 
their successive DNA half-sites (Chandra et al., 2013).  
      Hnf4α has tissue specific expression driven by either its proximal promoter P1 (in 
adult liver, kidney, intestine) or an alternative promoter P2 (in fetal liver, adult colon, and 
adult pancreas), which is located 46kb upstream of P1 (Tanaka et al., 2006). At least six 
splice variants are expressed; variants Hnf4α1-3 are driven by P1 and variants Hnf4α7-9 
are driven by P2 (Fig 3.1c) (Eugene Bolotin, 2010). Hnf4α is highly expressed in the 
liver, kidney, and the intestines, and has detectable expression in pancreatic beta cells and 
the stomach (Duda, Chi, & Shoelson, 2004).  
        How HNF-4α becomes activated to regulate transcription of target genes is not 
entirely understood. One study resolves the crystal structure of the HNF-4α ligand-
binding domain and suggests that fatty acids are endogenous ligands of HNF-4α (Dhe-
Paganon, Duda, Iwamoto, Chi, & Shoelson, 2002). However, another study shows that 
coactivator rather than ligand binding leads to the active conformation of HNF-4α (Duda 
et al., 2004). Although the mechanism underlying HNF-4α  
transcriptional activity is still controversial, its important role in regulating metabolic 
processes such as glucose and lipid homeostasis has been of great interest (Hayhurst, Lee, 
Lambert, Ward, & Gonzalez, 2001). 
      Since beta cell dysfunction is the primary pathology of MODY1, several mouse 
models have focused on the role of HNF-4α in beta cells. First, HNF-4α has been 
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suggested to regulate glucose-stimulated insulin secretion (GSIS) in a Kir6.2 dependent 
manner. Kir6.2 is a potassium ion channel subunit in KATP-channel dependent insulin 
secretion (Gupta et al., 2005). Beta cell specific Hnf4α ablation in mice results in 
diminished first-phase insulin secretory response and impaired glucose tolerance (Gupta 
et al., 2005). Mechanistic study suggests that this impaired insulin secretion is due to 
downregulation of KCNJ11, the gene encoding Kir6.2 (Gupta et al., 2005). However, it is 
puzzling that although these mice are glucose intolerant due to diminished insulin 
secretion, they also exhibit hyperinsulinemia and mild hypoglycemia at fasted and fed 
status. This might be due to the relatively early age of the mice being studied (3-5 months 
old) compared to human MODY1 patients (15-25 years old) (Gupta et al., 2005). Indeed, 
children born haploinsufficient for Hnf4α also exhibit hypoglycemia and elevated basal 
insulin levels, which later evolves into diabetes due to reduced insulin secretion (Pearson 
et al., 2007). A similar study of beta cell specific Hnf4α ablation also exhibits deficiency 
in GSIS, but shows no decrease of KCNJ11 expression, suggesting that other targets of 
HNF-4α might also be involved in regulating GSIS (Miura et al., 2006).  
       Second, HNF-4α has been suggested to regulate beta cell proliferation in response to 
increased metabolic demand during pregnancy (Gupta et al., 2007). Beta cell specific 
ablation of Hnf4α results in fewer beta cell replications, reduced beta cell mass, and 
impaired glucose tolerance during pregnancy (Gupta et al., 2007). Specifically, HNF-4α 
is required to activate the Ras/ERK signaling cascade, which promotes the proliferative 
response in beta cells during pregnancy. HNF-4α directly activates suppression of 
tumorigenicity 5 (St5), a novel positive regulator of ERK signaling in beta cells, to 
influence ERK signaling. Thus, the downregulation of St5 caused by Hnf4α deficiency 
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contributes to the reduction in ERK activation (Gupta et al., 2007). Furthermore, a recent 
study demonstrated that overexpression of Hnf4α in human islets is sufficient to initiate 
cell cycle entry detected by BrdU incorporation (Rieck et al., 2012). However, these 
rapidly proliferating cells exhibit loss of beta cell lineage, increased cell cycle arrest, and 
increased cell apoptosis (Rieck et al., 2012).  
      Third, HNF-4α is at the center of the transcriptional network of beta cells (Gupta et 
al., 2007). A microarray study comparing gene expression in the normal mouse Hnf4α 
mutant islets relative to control islets revealed 128 significantly upregulated genes and 57 
downregulated genes in the mutant islets (Gupta et al., 2007). Gene ontology analysis 
shows that a large percentage of HNF-4α regulated genes are related to metabolism, 
proliferation, and signal transduction. This study shows that HNF-4α might have 
extensive roles in regulating beta cell function, which requires further investigation. 
       Although the role of HNF-4α in beta cell function and proliferation has been 
investigated at normal physiological conditions and during pregnancy, it is also important 
to investigate whether HNF-4α plays a role in obesity-induced beta cell compensation, 
which is much more relevant to human T2D. Indeed, in addition to its role as a MODY 
gene, Hnf4α has also been suggested to be a T2D risk gene (Gupta & Kaestner, 2004; 
Silander et al., 2004). SNPs spanning the P1, P2, and exons 1-3 regions of Hnf4α have 
been associated with increased susceptibility to T2D in multiple ethnic groups (S. K. 
Hansen et al., 2005; Lehman et al., 2007; Love-Gregory et al., 2004; Silander et al., 
2004). However, these results are still highly controversial. For example, one recent study 
demonstrated that in a European American population of 1270 T2D cases and 1017 
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controls, there is no association of Hnf4α variants with risk of T2D (Hellwege et al., 
2011).  
      In order to study the role of HNF-4α in obesity-induced beta cell adaptation, I used 
ob/ob mice, a genetic model of murine obesity, which is caused by mutation of the leptin 
gene (Ingalls, Dickie, & Snell, 1950). Leptin is a hormone that restricts food intake and 
controls body weight by acting on hypothalamus, and its mutation causes unrestricted 
food consumption and decreased energy expenditure, which leads to obesity (Seufert, 
2004). Different mouse strains have different susceptibility to the leptin mutation. For 
example, BTBRob/ob mice are very susceptible and become obese, insulin resistant, and 
develop severe diabetes from a young age of 6 weeks (Clee, Nadler, & Attie, 2005). 
B6ob/ob mice also become obese and insulin resistant at 6 weeks of age. However, B6ob/ob 
mice remain diabetes-resistant up to 16 weeks of age, because they compensate for the 
obesity-induced insulin resistance via stimulation of beta cell proliferation and increased 
insulin secretion. Thus, the B6ob/ob mice is an optimal mouse model for studying beta cell 
proliferation in adaptation to obesity (Clee et al., 2005).  
     Interestingly, expression of Hnf4α is upregulated in islets of B6ob/ob mice at 10 weeks 
of age, when the mice exhibit adaptive beta cell proliferation and hyperinsulinemia 
(Keller et al., 2008). In contrast, expression of Hnf4α is not upregulated in the BTBRob/ob 
mice at the same age, in which failure of adaptive beta cell proliferation leads to diabetes 
(29). Therefore, I hypothesize that upregulation of Hnf4α expression in B6ob/ob mice plays 
an essential role in regulating beta cell replication in adaptation to obesity. In addition, 
HNF-4α may regulate both insulin secretion and beta cell replication in an obese mouse 
model. 
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Results	  
Generating	  Hnf4aL/L;	  Pdx1-­‐CreLate;	  ob/ob	  mice	  with	  a	  congenic	  B6	  background	  	  
     In order to investigate the role of HNF-4α on beta-cell function in adaptation to 
obesity-induced insulin resistance, I bred Hnf4αloxP mice on a B6 background, which has 
the maximal beta cell proliferation capacity (Clee et al., 2005). Hnf4αL/+; Pdx1-CreLate 
mice, which were originally on a 129 genetic background, were backcrossed for six 
generations to B6 mice to produce B6 congenic mice. Congenic mice strains are 
conventionally derived by backcrossing a donor strain (129) that harbors a gene allele of 
interest (Hnf4αloxP) with a recipient inbred strain (B6) for at least ten generations. 
According to Mendel’s law, ten generations of backcrossing results in mice heterozygous 
for the locus of interest on a genome which is approximately 99.90% identical to that of 
the recipient genome. This traditional method, which takes 3 years to complete, has been 
advanced by a speedy and efficient genetic polymorphic marker-based breeding strategy 
(Markel et al., 1997). The optimal breeders of each generation are selected based on a 
screen for microsatellite markers that have different sizes in the donor strain and the 
recipient strain. The pups that have the least amount of donor markers are used for the 
next backcross (Fig 3.2a).         
     Hnf4αL/+; Pdx1-CreLate mice were backcrossed with B6 mice for six generations. Pups 
of each backcrossing were genotyped for microsatellite markers flanking the Hnf4α 
locus. Pups with B6 genetic markers closest to Hnf4α locus were selected for the next 
backcross (Fig 3.2b). Hnf4αL/+; Pdx1-CreLate mice with B6 congenic background were 
then bred with B6ob/+ mice to finally generate control Hnf4αL/L; ob/ob  mice and mutant 
Hnf4aL/L; Pdx1-CreLate; ob/ob mice. All genotypes were determined by PCR (Fig 3.2c). 
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The Pdx1-CreLate transgene is not expressed in early pancreatic progenitors, in pancreatic 
ducts, or acinar cells, like other Pdx1-Cre transgene (Herrera, 2000). Rather, it is 
specifically expressed and efficiently ablates loxP-flanked DNA sequences in mature beta 
cells, thus providing a beta-cell specific Hnf4a ablation model. 
Pdx1-­‐CreLate	  recombinase	  fails	  to	  excise	  Hnf4α	  loxP	  flanked	  site	  
     After obtaining control Hnf4aL/L; ob/ob mice and mutant Hnf4aL/L; Pdx1-CreLate; 
ob/ob mice, I first determined whether Hnf4α was ablated in the beta cells. Since mouse 
islets are 80% beta cells, whole islets were isolated to measure Hnf4α expression. 
Surprisingly, q-PCR analysis of mRNA isolated from islets showed no ablation of Hnf4α 
in islets from mutant mice compared to islets from control mice (Fig 3.3a). I also 
measured mRNA expressions of several HNF-4α target genes, including Hepatocyte 
nuclear factor 1 homeobox α (Hnf1α), Live pyruvate kinase (LPK), Kir6.2, and 
Glucokinase (Gck) (Boj, Parrizas, Maestro, & Ferrer, 2001). Their expressions also 
remain the same in mutant mice compared to control mice (Fig 3.3a). In addition, both 
western blot and immunostaining for HNF-4α in islets confirmed on the protein level that 
Hnf4α was not ablated in islets of Hnf4aL/L; Pdx1-CreLate; ob/ob mutant mice (Fig 
3.3b,c). 
      To troubleshoot the failure of gene ablation, Pdx1-CreLate transgenic mice were tested 
for the presence of Cre recombinase. First, genotyping primers were designed to make  
sure that Pdx1-CreLate transgenic mice were not confused with Pdx1-CreER transgenic 
mice during breeding. Since the Pdx1-CreLate transgene differs from the Pdx1-CreER 
transgene following the Cre sequence, specific primers were designed to differentiate 
these two Cre transgenes (Fig 3.4a). Mice within my colony, presumably with the Pdx1- 
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Fig 3.2 Generating congenic B6 Hnf4aL/L; Pdx1-CreLate; ob/ob mice. a Backcrossing 
Hnf4αL/+ 129 strain mice to B6 mice to derive congenic Hnf4αL/+ B6 mice. b Genotyping 
of pups for microsatellite polymorphism markers in the donor 129 strain and the recipient 
B6 strain. From left to right are four 129 controls, four B6 control, and eight pups. Pups 
with B6 genetic markers are labeled with light green stars and pups with both 129 and B6 
genetic markers are labeled with orange stars. Mice with B6 markers are chosen for the 
next generation of backcrossing. c Top panel: Genotyping for Hnf4α loxP allele and wild 
type allele. Lower panel: Genotyping for ob mutant allele and ob wild type allele. !
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CreLate transgene, and mice of Pdx1-CreER colony were genotyped. Accurate sizes of 
PCR products from Pdx1-CreLate mice were produced, indicating that the correct Cre line 
was presented in my mouse colony (Fig 3.4b). 
       Next, I tested the recombinase activity of Pdx1-CreLate. Pdx1-CreLate mice were 
crossed with Rosa-loxP-STOP-loxP-YFP (shortened as Rosa-YFP) mice to generate 
Pdx1-CreLate; Rosa-YFP mice. Upon Cre recombination, a loxP flanked STOP codon is 
excised, which leads to expression of YFP in Cre+ cells and all progeny of Cre+ cells. 
This is a powerful system to visualize the expression pattern of specific Cre 
recombinases. Immunostaining of YFP demonstrates that Pdx1-CreLate is not active in 
any islet beta cells as expected (Fig 3.4c). One slide of liver tissue positive for YFP was 
used as control to verify that the YFP staining was effective (Fig 3.4c). In summary, the 
Pdx1-CreLate recombinase is silenced, which occasionally happens to transgenes for  
variable reasons (Bestor, 2000; Chevalier-Mariette et al., 2003; Garrick, Fiering, Martin, 
& Whitelaw, 1998). This explains the failure of Hnf4α ablation with this Pdx1-CreLate 
line.  
       Following these results, I went on to validate the Hnf4α loxP allele with another Cre 
recombinase. Adenovirus-associated virus packaged Cre (AAV-Cre) were injected retro-
orbitally into Hnf4αL/L; ob/+ mice to induce Hnf4α ablation in the liver. AAV-GFP was 
also injected in a separate group of mice as a control. Eleven days after injection of either 
AAV-Cre or AAV-GFP, mice were sacrificed and liver tissues were collected. Western  
blot of liver lysis demonstrates efficient ablation of HNF-4α on AAV-Cre injected mouse 
comparing to AAV-GFP injected mice or mice without injection (Fig 3.5a). Furthermore, 
liver sections were immunostained for HNF-4α, and AAV-Cre injected mice exhibited 
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Fig 3.3 Pdx1-CreLate recombinase failed to excise Hnf4α loxP flanked site. a q-PCR 
analysis for mRNA expression of Hnf4α and its target genes. mRNA were isolated from 
islets of control Hnf4αL/L; ob/ob mice and mutant Hnf4aL/L; Pdx1-CreLate; ob/ob mice. No 
differences in gene expression were observed between control and mutant islets. b 
Western blot shows no difference of HNF-4α protein level between islets of control and 
mutant mice. c Immunostaining of pancreas sections shows no ablation of HNF-4α 
protein in islets of mutant mice. 
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Fig 3.4 Pdx1-CreLate recombinase is silenced. a Comparison of the Pdx1-CreLate transgene 
and the Pdx1-CreER transgene constructs, which differ following the Cre sequence. PCR 
primers were designed to differentiate between these two Cre lines. b Genotyping of 
Pdx1-CreLate mice and Pdx1-CreER mice. Pdx1-CreLate gene has bands with primer sets A 
and C, while Pdx1-CreER gene has bands with primer sets A and B. c Pdx1-CreLate; Rosa-
YFP mice were generated and the expression pattern of Pdx1-CreLate recombinase was 
examined. The results show that Pdx1-CreLate recombinase was silenced because there 
was no YFP expression in beta cells. On the far right is a YFP+ liver section to validate 
the effectiveness of the YFP staining. !
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very efficient ablation of HNF-4α protein in more than 90% of the hepatocytes, 
indicating that Hnf4α loxP allele is susceptible to Cre recombination (Fig 3.5b). 
Generating	  Hnf4αL/L;	  Mip-­‐CreER;	  ob/ob	  mice	  
     Since Pdx1-CreLate is silenced in my mouse colony, I bred Mip-CreER mice with 
Hnf4αL/L mice and generated control Hnf4aL/L; ob/ob mice and mutant Hnf4αL/L; Mip-
CreER; ob/ob mice for further studies. Mip-CreER is an inducible Cre line driven by the 
mouse insulin promoter (Wicksteed et al., 2010a). CreER translocates into the nucleus and 
activates recombination only upon administration of tamoxifen, an estrogen receptor 
ligand.  
      First, I verified Mip-CreER recombinase efficiency by crossing Mip-CreER mice with 
Rosa-YFP mice. Tamoxifen was injected 2mg/day for three days into Mip-CreER; Rosa-
YFP mice. Three days after the last injection, mice were sacrificed and the pancreata 
were isolated, fixed, and sectioned. Pancreas sections were co-staining for insulin and 
YFP. Mip-CreER; Rosa-YFP mice exhibit YFP positive staining in a large portion of their 
beta cells, indicating efficient Cre recombination (Fig 3.6a).  
       Next, I tested the Hnf4α ablation efficacy in Hnf4αL/L; Mip-CreER; ob/ob mice with 
Hnf4aL/L; ob/ob mice as controls. To induce Cre recombination and Hnf4α ablation in 
beta cells, I injected 2mg/day tamoxifen for two successive days. Mice were sacrificed 
nine days after the last tamoxifen injection and pancreas tissues were harvested.  
Immunostaining of pancreas sections revealed a partial ablation of HNF-4α in mutant 
islets. This partial ablation could be caused by mosaic activity of the CreER recombinase,  
or a relatively long half-life of the HNF-4α protein (Fig 3.6b).  
       To test the effects of prolonged tamoxifen administration, a tamoxifen pellet was 
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Fig 3.5 Validation of the Hnf4α loxP allele. a AAV-Cre were injected retro-orbitally into 
Hnf4aL/L; ob/+ mice to induce Hnf4α ablation in the liver. AAV-GFP was used as control 
virus. Western blot of lysed liver tissue showed efficient ablation of HNF-4α protein in 
AAV-Cre injected mouse. b Immunostaining of liver sections also proved efficient 
ablation of HNF-4α protein in >90% of hepatocyte supon AAV-Cre injection. !
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Fig 3.6 Hnf4α is ablated in islets of Hnf4αL/L; Mip-CreER; ob/ob mice. a Mip-CreER mice 
were crossed with Rosa-YFP mice to evaluate Cre recombination efficiency. Three days 
after two injections of tamoxifen, mice were sacrificed. Immunostaining of pancreas 
sections reveal YFP expression in the majority of beta cells, suggesting that Mip-CreER is 
effective in pancreatic beta cells. b Hnf4aL/L; ob/ob mice and Hnf4αL/L; Mip-CreER; ob/ob 
mice were injected with tamoxifen to test Hnf4α ablation. Nine days after tamoxifen 
injection, mice were sacrificed. Partial ablation of HNF-4α protein is observed in 
pancreas sections of mutant mice compared to control mice. c Western blot of HNF-4α in 
islets of control and mutant mice. Six weeks after tamoxifen pellet embedding, HNF-4α 
protein is efficiently ablated in islets of mutant mice. In addition, partial ablation is 
observed in mutant mice five days after injection, indicating a relatively long half-life of 
HNF-4α protein. Furthermore, ob/ob mice have higher HNF-4α protein levels than ob/+ 
mice, confirming that Hnf4α is upregulated upon obesity. !
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 embedded under the skin of both control mice and mutant mice. These pellets allow 21 
days of tamoxifen release, at the rate of about 1mg of tamoxifen per day. Six weeks after 
pellet embedding, islets were isolated for protein extraction. Western blot confirmed the 
ablation of HNF-4α protein in mutant mice (Fig 3.6c). In addition, control and mutant 
mice heterozygous for the ob mutation (Hnf4αL/L; ob/+, and Hnf4αL/L; Mip-CreER; ob/+, 
respectively) were injected with tamoxifen and sacrificed five days later. Partial ablation 
of HNF-4α protein was observed in mutant mice compared to control mice, consistent 
with previous results that HNF-4α protein has a relatively long half-life. It is worth noting 
that there seems to be higher HNF-4α protein level in control ob/ob mice than in control 
ob/+ mice, confirming that Hnf4α expression is positively correlated with increased body 
weight and increased metabolic demand for beta cell proliferation. 
HNF-­‐4α	  is	  required	  for	  beta	  cell	  proliferation	  in	  obese	  mouse	  
     B6ob/ob mice have increased insulin secretion from 7 to 14 weeks of age, which helps 
prevent the severe hyperglycemia normally associated with obesity-induced insulin 
resistance (Clee et al., 2005). The most rapid upregulation of insulin secretion in male 
B6ob/ob mice occurs from 7 to 10 weeks of age. Interestingly, Hnf4a expression is also 
upregulated in islets of B6ob/ob mice at this timepoint (Keller et al., 2008). Therefore, I 
hypothesized that 7 to 10 weeks of age is the time window during which beta cell 
proliferation increases the most, in an HNF-4α-dependent manner, and leads to beta cell 
mass expansion. Indeed, control ob/ob mice possess huge islets and higher percentage of 
BrdU positive cells at 10 weeks of age compared to lean mice (data not shown). In order 
to investigate the role of HNF-4α in the adaptive beta cell proliferation in response to 
obesity, I induced Hnf4α ablation from 7-week old male ob/ob mice, and analyzed the 
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mice at 10 weeks of age. 
     Both control (Hnf4aL/L; ob/ob) and mutant (Hnf4αL/L; Mip-CreER; ob/ob) 7 weeks old 
mice were embedded with tamoxifen pellets, which allow for 21 days of continuous 
tamoxifen release. At 10 weeks of age, mice were fasted overnight for glucose tolerance 
tests. Pancreas sections were immunostained for Ki67, a marker for proliferative cells 
(Fig 3.7a). Nine control and seven mutant mice with comparable body weight were  
analyzed. About 3000 beta cells were manually counted for each mouse. Beta cell 
proliferation rate was calculated as the ratio of Ki67/insulin double positive cells divided 
by the total number of insulin+ cells. Interestingly, mutant mice have a lower beta cell 
replication rate than control mice (Fig 3.7b). This result demonstrates for the first time 
that HNF-4α is required for beta cell proliferation in obesity. However, no difference in 
beta cell mass is observed between control and mutant mice (Fig 3.7c). 
       Since HNF-4α has been shown to regulate glucose tolerance by promoting insulin 
secretion, I measured fasting and fed glucose levels of both groups, and there are no 
significant differences. Glucose tolerance tests were performed following overnight 
fasting with 1mg/g body weight glucose injection.  No difference in glucose tolerance is 
observed between control and mutant mice, indicating that the effects of decreased beta 
cell proliferation for three weeks are not severe enough to affect glucose homeostasis. 
Overexpression	  of	  Hnf4α	  has	  no	  protective	  role	  in	  HFD	  induced	  hyperglycemia	  
         HNF-4α is required not only for beta cell metabolic functions, but also for the 
proliferative response of the beta cell to increased metabolic demand (Gupta et al., 2007). 
I hypothesized that overexpressing Hnf4α would promote beta cell proliferation in vivo,  
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Fig 3.7 Hnf4α ablation in beta cells results in reduced beta cell proliferation. a 
Immunostaining of Ki67 and insulin in control and mutant ob/ob mice. Male mice were 
embedded with tamoxifen pellets at 7 weeks of age and sacrificed at 10 weeks of age. b 
Beta cell proliferation rates were calculated as the ratio of the number of Ki67+/Insulin+ 
cells divided by the total number of insulin+ cells. 9 control mice and 7 mutant mice were 
analyzed. About 3000 beta cells were manually counted for each mouse. c Beta cell mass 
analysis reveals no difference between control and mutant mice. d Fed and fasting 
glucose levels of control and mutant mice are similar. e Glucose tolerance tests were 
performed on 10-weeks old control and mutant mice. 1mg/g body weight of glucose was 
injected after overnight fasting. No difference in glucose tolerance is observed between 
the two groups. 
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which may result in improved glucose tolerance. Two mouse models of overexpressing 
Hnf4α were designed. First, I bred triple transgenic lines of Tre-Hnf4α/R26-
rtTA/MipCreER mice (Fig 3.8a). The Mip-CreER recombinase is activated specifically in 
beta cells by administration of tamoxifen as mentioned previously, and results in excision 
of the stop cassette from the Rosa26-rtTA locus. Once the stop cassette is excised, the 
Rosa26 promoter induces the expression of rtTA (reverse tetracycline transcriptional 
activator) solely in beta cells. Treatment with doxycycline activates rtTA, promotes its 
binding to the TRE element, and turns on expression of the Tre-Hnf4α transgene 
specifically in the beta cells (Balcazar et al., 2009; Rachdi et al., 2006). Unfortunately, no 
triple transgenic pups were born. Therefore, I dropped this line and proceeded with the 
second overexpression model, the Tre-Hnf4α/Rip-rtTA mouse line. 
     In Tre-Hnf4α/Rip-rtTA mice, rtTA is expressed specifically in the beta cells under the 
rat-insulin-promoter (Rip). Upon administration of doxycycline, rtTA binds to TRE 
element, which in turn promotes Hnf4α overexpression solely in beta cells (Fig 3.8b). 
Mice were given 2mg/ml doxycycline in drinking water when they were 12 weeks old. 
Four weeks later, islets of both control mice (Tre-Hnf4α) and overexpression mice (Tre-
Hnf4α; Rip-rtTA) were isolated, and relative expression of Hnf4α was measured by qPCR 
on islet mRNA. Human-Hnf4α8, which is the transgene under the Tre promoter, is 
overexpressed 9 fold in islets of overexpressing group compared to islets of the control 
group (Fig 3.9a). Endogenous mouse-Hnf4α exhibited no change in expression. However, 
expressions of several HNF-4α targets are not up-regulated upon Hnf4α overexpression, 
including Kir6.2 and St5 (Fig 3.9a). Glucose tolerance tests were performed on Hnf4α  
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Fig 3.8 Hnf4α overexpression mouse models. a Tre-Hnf4α /R26-rtTA/MipCreER mouse 
model. The Mip-CreER recombinase is expressed specifically in beta cells. After 
administration of tamoxifen, the CreER recombinase translocates into the nucleus, and 
results in excision of the stop cassette from the Rosa26-rtTA locus. Once the stop cassette 
is excised, the Rosa26 promoter induces the expression of rtTA (reverse tetracyclin 
transcriptional activator) solely in beta cells. Treatment with doxycycline activates rtTA, 
promotes its binding to the TRE element, and induces overexpression of the Tre-Hnf4α 
transgene specifically in beta cells. b Tre-Hnf4α /Rip-rtTA mouse model. rtTA is 
expressed specifically in beta cells under the rat-insulin-promoter (Rip). Upon 
administration of doxycycline, rtTA binds to TRE element, which in turn promotes 
Hnf4α overexpression solely in beta cells. 
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Fig 3.9 Hnf4α overexpression has no protective role in HFD-induced hyperglycemia. a 
mRNA expression of human-Hnf4α8, Ki67, Kir6.2, St5, and mouse-Hnf4α in isolated 
islets from doxycycline treated control mice (Tre-Hnf4α) and overexpression mice (Tre-
Hnf4α; Rip-rtTA). Human-Hnf4α8 is upregulated for 9-fold in overexpression group. b 
Glucose tolerance tests of chow diet fed control mice and overexpression mice. n=4 of 
each group. All male mice were 4 months old. c Resting and fed glucose levels of chow 
diet fed control mice and overexpression mice. n=4 of each group. All male mice were 4 
months old. Glucose tolerance test (d), resting and fasting glucose levels (e), resting and 
fasting insulin levels (f), body weight (g) of HFD-fed male mice. n=4-5 for each group. 
Glucose tolerance test (h), resting and fasting glucose levels (i), resting and fasting 
insulin levels (j), body weight (k) of HFD-fed female mice. n=4 for each group.  
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overexpression mice (Tre-Hnf4α; Rip-rtTA with doxycycline) and two control groups 
 (Tre-Hnf4α; Rip-rtTA without doxycycline and Tre-Hnf4α mice with doxycycline). No 
differences in glucose tolerance were observed among the different groups (Fig 3.9b). 
Furthermore, fed and fasting glucose levels were measured and no differences were 
observed (Fig 3.9c). In summary, overexpressing Hnf4α is not sufficient to improve 
glucose tolerance under basal physiological conditions. This is not surprising since under 
basal conditions, there is no need for improvement of beta cell proliferation. Therefore, 
overexpressing a positive regulator of beta cell proliferation has no effect on glucose 
tolerance. 
        In order to challenge the mice with higher metabolic demand, mice were put on high 
fat diet for three months (one month old to four months old). Overexpression of Hnf4α 
was induced by doxycycline administration for a month (three to four months old). High 
fat diet successfully promoted obesity in both male and female mice, with male mice 
weighed around 40 grams and female mice weighed around 30 grams (Fig 3.9g,k). 
However, there were no differences in glucose tolerance (Fig 3.9d,h), fed and fasting 
glucose (Fig 3.9e,i), or fed and fasting insulin levels (Fig 3.9f,j) in Hnf4α overexpressing 
obese mice compared to control obese mice. In summary, Hnf4α overexpression does not 
provide protection against glucose intolerance in an obese mouse model. 
Overexpression	  of	  St5	  has	  no	  effect	  on	  glucose	  tolerance	  or	  beta	  cell	  proliferation	  
       HNF-4α regulates the Ras/ERK pathway to promote beta cell proliferation in an 
ST5-dependent manner during pregnancy (9). St5 is a direct transcriptional target of 
HNF-4α and its expression decreases in Hnf4α-deficient islets. In vitro studies show that 
ST5 positively regulates Ras/ERK pathway. Therefore, I hypothesized that 
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overexpression of St5 in beta cells might be exploited to increase beta cell proliferation 
via augmented Ras/ERK signaling. 
      The experimental strategy used to overexpress St5 was similar to the Hnf4α 
overexpression model. Both control (Tre-St5) and overexpression (Tre-St5/Rip-rtTA) 
mice were given doxycycline in drinking water for 3 weeks (7 to 10 weeks old). Since 
mice have shown resistance to doxycycline drinking water and lagging of body weight 
growth compared to mice on normal water in a previous study, 2.5% sucrose was added 
into drinking water to improve taste. Islet mRNA from both control and St5 
overexpression mice were isolated. qPCR shows dramatic overexpression of human-St5 
in Tre-St5/Rip-rtTA mouse islets while endogenous mouse-St5 expression remains the 
same, relative to controls (Fig 3.10a). Immunostaining of pancreas sections confirms the 
extensive upregulation of ST5 protein in beta cells of the overexpression group (Fig 
3.10b). In control mice, ST5 protein is undetectable in islets. In the overexpression group, 
ST5 exhibited a mosaic overexpression pattern, with approximately 60% of beta cells 
producing high levels of ST5 protein (Fig 3.10b).  
       After validating the St5 overexpression mouse model, I performed glucose tolerance 
tests to investigate the effects of beta cell specific St5 overexpression on glucose 
homeostasis. 10 weeks old male mice from both control and overexpression group were 
tested and there is no difference between glucose tolerance or resting and fasting glucose 
(Fig 3.10c,d). Female mice also display no significant differences (Fig 3.10e,f). Next, I 
examined the effects of St5 overexpression on beta cell proliferation. Ki67 and insulin 
immunostaining were used as markers for replicating cells and beta cells, respectively. 
Five control female mice and five St5 overexpression female mice were 
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Fig 3.10 Overexpression of St5 has no effect on glucose tolerance or beta cell replication. 
a qPCR results demonstrated that human-St5 is highly overexpressed in isolated mouse 
islets while endogenous mouse-St5 expression is unaffected. b Immunostaining of 
pancreas sections reveals extensive upregulation of ST5 protein in islets of 
overexpression group. Glucose tolerance test (c) and resting and fasting glucose levels 
(d) of control and overexpression male mice at 10 weeks old. Glucose tolerance test (e) 
and resting and fasting glucose levels (f) of control and overexpression female mice at 10 
weeks old. g Co-immunostaining of Ki67 and insulin in islets of both control and 
overexpression groups. h Quantification of proliferating beta cells. Proliferation rate was 
quantified as the ratio of the number of Ki67+/insulin+ cells divided by the total number 
of insulin+ cells. n=4 for each group. All female mice were 10 weeks old. i Beta cell mass 
of control and overexpression mice. n=5 of each group. All mice were treated with 
doxycycline for 3 weeks (7 to 10 weeks of age). Data shown in a and b were generated 
by Jia Zhang. 
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analyzed, and no statistically differences in beta cell proliferation were observed between 
the two groups (Fig 3.10g,h). Beta cell mass was also measured, and there was no 
difference (Fig 3.10i). In stark contrast to my original hypothesis, there is actually a trend 
that St5 overexpression might result in lower beta cell proliferation rate and lower beta 
cell mass.  
Discussion	  	  
     Previous studies in our lab have shown that HNF-4α is required for both beta cell 
function and beta cell proliferation (Gupta et al., 2007; Gupta et al., 2005). Mice lacking 
Hnf4α in beta cells are glucose-intolerant due to an impaired first-phase insulin secretory 
response (Gupta et al., 2005). Furthermore, HNF-4α also plays an essential role in the 
proliferative response of beta cells to the altered metabolic demands of pregnancy. Mice 
with beta cell specific Hnf4a ablation failed to replicate and expand beta cell mass during 
pregnancy, which led to lower insulin content and impaired glucose tolerance (Gupta et 
al., 2007). Mechanistic studies show that Ras/ERK signaling is downregulated in Hnf4α 
deficient beta cells (Gupta et al., 2007). ST5, a direct target of HNF-4α, is the molecular 
link between HNF-4α and Ras/ERK signaling. ST5 is homologous to known guanine 
exchange factors and its overexpression leads to increased ERK activation (Majidi, 
Hubbs, & Lichy, 1998). Min6 cells treated with St5 shRNA display lower basal and EGF-
stimulated p-ERK protein levels, suggesting that ST5 is a novel regulator of ERK 
signaling in beta cells. 
     Since Hnf4α deficiency is associated with both MODY1 in humans and gestational 
diabetes in mouse, it is important to investigate whether HNF-4α also plays a role in 
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obesity-induced beta cell compensation, which is much more relevant to human health. 
Interestingly, Hnf4α is upregualted in islets of B6ob/ob mice, which have compensatory 
beta cell proliferation during obesity, but not BTBRob/ob mice, which fail to augment beta 
cell proliferation in obesity and become hyperglycemic. These results suggest that HNF-
4α plays an important role in regulating beta cell replication during obesity-induced 
insulin resistance (Keller et al., 2008). Two obesity mouse models were investigated in 
my studies. The first was genetically induced obesity with a leptin gene mutation (ob/ob 
mouse model). The second was the high-fat-diet induced obesity mouse model.  
 
HNF-4α is required for adaptive beta cell replication in ob/ob mice 
       In this study, I induced Hnf4α ablation in beta cells of obese mice to directly 
determine the requirement of HNF-4α in beta cell proliferation during obesity. B6ob/ob 
mice provide an ideal model for studying adaptive beta cell proliferation in response to 
obesity because they have only mild hyperglycemia achieved by upregulated beta cell 
proliferation between 6 to 14 weeks of age (31). Both control (Hnf4aL/L; ob/ob) and 
mutant (Hnf4αL/L; Mip-CreER; ob/ob) mice were embedded with tamoxifen pellets from 7 
to 10 weeks of age. Male mice were chosen for this study because they exhibit a higher 
capacity of beta cell compensation during obesity (31). 
     Immunostaining and western blot show >90% ablation of HNF-4α protein in islets 
from mutant mice. Staining for Ki67 in islets revealed a 50% proliferation rate in Hnf4α 
mutant beta cells compared to control beta cells, suggesting that HNF-4α is required for 
beta cell proliferation in obese mice. However, despite the deficiency in proliferation, 
beta cell mass remains the same in mutant mice compared to control mice. Additionally, 
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no differences are observed in fed or fasting glucose levels. Mutant mice also exhibit 
normal glucose tolerance. One possible explanation of the lack of physiological 
phenotype is that ob/ob mice gain more weight than lean mice from as early as two weeks 
of age (Q. Gao et al., 2007), indicating that their beta cells might start to increase 
proliferation at a very early age. Therefore, beta cell mass may have already been 
established when the mice are 7 weeks old. In this case, the reduced beta cell 
proliferation achieved by ablation of Hnf4α for three weeks might not be enough to lead 
to an observable decrease in beta cell mass. Two different approaches could be utilized to 
answer these remaining questions. First, prolonged Hnf4α ablation in ob/ob mice will 
provide more insight to the requirement of HNF-4α for maintenance of beta cell mass 
during obesity. Alternatively, it will also be informative to ablate Hnf4α from an earlier 
stage, such as two weeks of age, before beta cell mass starts to expand on the ob/ob 
background. In this way, the effect of Hnf4α ablation on beta cell proliferation might be 
more severe.  
       It will also be benificial to investigate the level of Ras/ERK signaling in Hnf4α 
mutant ob/ob mice, to determine whether HNF-4α regulates beta cell proliferation via the 
same pathway in obesity as during pregnancy. St5 expression measurements in this model 
will help partially elucidate the mechanism of impaired beta cell proliferation in Hnf4α-
deficient beta cells. Because the mechanisms of beta cell proliferation in obesity and 
pregnancy are not exactly the same (Rieck et al., 2009), it would be beneficial to 
investigate whether HNF-4α is involved in obesity-associated beta cell proliferation 
pathways. For example, high blood glucose levels and glycolytic pathways have been 
suggested to induce beta cell proliferation. Therefore, glycolytic pathway could be 
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investigated in Hnf4α mutant ob/ob beta cells by manipulating glucokinase by its 
activator. It would also be interesting to test the insulin secretion capacity of Hnf4α 
mutant beta cells in obese mice. This could be accomplished by isolating islets for 
glucose-stimulated insulin secretion assays, or by measuring insulin levels in vivo after 
injecting glucose. Since HNF-4α regulates insulin secretion by directly controlling Kir6.2 
expression, it would be valuable to compare the expression of Kir6.2 in islets between 
control and mutant obese mice. A microarray on islet mRNA should be performed to 
compare the expression profiles between control and mutant mice. This will provide a 
comprehensive understanding of the role of the transcription factor HNF-4α in beta cell 
function during obesity. 
 
Hnf4α overexpression is not sufficient to improve glucose tolerance in HFD induced 
obese mice 
     In this study, I investigated the role of HNF-4α on beta cell proliferation during 
obesity by overexpressing Hnf4α in beta cells of high-fat-diet induced obese mice. My 
hypothesis was that overexpressing Hnf4α would result in increased beta cell 
proliferation and improved glucose tolerance during obesity. Mice were given high-fat-
diet from 1 to 4 months of age. Both control mice (Tre-Hnf4α) and Hnf4α overexpression 
mice (Tre-Hnf4α; Rip-rtTA) were administrated doxycycline in drinking water for the last 
3 weeks of the high-fat-diet. qPCR results demonstrate that human-Hnf4α8 is upregulated 
9-fold in islets from the Hnf4α overexpression group compared to islets from the control 
group. Glucose tolerance and resting/fasting glucose levels are the same in control and 
Hnf4α mutant mice on chow-diet fed mice. Moreover, no differences are observed in 
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glucose tolerance, resting/fasting glucose, or resting/fasting insulin levels between the 
control and mutant groups on HFD (both males and females). Overall, these results 
suggest that Hnf4α overexpression is not sufficient to improve glucose homeostasis in 
obese mice. 
      It would be helpful to quantify beta cell proliferation in both control and mutant 
group. It is possible that overexpressing Hnf4α induces a small increase in beta cell 
proliferation, to an extent that no detectable physiological phenotype could be detected. A 
recent study in our lab demonstrates that Hnf4α overexpression in human islets results in 
increased beta cells entry into cell cycle; however, these cells fail to complete the cell 
cycle. Indeed, the rapidly proliferating beta cells harbored signs of DNA damage and 
apoptosis. It would be important to test if this is the case for Hnf4α overexpression in 
mouse beta cells. 
 
St5 overexpression is not sufficient to increase beta cell proliferation 
     In this study, I investigated the effects of St5 overexpression on beta cells proliferation 
and glucose homeostasis. Because ST5 is a positive regulator of ERK signaling, and ERK 
signaling is known to increase beta cell proliferation during mouse pregnancy, I 
hypothesized that overexpressing St5 specifically in beta cells would cause increased beta 
cell proliferation. Both control mice (Tre-St5) and St5 overexpression mice (Tre-St5; Rip-
rtTA) were administrated doxycycline in drinking water from 7 to 10 weeks of age. Q-
PCR results demonstrate that human-St5 mRNA is upregulated more than 300-fold in 
islets from the overexpression group compared to islets from the control group. 
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Immunostaining confirmed the dramatic increase of ST5 protein in beta cells from the 
overexpression group. 
      Glucose tolerance and resting/fasting glucose levels are the same in the control and 
mutant groups, suggesting that St5 overexpression is not sufficient to improve glucose 
homeostasis. Furthermore, no increase in beta cell proliferation or beta cell mass were 
observed between control and overexpression mice, suggesting that overexpressing St5 in 
beta cells is not sufficient to induce beta cell proliferation. 
       It would be beneficial to repeat this study with an additional stress, such as 
pregnancy or obesity, to test whether ST5 plays a role in beta cell proliferation when 
there are higher metabolic demands. This is a possible outcome since ST5 is a knowb 
regulator of the ERK pathway, which has been shown to regulate beta cell proliferation 
during pregnancy.  
Materials	  and	  methods	  
Mice: Hnf4α loxP mice and Pdx1-CreLate mice have been described previously(9). 
Hnf4αL/+; Pdx1-CreLate mice were backcrossed with B6 mice for six generations to 
achieve congenic B6 background. Since Hnf4α is located at 94cM of chromosome 2, sets 
of genotyping primers containing polymorphisms between the donor 129 strain and the 
recipient B6 strain were generated at ~10cM intervals on chromosome 2, according to the 
list in Ref (Schalkwyk et al., 1999). After PCR of genomic DNA extracted from tails, 
non-denaturing 8% acrylamide gels were run as 45V for 3 hours at room temperature. 
Pups with the most acquisition of the recipient B6 gene background detected by the 
polymorphism markers were chosen for next generation backcrossing. This marker-
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assisted breeding allowed us to generate congenic B6 mice in six generations instead of 
the conventionally used ten generations (Markel et al., 1997). After six generations, 
markers >8cM away from the Hnf4α locus were all from B6 background. In addition, 
these mice were all black. Hnf4αL/+; Pdx1-CreLate mice were further crossed with B6ob/+ 
mice to derive Hnf4αL/+; Pdx1-CreLate; ob/+ mice. These mice were crossed to produce 
mice homozygous for the Hnf4α loxP allele (Hnf4aL/L; Pdx1-CreLate; ob/+). Since ob/ob 
mice are sterile, ob/+ mice had to be bred to generate ob/ob mice. Specifically, Hnf4aL/L; 
Pdx1-CreLate; ob/+ mice were crossed with Hnf4aL/L; ob/+ mice to produce control 
Hnf4aL/L; ob/ob mice and mutant Hnf4aL/L; Pdx1-CreLate; ob/ob mice.  
         Hnf4αL/L; Mip-CreER; ob/ob mice were generated by crossing Hnf4αL/L; ob/+ mice 
with Mip-CreER mice. To induce Hnf4α ablation, tamoxifen pellets (free base, 25 
mg/pellet, 21 day release, E-361; Innovative Research of America) were implanted 
subcutaneously into the mice. Analysis was performed 3 weeks after implantation. 
Alternatively, 2mg/ml tamoxifen dissolved in sunflower oil was injected. 
          Pdx1-CreLate mice and Mip-CreER mice were crossed with Rosa-loxP-STOP-loxP-
YFP mice to determine Cre recombinase expression pattern and efficiency. 
Tre-Hnf4α/R26-rtTA/MipCreER mice were generated by crossing the three respective 
transgenic mice strains. Tre-Hnf4α/Rip-rtTA mice were generated by crossing the two 
respective transgenic mice strains. 1g/kg doxycycline was administrated in drinking 
water for both control (Tre-Hnf4α) and overexpressing (Tre-Hnf4α; Rip-rtTA) mice. Mice 
without doxycycline treatment (Tre-Hnf4α; Rip-rtTA) also served as controls. High-fat-
diet was given to mice from 1 month to 4 months of age. Doxycyclin was given for the 
last 3 weeks of their lives. Mice were sacrificed at 4 months of age. 
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           Tre-St5/Rip-rtTA mice were generated by crossing the two respective transgenic 
mice lines. 1g/kg doxycycline with 2.5% sucrose was administrated in drinking water for 
both control (Tre-St5) and overexpression (Tre-St5; Rip-rtTA) mice. 
 
Islet isolation and real-time PCR: Islets were isolated using standard collagenase 
procedures followed by purification through a Ficoll gradient (Sigma-Aldrich Corp, 
Ficoll PM 400) as described previously (Kaestner et al., 2007). Islets were handpicked 
under a light microscope. Total RNA was isolated in Trizol (Life Technologies) and 
reversely transcribed using 1µg oligo (dT) primer, Superscript II Reverse Transcriptase, 
and accompanying reagents (Life Technologies). PCR reaction mixes were assembled 
using the Brilliant III SYBR Green QPCR Master Mix (Agilent Technologies, Inc., Santa 
Clara CA, USA). PCR reactions were performed on an Mx4000 Multiplex Quantitative 
PCR System (Agilent Technologies). All reactions were performed in triplicate with 
reference dye normalization. Median cycling threshold values were used for analysis.  
 
Western Blotting: For western blots, islets or liver were isolated and lysed in lysis buffer 
containing 50mmol/l Tris (pH 8.0), 5mmol/l EDTA, 150mmol/l NaCl, 1% Triton, 1% 
SDS, 0.5% sodium deoxycholic acid and Complete Protease Inhibitor Cocktail Tablets 
(Genentech Roche, Newtown, PA, USA). Protein concentrations were measured by 
Bradford Assay using SpectraMax Plus 384 (Molecular Devices). Total lysate were 
heated at 95º C for 10 min and loaded on 4-12% Bis-Tris gel (Novex, Wadsworth, OH, 
USA). Proteins were transferred to PVDF membranes by iBlot Dry Blotting System (Life 
Technologies) and detected by antibodies against Hnf4α (R&D) and rat anti-beta-actin 
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(Cell Signaling). The ECL-Plus detection system (GE Healthcare Biosciences, Pittsburgh, 
PA, USA) was used to detect the signal. 
 
Immunostaining: Pancreata were dissected, flattened by forceps, fixed in 4% para-
formaldehyde for 24 hours, and paraffin embedded so that tissues with the maximum 
pancreatic footprint were sectioned. Tissues were sectioned to 5µm thickness. 
Deparaffinized and rehydrated slides were subjected to antigen retrieval by pressure 
cooker in 10mmol/l pH 6.0 citric acid buffer. For beta cell proliferation, simultaneous 
immunofluorescent staining was performed for insulin and BrdU, or insulin and Ki67. 
Beta cell proliferation rate was quantified as the number of BrdU(or Ki67)/ insulin 
double positive cells divided by insulin positive cells. For beta cell mass, three sections 
(40 µm apart) from each animal were immunostained for insulin using the standard DAB 
method without counterstaining. The entire tissue section was scanned with Meyer 
PathScan Enabler IV Histology Slide Scanner and Silverfast Pathscan 6.6 software. The 
percentage of beta cell area relative to the total pancreatic area was measured and 
calculated using ImageJ. Beta cell mass was derived from the total pancreas weight 
multiplied by the percentage of beta cell area. For Cre recombinase expression test, 
simultaneous immunofluorescent staining was performed for insulin and YFP. 
 
Glucose tolerance test and insulin assay: Animals were fasted overnight and fasting and 
fed glucose levels were determined by glucometer. 2g/kg body weight of glucose (Sigma-
Aldrich Corp., St. Louis, MO, USA) was injected intraperitoneally. For ob/ob mice, 
1g/kg body weight of glucose was injected. Glucose levels were measured at 15, 30, 60, 
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90, and 120 minutes postinjection by Glucometer Breeze2 (Bayer AG, Leverkusen, 
Germany). To determine plasma insulin levels, blood was collected from the tail vein of 
mice before and after overnight fasting. Plasma insulin concentrations were measured by 
ELISA. 
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Chapter 4 Elevated hepatic betatrophin expression does not increase human beta-
cell replication  
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Abstract	  
The recent discovery of the hormone betatrophin, a protein secreted by the liver and 
white adipose tissue in conditions of insulin resistance and shown to dramatically 
stimulate replication of mouse insulin-producing beta-cells, has raised high hopes for the 
rapid development of a novel therapeutic approach for the treatment of diabetes.  
However, at present the effects of betatrophin on human beta cells are not known. Here 
we employ administration of the insulin receptor antagonist S961, shown to increase 
betatrophin gene expression and stimulate beta-cell replication in mice, to test its effect 
on human beta cells. While mouse beta cells, both in their normal location in the pancreas 
and in islets transplanted under the kidney capsule, respond with a dramatic increase in 
beta cell DNA replication, engrafted human beta cells are completely unresponsive. 
These results put into question whether betatrophin can be developed as a therapeutic for 
human diabetes. 
Results	  and	  Discussion	  
           A common feature of both type 1 and type 2 diabetes is an insufficient number of 
insulin-producing beta cells in the endocrine pancreas. While promising in principle, 
targeted expansion of human beta-cells as a therapeutic strategy for diabetes has not yet 
been achieved (Bonner-Weir & Weir, 2005a). After beta cells have been specified from 
pancreas endocrine precursors in fetal life, postnatal beta cell mass expansion is the result 
of replication of preexisting beta cells, and is not dependent on tissue-resident progenitor 
cells, at least in rodents (Dor et al., 2004). The basic proliferation rate of beta cells in 
adult mammals is very low under normal physiological conditions, typically less than 1% 
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(Kaestner et al., 2007). However, when metabolically challenged, such as during 
pregnancy, diet-induced insulin resistance, and experimental beta cell ablation, beta cells 
have the capacity to expand by proliferation, at least in rodents (Heit, Karnik, & Kim, 
2006a). In particular, hepatic insulin resistance has been shown decades ago to be a 
powerful promoter of beta-cell replication in mice (Bruning et al., 1997; Kido et al., 
2000; Withers et al., 1998). Recently, increased glycolytic flux in beta cells, as occurs 
when blood glucose levels are elevated, was proposed as one mediator of increased beta-
cell replication (Glaser et al., 2011). Whether additional signals contribute to beta-cell 
replication during the insulin resistant state remains unknown. 
 Using a pharmacological inhibitor of insulin action, Yi and colleagues screened 
for a potential secreted molecule that might represent the mitogenic signal to beta cells in 
conditions of insulin resistance (Yi et al., 2013). They identified betatrophin, also know 
as lipasin (R. Zhang, 2012) or angiopoetin-like 8 (Quagliarini et al., 2012), as a secreted 
protein synthesized in liver and to a lesser extent in white adipose tissue, as a potential 
beta cell mitogen (Yi et al., 2013). Betatrophin mRNA expression was induced four- to 
five-fold in the liver and white adipose tissue of mice treated with the insulin receptor 
antagonist S961 (L. Schaffer et al., 2008). This change in betatrophin expression 
following S961 administration was accompanied by a dose-dependent increase in beta-
cell replication (~4-fold to 12-fold). Strikingly, overexpression of a myc-tagged 
betatrophin protein in the liver via hydrodynamic injection resulted in a similar increase 
in beta cell replication in mice, indicating that it is central to the proliferative response 
seen by inducing insulin resistance through treatment with S961 (Yi et al., 2013). While 
the mechanism of action of betatrophin is currently unknown, its description has lead to 
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wide-spread hopes that this hormone might represent a new therapeutic avenue for 
treating diabetes. 
        Importantly, it has not yet been determined whether betatrophin can also stimulate 
replication of human beta-cells. To address this question, I asked whether human islets 
transplanted under the kidney capsule of immunodeficient mice increase their 
proliferation rate in response to increased betatrophin levels. First, I established that 
immunodeficient NOD-Scid (NOD.CB17-Prkdcscid/J) mice respond to the insulin 
receptor inhibitor S961 in a fashion similar to that seen by Yi and colleagues in 
C57BL/6J mice (Yi et al., 2013). As shown in Fig 4.1a, delivery of S961 using osmotic 
minipumps indeed caused insulin resistance in NOD-Scid mice within 48 hours, and this 
effect persisted for the entire treatment period. Next, I evaluated whether expression of 
betatrophin is induced in the liver of NOD-Scid mice. Messenger RNA levels of 
betatrophin were induced about 5-fold as determined by quantitative reverse transcription 
PCR (Fig 4.1b), similarly to what was published previously for C57BL/6 mice (Yi et al., 
2013). However, mRNA levels of betatrophin were not induced in white adipose tissues 
as shown in Yi’s paper, probably due to the difference in mouse strains (Fig 4.1c). In 
addition, in the previous paper, betatrophin had a trend of being induced in fat tissue, but 
in a statistically non-significant manner. These results suggest that white adipose tissue is 
not the source of betatrophin that drives beta cell proliferation in vivo.  
          Next, I proceeded to assay replication of beta cells in the endocrine pancreas of 
S961-treated NOD-Scid mice by measuring incorporation of the thymidine analogue 
BrdU (bromodeoxyuridine) into beta cells. The number of replicating beta cells was 
dramatically increased in S961-treated mice compared to vehicle controls (Fig. 4.1d,g).  
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Fig. 4.1. Elevated betatrophin expression does not stimulate replication of human beta-
cells. a Random blood glucose levels of NOD/Scid mice treated with vehicle (n=6) or the 
insulin receptor antagonist S961 (n=10).  Glucose levels in S961-treated mice were 
significantly elevated from day 1 to 7 (p<0.001).  b Hepatic betatrophin mRNA levels in 
mice treated with vehicle (n=3) or S961 (n=4) as determined by qRT-PCR. Messenger 
RNA levels were normalized to those of TBP (TATA-box binding protein) as internal 
control, and are expressed as fold over vehicle. *, p < 0.05 c White adipose tissue 
betatrophin mRNA levels in mice treated with vehicle (n=6) or S961 (n=6) as determined 
by qRT-PCR. Messenger RNA levels were normalized to those of beta-actin as internal 
control. d-i Beta-cell replication in NOD/Scid mice treated with vehicle or S961was 
determined by BrdU incorporation (red signal). Beta cells were identified by insulin 
immunofluorescence staining (green). d Beta cells in the endocrine pancreas of vehicle-
treated mice. e Transplanted human islets recovered from the kidney capsule of vehicle-
treated mice. f Transplanted mouse islets recovered from the kidney capsule of vehicle-
treated mice. g Beta-cells in the endocrine pancreas of S961-treated mice. Note the 
frequent BrdU-positive beta-cells (yellow arrow). h Transplanted human islets recovered 
from the kidney capsule of S961-treated mice. i Transplanted mouse islets recovered 
from the kidney capsule of S961-treated mice. Note the frequent BrdU-positive beta cells 
(yellow arrow). j Beta-cell replication was quantified as the percentage of BrdU+/insulin+ 
double-positive cells of the total number of insulin positive cells in beta-cells from the six 
conditions shown in d-i. n=5 for vehicle and for S961. **, p < 0.01. k Beta-cell 
replication was also quantified as the percentage of Ki67+/insulin+ double-positive cells 
of the total number of insulin positive cells in beta-cells from the six conditions. 	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Quantification of the data showed a mitogenic effect of about 15-fold, again in line with 
what had been observed in C57BL/6J mice (Fig 4.1j) (Yi et al., 2013). Co-
immunostaining for  insulin	  and	  Ki67,	  another	  marker	  of	  cell	  proliferation,	  revealed	  a	  5-­‐fold	  increase	  in	  beta	  cell	  replication	  in	  the	  S961	  treated	  mice	  (Fig	  4.1k).	  The	  discrepancy	  between	  the	  BrdU+	  cell	  ratio	  and	  the	  Ki67+	  cell	  ratio	  is	  not	  surprising	  since	  BrdU	  labeling	  captures	  all	  cells	  proliferating	  during	  the	  72-­‐hour	  time	  period	  of	  BrdU	  administration,	  while	  Ki67	  staining	  only	  detects	  the	  cells	  that	  were	  actively	  replicating	  at	  the	  time	  of	  sacrifice.	  
 Having validated the experimental model, I tested the effects of S961 treatment 
and elevated betatrophin levels on human beta cell replication. To this end, I transplanted 
islets obtained from deceased, non-diabetic organ donors (see Table 4.1 for donor 
information) under the kidney capsule of S961-treated NOD-Scid mice. In contrast to the 
dramatic increase in proliferation seen in the mouse endocrine pancreas documented 
above, human beta cells did not respond to S961 treatment and elevated betatrophin 
expression with increased BrdU incorporation (Fig 4.1e versus Fig 4.1h). Quantification 
of BrdU+/insulin+ double positive cells confirmed that the percentage of replicating 
human beta cells was negligible in both vehicle and S961-treated mice (Fig 4.1j). Co-
immunostaining for Ki67 and insulin also confirmed that engrafted human beta cells do 
not respond to betatrophin elevation in the same manner as the beta cells of the mouse 
pancreas (Fig 4.1k). 
 An important caveat to this study is that we are not able to analyze human beta 
cells in their normal location, but only after transplantation under the kidney capsule. One 
could envision, for instance, that the betatrophin produced in the liver does not reach the 
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islets in the kidney capsule in the same concentration as is seen by beta cells in the 
endocrine pancreas. In addition, it is possible that betatrophin exerts its effects not 
directly by binding to a receptor on beta-cells, but indirectly, for instance by altering 
beta-cell innervation, or by activating another cell or signal not present under the kidney 
capsule. To address this issue, I simultaneously transplanted mouse islets under the right 
kidney capsule and human islets under the left kidney capsule of the same NOD-Scid 
mice. Strikingly, mouse islets were responsive to S961 treatment regardless of location, 
and showed a robust increase in beta-cell replication even when placed under the kidney 
capsule (Fig 4.1f,I,j). In fact, the replication rate of transplanted mouse beta cells was 
similar in magnitude to that seen in beta cells in the endocrine pancreas of the same mice. 
Co-immunostaining for Ki67 and insulin also confirmed that mouse islets transplanted 
under kidney capsules respond to S961 treatment and display an increased replication rate 
(Fig 4.1k). 
          Another potential explanation for why the human beta cells were unresponsive to 
S961 treatment is that mouse betatrophin may not act on its human receptor. To address 
this, I sought to overexpress the human version of betatrophin (h-betatrophin) in the 
mouse liver, then assess the impact on beta cell replication. cDNA encoding h-
betatrophin was cloned into a plasmid with the sleeping beauty transposon backbone, 
then introduced into mouse hepatocytes via hydrodynamic tail vein injection. One week 
after the injection, mRNA expression of h-betatrophin in the mouse liver were measured 
by q-PCR (Fig 4.2a). Mice injected with h-betatrophin cDNA possess a 30-fold increase 
of h-betatrophin mRNA in their livers than mice injected with control plasmids (Fig 
4.2b). Next, I co-stained BrdU and insulin in the mouse pancreas (Fig 4.2c,d).  
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Fig 4.2 Overexpression of human betatrophin results in elevated beta cell proliferation a 
Experimental scheme of hydrodynamic injection. b Hepatic mRNA levels of both mouse 
betatrophin and human betatrophin in mice injected with either control plasmids (CT) or 
plasmids with h-betatrophin cDNA (OV), as determined by qRT-PCR. Messenger RNA 
levels were normalized to those of beta-actin as internal control, and are expressed as fold 
over control. c,d Beta-cell replication in mice injected with control or h-betatrophin 
plasmids was determined by BrdU incorporation (red signal). Beta cells were identified 
by insulin immunofluorescence staining (green). e Beta-cell replication was quantified as 
the percentage of BrdU+/insulin+ double-positive cells of the total number of insulin 
positive cells in mice injected with either control plasmid (CT) or plasmids with h-
betatrophin cDNA (OV). 
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       Overexpression of h-betatrophin mRNA resulted in a 4-fold increase of endogenous 
mouse beta cell proliferation (Fig 4.2e), indicating that human betatrophin protein can 
exert its effect on endogenous mouse beta cells. 
        To test the effect of h-betatrophin on engrafted human islets, I will repeat the 
transplantation experiments with NOD-Scid mice as mentioned previously. Mice  
harboring human and mouse islet grafts will be injected hydrodynamically with h-
betatrophin or control plasmids, then the transplanted tissues, along with the liver and 
pancreas, will be collected for analysis. Furthermore, an adeno-associated virus (AAV) 
containing h-betatrophin cDNA is also being generated as a second approach to induce h-
betatrophin overexpression in the mouse liver. 
         In summary, I have shown that the insulin-resistant state produced by treating mice 
with the insulin receptor antagonist S961 causes a dramatic increase in murine beta-cell 
replication, and that this effect occurs regardless of whether beta-cells are in their native 
environment in the endocrine pancreas, or in the ectopic location under the kidney 
capsule. This dramatic increase in replication rate is accompanied by the previously 
documented increase in betatrophin expression in the liver (Yi et al., 2013). 
Unfortunately, human islets transplanted under the kidney capsule were not responsive, 
and maintained negligible levels of beta-cell replication even when betatrophin 
production was elevated.   
          To test the effect of h-betatrophin protein on human islets, I first tested h-
betatrophin protein on endogenous mouse islets. mRNA levels of h-betatrophin were 
increased 30-fold and endogenous mouse beta cell BrdU incorporation rate was increased 
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2.5-fold. Ongoing studies are being performed to test the effect of human betatrophin 
protein on transplanted human beta cells.  
          A second important issue is the age of the beta-cell responding to a mitogenic 
signal, as there is a well-documented decline in beta-cell replication rate with age in both 
mouse and human (Kushner, 2013).  One of the three organ donors in our study was only 
four-years old (Table 4.1), and thus of an even younger relative age than the mice 
employed, indicating that even young human beta-cells are not responsive to betatrophin. 
In conclusion, these data put into question whether betatrophin is a mitogen for human 
beta-cells, and whether betatrophin will be a useful therapeutic approach for human 
diabetes. 
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Table 4.1 Summary information for the deceased organ donors used for the human islet 
transplantation studies. 
Donor ID Age Sex BMI Race Cause of death 
1 AAER055 53 M 29 Hispanic Head Trauma 
2 AAFC089 46 M 28.8 White NA 
3 ICRH-51 4 F 16.1 Hispanic Head Trauma 
4 AAGW388 43 M 30.6 White Head Trauma 
5 ICRH-52 18 M 23.5 White Head Trauma 
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Materials and Methods 
 
Mice and glucose measurements:  Immunodeficient Nod-Scid (NOD.CB17-Prkdcscid/J) 
female mice were purchased from Jackson Laboratory (Cat No. 001303) and used for 
experiments at 8 weeks of age. Random blood glucose levels were measured from tail 
vein blood using glucometer Breeze2 (Bayer AG, Leverkusen, Germany). 
 
Mouse islet isolation:  Adult C57BL6/J mice were used for islet isolation.  Islets were 
released with standard collagenase treatment followed by purification through a Ficoll 
gradient (Sigma-Aldrich Corp, St. Louis, MO, USA, Ficoll PM 400) as described 
previously (Gupta et al., 2007).  Islets were handpicked under a light microscope before 
transplantation. 
 
 Islet transplantation: During surgical procedures, mice were maintained on inhalation 
anesthesia (isofluorane 2-4%). 500 human islets were transplanted under the left kidney 
capsule and 100 mouse islets were transplanted under the right kidney capsule of each 
mouse. Mice were allowed to recover from the surgery for one week before implantation 
of osmotic minipumps. 
 
S961 treatment: S961 was received as a generous gift from Dr. Lauge Schafffer (Novo 
Nordisk) (L. Schaffer et al., 2008). Vehicle (H2O) or 10nmol S961 was loaded into Alzet 
2001 osmotic pumps  and implanted subcutaneously on the back of mice one week after 
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islet transplantation. Mice were sacrificed for tissue harvesting seven days after S961 or 
vehicle treatment. 
 
Real-time PCR analysis: Total RNA from liver was isolated in Trizol (Life Technologies, 
Grand Island, NY, USA) and reverse transcribed using oligo (dT) primer, Superscript II 
Reverse Transcriptase, and accompanying reagents (Life Technologies). PCR reaction 
mixes were assembled using the Brilliant III SYBR Green QPCR Master Mix (Agilent 
Technologies, Inc., Santa Clara CA, USA). PCR reactions were performed on an Mx4000 
Multiplex Quantitative PCR System (Agilent Technologies). All reactions were 
performed in triplicates with reference dye normalization. Median cycling threshold 
values were used for analysis. 
 
Immunohistochemistry: 72 hours before euthanizing the mice, 1g/L BrdU (Sigma-Aldrich 
Corp., St. Louis, MO, USA) was administrated in the drinking water. Both kidneys were 
dissected and fixed with 10% formalin (Fisher PROTOCOL, Pittsburgh, PA, USA).  The 
pancreas was dissected, flattened by forceps, fixed in 4% para-formaldehyde, and 
paraffin-embedded so that tissues with the maximum pancreatic footprint were sectioned. 
Tissues were sectioned to 5µm thickness. Deparaffinized and rehydrated slides were 
subjected to antigen retrieval by pressure cooker in 10mmol/l pH 6.0 citric acid buffer. 
Simultaneous immunofluorescent staining was performed for BrdU and insulin. The 
primary antibodies used were guinea pig anti-insulin (1:1000 dilution, Dako North 
America, Inc., Carpinteria, CA, USA) and rat anti-BrdU (1:500 dilution, AbD Serotec; 
Raleigh, NC, USA). Secondary antibodies were Cy2-anti-guinea pig (1:200) and Cy3-
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anti-rat (1:200). The beta cell proliferation rate was quantified as the number of 
BrdU+/insulin+ double positive cells divided by the number of insulin positive cells. As 
least 1,000 beta cells were counted, respectively, for human islets under the kidney 
capsule, mouse islets under the kidney capsule, and endogenous mouse islets in the 
pancreas. 
 
Construction of expression vectors: A plasmid containing human betatrophin cDNA was 
obtained from OriGene. The h-betatrophin cDNA sequence was amplified by PCR then 
cloned into the EagI site of a vector backbone containing the sleeping beauty (SB) 
transposon.  In this context, h-betatrophin is under control of the SV40 Promoter.  PCR-
amplified h-betatrophin cDNA was also introduced into the NotI and HindIII sites of an 
AAV vector obtained from Penn Vector Core (PVC). The final AAV vector containing h-
betatrophin under control of the liver-specific TBG promoter was then submitted to the 
PVC for packaging into a functional AAV.  All clones were sequenced and subjected to 
diagnostic restriction digestion to ensure their fidelity. 
 
Hydrodynamic tail vein injection: The injections were performed according to publish 
methods (Wilber et al., 2005). Briefly, 10µg of control or h-betatrophin-expressing 
plasmid DNA in the SB transposon backbone were first diluted in lactated ringer’s 
solution. Mice were injected with 10% body weight volumes (ml/g) of diluted plasmid 
DNA within 7 s through the lateral tail veins and sacrificed eight days later. Livers were 
collected for expression analysis while pancreata were prepared for 
immunohistochemistry.   
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  Mounting evidence in both human and mouse studies have emphasized beta cell 
deficiency as a key pathogenic determinant for both T1D and T2D [19, 52]. Therefore, 
cell replacement therapy is thought to be well suited for diabetic patients whose 
endogenous beta cell number is below the threshold to successfully alleviate 
hyperglycemia chronically. However, a major hurdle for cell replacement-based diabetes 
therapy is the difficulty to supply vast numbers of functioning insulin-producing cells. 
Beta cell proliferation has been shown to be the predominant mechanism of maintaining 
beta cell mass during adult life, at least in rodents [85]. Beta cells have exhibited adaptive 
capacity of expanding under metabolic stresses such as pregnancy, obesity, and 
pancreatic injury in mice [75, 76, 82]. Therefore, it is promising to utilize the 
regenerative capacity of beta cells to produce an unlimited supply of fully functional beta 
cells through the proliferation of pre-existing terminally differentiated adult beta cells.  
          My research attempted to investigate important molecular players associated with 
or responsible for beta cell proliferation during physiological expansion of beta cell mass. 
In the first part of my thesis, I utilized a pancreas-specific gene ablation mouse model to 
study the role of CISH in beta cell proliferation during pregnancy. In the second part of 
my thesis, I investigated the role of HNF-4α on beta cell proliferation in adaption to 
obesity-induced insulin resistance, which is a highly related model to human disease. I 
investigated ob/ob mice with Hnf4α ablation and HFD-fed mice with Hnf4α 
overexpression. Along this line, I also investigated the role of an HNF-4α target, ST5, 
which is a novel regulator of Ras/ERK pathway, on beta cell proliferation. In the third 
part of my thesis, I studied the role of betatrophin, a prominent mouse beta cell mitogen, 
on human beta cell proliferation. We transplanted human islets into kidney capsules of 
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immune-deficient mice and induced betatrophin overexpression by either administrating 
a drug inducing insulin-resistance (S961) or forcing ectopic human-betatrophin 
expression by hydrodynamic injection. 
        This dissertation makes several contributions to the knowledge of beta cell 
regeneration. First, this is the first time that a mouse model with pancreas-specific 
ablation of Cish, a proposed molecular suppressor of lactogen signaling, is reported. Cish 
ablation is not sufficient to promote elevated STAT5 signaling or induce increased beta 
cell proliferation during pregnancy. Cish mutant mice exhibited normal STAT5 signaling 
in concomitant with undisturbed beta cell proliferation rate and glucose homeostasis. This 
is probably due to a compensating effect from Socs2 upregulation in Cish-deficient islets.  
        Second, I extend the role of HNF-4α as a regulator of beta cell proliferation from 
pregnancy model to obesity model. Obesity and pregnancy both induce insulin resistance 
and robust beta cell proliferation in rodents, but they utilize different molecular pathways 
for beta cell replication. Therefore, it is exciting to learn that HNF-4α regulates beta cell 
proliferation not only during pregnancy, but also during obesity.  Beta cell-specific Hnf4α 
ablation results in decreased beta cell proliferation in ob/ob mice. Beta cell mass is not 
affected, probably due to a relatively short period of Hnf4α ablation in comparison to the 
length of overweight. Glucose homeostasis also remained normal in Hnf4a mutant mice, 
consistent with the unchanged beta cell mass. Furthermore, I also investigate whether 
overexpressing Hnf4α in beta cells affects glucose homeostasis in HFD-fed mice. 
Overexpression of Hnf4α is induced by administration of doxycycline in the drinking 
water of Tre-Hnf4α; Rip-rtTA mice. Nine-folds increase of h-Hnf4α mRNA in islets did 
not have any effect on glucose homeostasis in either chow-diet fed mice or HFD-fed 
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mice, indicating that overexpression of Hnf4α is not sufficient to promote a protective 
role in HFD-induced hyperglycemia. Along the same line, I also overexpressed St5, a 
target of HNF-4α, in beta cells. No increase of beta cell proliferation was observed in St5 
overexpressing mice. 
         Third, I investigated the role of betatrophin on human islets. Betatrophin has been 
shown to be a potent beta cell mitogen for mouse islets [162]. I first tested the role of 
endogenous mouse betatrophin on human beta cells by transplanting human islets into 
immune-deficient mice. Administration of S961 by osmotic pumps induces a 4-fold 
increase of betatrophin mRNA in the liver and more than 10-fold increase of BrdU 
incorporation in both endogenous mouse beta cells and transplanted mouse beta cells 
under kidney capsule. However, human islets in the grafts exhibited no response to 
mouse betatrophin, indicating that betatrophin is not a mitogen for human beta cells.  
 
Future directions 
Effect of Cish /Socs2 double ablation on beta cell proliferation during pregnancy 
        Since both Cish and Socs2 are up-regulated in the islets of pregnant mice and Socs2 
is further induced in Cish-deficient islets at pregnant day 9.5, I hypothesize that SOCS2 is 
compensating for loss of CISH as a suppressor for PRL/JAK2/STAT5 signaling. I am 
now breeding mice with Cish and Socs2 double conditional alleles. The final CishL/L; 
Socs2L/L; Pdx1-CreER mice will be compared with littermate CishL/L; Socs2L/L mice as 
controls. 
        It is very important to determine which gestational stage to investigate these mice. 
During normal pregnancy, Cish and Socs2 expressions are elevated from P9, and keeps 
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elevated until the end of pregnancy [84]. Beta cell proliferation also starts to increase at 
around P9, peaks at around P14, and quickly decreases at P18. Interestingly, a cohort of 
cyclins expressions peak at P9.5, which is 5 days in advance of the peak of proliferation 
[209]. The jet-lag between the peak of cyclins and the peak of proliferations might be due 
to negative regulation of proliferation like CISH and SOCS2. Indeed, it seems CISH and 
SOCS2 regulation are finely-tuned at P9, when expression of Socs2 is upregulated in 
Cish ablation mice, but not at P14.5. Therefore, it is worth investigating at P9 when CISH 
and SOCS2 might function to repress cyclin genes via JAK2/STAT5 signaling to prevent 
premature overshooting of beta cell proliferation. 
        Furthermore, it should be proceeded with caution when inducing Cish and Socs2 
ablation during pregnancy by tamoxifen injection. Tamoxifen has been shown to induce 
abortion at early stage of pregnancy in mice since it is an analog to estrogen. It should not 
be injected before pregnant day 5 and low dose should be used before pregnant day 8. 
Preliminary data have exhibited effective ablation of Cish at pregnant day 13 by 
tamoxifen injection without causing abortion. Further experiments are needed to 
determine whether Socs2 could also be ablated in a similarly efficient way during 
pregnancy.  
        STAT5 signaling levels could be detected by western blot of p-STAT5 protein in 
islets and also qPCR of STAT5 target genes in pregnant mice. Levels of p-JAK2 should 
also be measured. Proliferation rate, insulin secretion, and glucose tolerance should be 
compared between control and mutant mice. Finally, it is worth proceeding with Cish and 
Socs2 double ablation in human islets using lentiviral shRNA to further investigate 
whether ablation of these two genes has a mitogenic effect on human beta cells. 
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Effect of HNF-4α on beta cell proliferation and beta cell function in obesity 
       Ablation of Hnf4α for three weeks (from 7-10 weeks) in ob/ob mice results in 
decreased beta cell proliferation but unchanged beta cell mass and glucose homeostasis. 
It would be interesting to ablate Hnf4α from 3 weeks old ob/ob mice, when they start to 
gain more weight than lean mice and presumably trigger adaptive beta cell proliferation. 
Hnf4α deficiency from this earlier stage may lead to failure of beta cell mass expansion 
from the beginning and result in glucose intolerance. 
        It will be intriguing to study the mechanism of how HNF-4α regulates beta cell 
replication during obesity. One potential pathway is glucose metabolism. ob/ob mice 
have chronic mild hyperglycemia, and glucose metabolism in beta cells has been 
indicated to be a key regulator of beta cell proliferation. Expression of key regulators of 
glucose influx pathway should be measured, including Glut-2 and glucokinase. 
Furthermoe, HNF-4α has been shown to regulate beta cell proliferation in pregnant mice 
by ST5-Ras-ERK signaling [197]. This is also a potential pathway of HNF-4α regulation 
in obesity. 
       In addition, HNF-4α might also affect insulin secretion function in beta cells. Kir6.2, 
a KATP channel subunit, has been shown to be a direct target of HNF-4α [59]. And Hnf4α 
mutant mice exhibited diminished first-phase insulin secretory response with decreased 
Kir6.2 expression. Insulin secretion should be measured either with in vivo glucose 
injection or in vitro islet perifusion to study whether HNF-4α regulates insulin secretion 
pathway in obese islets. 
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        Next, it would be helpful to perform microarray analysis on Hnf4α control and 
mutant islets from ob/ob mice to gain more knowledge of how HNF-4α regulates beta 
cell function during obesity. The mechanism of beta cell proliferation during pregnancy, 
obesity, and normal conditions are not the same. Therefore, comparing the microarray 
data from previous pregnancy model and the current obesity model will give us more 
information on the function of HNF-4α under different metabolic stresses. 
       Furthermore, ST5 is a direct target of HNF-4α. It is upregulated during pregnancy 
and it regulates Ras/ERK signaling. My preliminary data demonstrated that 
overexpression of  St5 has no effect on glucose homeostasis or beta cell proliferation 
under normal conditions. The function of ST5 should be further investigated under 
metabolic stress such as pregnancy and obesity since Ras/ERK pathway plays key roles 
in beta cell replication under these conditions. 
 
Effect of betatrophin on human beta cell proliferation 
        It has been of great interest since the publication of Dr. Melton’s paper reporting 
that betatrophin is a potent mouse beta cell mitogen, which brings a lot of hope to the 
development of the cell-replacement therapy of diabetes patients. The same insulin 
resistance-inducing drug, though, did not promote human islet proliferation under mouse 
kidney capsule although expression of betatrophin is upregulated in mouse liver. 
       Since mouse betatrophin protein is 74% homologous to human betatrophin protein, it 
is possible that human islet does not recognize mouse betatrophin protein. Therefore, we 
are now trying to overexpress human betatrophin in mouse liver to study whether 
transplanted human islets respond to human betatrophin. Two approaches are being 
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tested. First, AAV facilitated h-betatrophin cDNA injection. Second, hydrodynamic 
injection of h-betatrophin plasmid with a transposon backbone. Preliminary data 
demonstrated that h-betatrophin mRNA is overexpressed 30-fold in mouse liver by 
hydrodynamic injection. Endogenous mouse beta cells exhibited a 4-fold increase in 
proliferation, which is not as prominent as overexpressing mouse betatrophin. This is 
probably due to the relative lower levels of h-betatrophin mRNA comparing to 
endogenous mouse betatrophin even in the overexpressing mouse. We are now trying to 
increase the dose of h-betatrophin overexpression by injecting more plasmids. Ultimately, 
we will overexpress h-betatrophin in human-islets transplanted mice to analyze if h-
betatrophin has an effect on human beta cell proliferation. 
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Appendix  Transcriptional regulation of endocrine cell specification 
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  Cell therapy for diabetes will be greatly aided by an unlimited and renewable supply 
of beta cells. Human pluripotent stem cells, including iPSCs and human ES cells, have 
the capacity to differentiate into insulin-producing cells (Hua et al., 2013). The 
differentiation and maturation of islet cells during embryogenesis involves a remarkably 
efficient and specific activation of a network of transcription factors, which either 
activate or silence their target genes, partially in combination with DNA methylation 
and/or histone methylation (Kroon et al., 2008). Although mouse genetics has provided 
mounting knowledge of the general functions of many key transcription factors, including 
PDX1, NKX6.1, NGN3, and NKX2.2, the precise molecular mechanisms by which they 
control their respective transcriptional targets during endocrine subtype specification 
have remained elusive. Therefore, approaches to generate beta cells from hES or iPSC 
have surpassed several milestones, but still needs perfection. One fundamental obstacle is 
to overcome the similarity of beta cells with other islet cell types, including alpha cells 
and delta cells, and induce uni-hormonal cells that express only insulin, instead of insulin 
and glucagon after in vitro differentiation. It would be intriguing to understand the 
mechanisms of how transcription factors and epigenetic modifications establish and 
maintain cell-type specific transcription.  
        During pancreatic development, the transcription factors NKX6.1, NKX2.2, and 
FOXA2 are each expressed in endocrine progenitors and later become restricted to 
specific endocrine subtypes (D'Amour et al., 2006). FOXA2 has been shown to play 
critical roles at multiple stages of pancreatic development, from the first induction of 
Pdx1 in the pancreatic primordium, to the regulation of glucose sensing and insulin 
secretory machinery in the mature beta cells (N. Gao et al., 2007; Lantz et al., 2004; C. S. 
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Lee et al., 2002). Conditional ablation of Foxa2 during pancreatogenesis results in loss of 
alpha cells, suggesting that FOXA2 also plays an important role in alpha cell 
specification (C. S. Lee et al., 2005).    
         Consistent with its restriction to beta cell, deletion of Nkx6.1 results in selective 
beta cell loss (Sander et al., 2000). Moreover, NKX6.1 functions as a transcriptional 
repressor of alpha cell-specific genes and loss of Nkx6.1 has been associated with ectopic 
activation of alpha cell-specific genes in mature beta cells in vitro (Schisler et al., 2005), 
suggesting that NKX6.1 specifies beta cell fate by repressing alpha cell specific genes. 
One recent study with endocrine precursor-specific ablation of Nkx6.1 demonstrated that 
NKX6.1 is critical for establishing beta cell identity during development (A. E. Schaffer 
et al., 2013). Overexpression of Nkx6.1 in Ngn3 positive cells resulted in increased 
number of beta cells in concomitant with decreased other endocrine cell types, and 
ablation of Nkx6.1 in Ngn3 positive cells resulted in opposite phenotype (A. E. Schaffer 
et al., 2013). Moreover, conditional Nkx6.1 ablation in adult beta cells resulted in rapid-
onset diabetes and hypoinsulinemia resulted from partial loss of beta cell identity marked 
by decreased insulin production and secretion (Taylor, Liu, & Sander, 2013). And 
Nkx6.1-deficient beta cells gradually acquired molecular characteristics of delta cells, 
suggesting that NKX6.1 is critical for maintaining a functional beta cell state (Taylor et 
al., 2013).  
        Nkx2.2 is expressed in both alpha cells and beta cells and deletion of Nkx2.2 resulted 
in the absence of all beta cells and most of alpha cells (Sussel et al., 1998), suggesting 
that NKX2.2 is necessary for the formation of both cell lineages. Further study showed 
that DNA methylation is one of the underlying mechanisms for the differential 
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programming of cell lineages. NKX2.2 formed a large repressor complex together with 
DNMT3a (a DNA methyltransferase), Grg3, and HDAC1 to maintain the methylation of 
promoter of Arx, an alpha cell factor (Papizan et al., 2011). Mutation of NKX2.2 tinman 
domain abolished the interaction between NKX2.2 and Grg3, resulted in ectopic 
expression of Arx in beta cells, and disrupted beta cell specification, suggesting that 
transcription factors and DNA methyltransferases interact with each other to regulate cell 
differentiation programs. Indeed, a beta cell-specific deletion of Dnmt3a resulted in de-
methylation of promoter region of Arx and beta-to-alpha reprogramming (Papizan et al., 
2011). Furthermore, epigenomic analysis suggested that differentiated alpha cells possess 
many more bivalently marked genes (genes that are marked by both activating H3K4me3 
mark and repressing H3K27me3 mark) than exocrine and beta cells, indicating the 
potential of promoting alpha-to-beta reprogramming by manipulating the histone 
methylation signature of alpha cells. Intriguingly, treatment of cultured human islets with 
a histone methyltransferase inhibitor leads to bi-hormonal cells with both insulin and 
glucagon, proving the plasticity of islet cells (Bramswig et al., 2013). 
           Therefore, to successfully direct endocrine precursors toward the beta cell lineage 
or to reprogram alpha cells or other endocrine cells to adopt beta cell identity, it is 
necessary to identify the direct transcriptional targets of critical cell fate determining 
transcription factors. Furthermore, it will be beneficial to understand how these 
transcription factors mediate epigenetic modifications to establish and maintain endocrine 
subtype-specific gene expression programs. Elucidating how islet cell type-specific 
transcription factors co-regulate gene expression with chromatin modifying enzymes at a 
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genome-wide level will be a major step forward in the understanding of how to promote 
beta cell fate. 
           Embryonic day 14.5 to 15.5 is the critical period of endocrine subtype 
specification. Ngn3 marks endocrine progenitors and their endocrine descendants at this 
stage. Therefore, purified endocrine progenitors were isolated from E15.5 pancreas by 
sorting GFP+ cells from Ngn3-eGFP embryos. One Ngn3-eGFP male mouse was set up 
with multiple CD1 female mice to allow half embryos with Ngn3-eGFP transgene. Mice 
were checked everyday for plugs to determine start date of pregnancy. Usually, 5 to 7 
cages of mating were set up together to ensure at least five pregnant mice on the same 
day. Fetuses were harvested on embryonic day 15.5 and embryonic pancreata were 
dissected under microscope. GFP+ pancreata were separated from GFP- pancreata under a 
fluorescence microscope (App. Fig 1a,b). GFP+ pancreata were then dissociated into 
single cell suspension with trypsin and subjected to FACS sorting. Approximately 4% 
GFP+ cells are expected, which is 5000-8000 GFP+ cells per pancreas (P. White, May, 
Lamounier, Brestelli, & Kaestner, 2008). 
          First, 362,000 Ngn3+ cells were sorted from 70 GFP+ embryonic pancreata, lysed, 
sonicated, and subjected to Foxa2 chromatin immunoprecipitation (ChIP). Chromatin 
library were than prepared for ChIP-sequencing (App. Fig 1c). In Ngn3+ cells, FOXA2 
bound to 1,460 sites according to GLITR analysis. In Ngn3- cells, FOXA2 bound to 
2,732 sites according to GLITR analysis. Some known targets of FOXA2 were checked 
by qPCR to ensure that ChIP-sequencing worked. For example, FOXA2 have higher 
occupancy at Pdx1 promoter in Ngn3+ cells than in Ngn3- cells (App. Fig 1d), which was 
also confirmed by qPCR (App. Fig 1e). Second, 1.5 x 106 GFP+ cells were isolated from 
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about 300 E14.5 pancreata by FACS and subjected to NKX6.1 ChIP. ChIP analysis 
demonstrated that in Ngn3+ cells at E14.5, NKX6.1 directly and specifically associates 
with the Arx enhancer, which is critical for Arx transcription repression (App. Fig 1f). 
Binding of NKX6.1 to Arx enhancer significantly reduces Arx expression, indicating that 
Nkx6.1 promotes beta cell lineage by repressing Arx expression in endocrine progenitor 
cells. 
         In conclusion, I established feasible protocol of ChIP-Seq analysis on a limited 
number of sorted embryonic cells (0.3 million cells). Genome wide DNA occupancy 
analysis were performed for FOXA2 and NKX6.1 in E14.5-E15.5 Ngn3+ cells, and 
resulted in new knowledge of endocrine cell lineage specification during embryogenesis. 
Further profiling of histone modifications and DNA methyltransferases occupancy would 
enhance our understanding of how establishing and maintaining of DNA methylation by 
both transcription factors and DNA modifying enzymes are accomplished. This 
knowledge will facilitate the differentiation of beta cells from alternative cell sources. It 
will also provide insight into the mechanisms that ensure the beta cell fate is maintained 
in a transplant setting. 	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Appendix Fig 1 a,b E15.5 embryonic pancreas under microscope. GFP+ pancreata are 
marked with green arrows and GFP- pancreata are marked with yellow arrows. GFP+ 
pancreata were chosen under fluorescence microscope for further FAC sorting. c Size 
analysis of ChIP-ed or input chromatin before library preparation for sequencing. d 
GLITR analysis of Foxa2 ChIP-Seq on GFP+ cells and GFP- cells. Shown here is the 
promoter region of Pdx1, where a peak is identified in GFP+ cells but not GFP- cells. e 
qPCR analysis confirmed enrichment at Pdx1 promoter region in GFP+ cells over GFP- 
cells after Foxa2 ChIP, comparing to inputs. Primers amplifying Pdx1 promoter region 
were used. f NKX6.1 binding is enriched at the Arx enhancer locus in sorted GFP+ cells 
from E15.5 pancreata. 
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